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Abstract 
 
Epstein Barr Virus (EBV) is a γ-herpesvirus infecting around 95% of the human 
population. EBV infection is life-long and asymptomatic in the majority of individuals, 
however EBV is associated with Nasopharyngeal Carcinoma, Burkitt's  
lymphoma and Hodgkin’s lymphoma.  The transcription factor Zta is an immediate early 
gene of EBV able to reactivate the virus from latency, cause cell cycle arrest and bind to 
sequence specific DNA elements.  Cercopithecine herpesvirus-15 is a closely related virus, 
infecting rhesus monkeys, with a homologue to Zta; ZtaRh.  A comparison of features of 
these proteins may be informative about critical residues in each protein.  Binding to 
almost all response elements is conserved between the two proteins.  A Zta response 
element (ZRE3Rh) in the CeHV-15 Rta gene promoter that is not functional for either 
protein was identified.  ZRE3 from EBV is methylation dependent for Zta binding.  
Analysis of ZRE3 using competition EMSA assays has shown the importance of 
methylation of individual CpG motifs.  ZtaRh is compromised in reactivating EBV from 
latency and this appears to be mediated by changes at the extreme C-terminus.  ZtaRh is 
unable to cause G1 cell cycle arrest, however this function maps to the transactivation 
domain.  Known binding partners of Zta were cloned to enable investigation of binding by 
ZtaRh or other mutants.  Co-transfection of p53 and Zta resulted in rapid degradation of 
both proteins.  Co-transfection of C/EBPα and Zta produced a larger additional Zta species.  
Neither effect was seen with a Zta CT mutant.  RNA from HEK293-ZKO cells transfected 
with Zta or a C-terminal Zta mutant was analysed using a QPCR array probing 595 human 
genes associated with cancer, revealing possible host cell proteins influenced by Zta. 
Further information on the precise mechanisms of Zta could contribute to the development 
of future therapies for the prevention or treatment of EBV related diseases. 
- 12 - 
 
Chapter 1      Introduction 
1.1 Introduction to Herpes viruses 
Herpesviridae are a family of enveloped, doubled stranded DNA viruses.  This type of 
virus can cause both latent and lytic infection, enabling a life-long infection of the host 
(Roizman and Baines, 1991).  There are around 90 species of herpesviridae that infect 
many types of animals.  There are 8 herpes viruses that infect humans including herpes 
simplex I and II, cytomegalovirus and Epstein Barr Virus (Table 1.1).  All these viruses are 
capable of causing disease in humans including chicken pox (Varicella zoster virus), oral 
and genital herpes (herpes simplex virus 1 and 2) and Kaposi’s sarcoma (Kaposi's 
sarcoma-associated herpesvirus).  Herpes viruses are classified into 3 sub-families 
generally according to the location during latency.  Alpha herpes viruses are situated in 
neurons during latency, beta herpes viruses in T lymphocytes and other cells and gamma 
herpes viruses reside in lymphocytes.  Although this criteria is not strictly accurate, for 
example Roseolovirus is a beta herpes virus but can latently infect lymphocytes, this 
classification is supported by nucleotide and protein homology (Davison, 2002).  
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HHV Name Sub Family Target cell type Main Disease Associations
1 Herpes simplex-1 (HSV-1) Alpha Mucoepithelia Oral and genital herpes, Herpes keratitis
2 Herpes simplex-2 (HSV-2) Alpha Mucoepithelia Genital and oral herpes
3 Varicella Zoster virus (VZV) Alpha Mucoepithelia Chickenpox, shingles
4 Epstein-Barr Virus (EBV) Gamma B lymphocyte, epithelia Infectious mononucleosis, Nasopharyngeal 
carcinoma, Burkitts's lymphoma
5 Cytomegalovirus (CMV) Beta Epithelia, monocytes,     
lymphocytes
Cytomegalovirus-retinitis 
6 Herpes lymphotropic virus Beta Lymphocytes Roseola infantum
7 Human herpes virus-7 (HHV-7) Beta T lymphocytes Roseola infantum
8 Kaposi's sarcoma- associated 
herpes virus (KSHV) Gamma Endothelial cells Kaposi's sarcoma 
 
Table 1.1: Human herpes viruses (HHV) 
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1.1.1 Gamma herpes virus 
The gamma herpesviridae contains two genera; the Lymphocryptoviruses, including 
Epstein Barr Virus (EBV), and the Rhadinoviruses, including Kaposi’s sarcoma 
associated herpesvirus (KSHV).  EBV and KSHV are the two gammaherpes viruses that 
infect humans.  KSHV is a causative agent for Kaposi’s sarcoma which generally occurs 
in immunocompromised patients (Moore and Chang, 1995).  Gammaherpes viruses 
infecting other species are also associated with cancer including porcine 
gammaherpesvirus infecting pigs (Ehlers et al., 1999).  The Rhadinovirus Herpesvirus 
saimiri causes T cell lymphomas in several monkey species except the natural spider 
monkey host (Fickenscher and Fleckenstein, 2001).    
 
1.2 Epstein Barr Virus 
1.2.1 Identification of EBV  
In Uganda in 1958 Denis Burkitt identified a type of lymphoma that caused jaw 
tumours in children (Burkitt, 1958), and reviewed in (Thompson and Kurzrock, 2004).  
The distribution of Burkitt’s lymphoma was distinctive climatically and geographically.  
Subsequent work by Anthony Epstein, Yvonne Barr and Bert Achong identified virus 
particles in tumour samples using electron microscopy (Epstein et al., 1965).  This virus 
was called Epstein Barr Virus.  Detection of the virus in DNA in the lymphomas and 
experimental induction of tumours in monkeys established EBV as the first virus 
identified as causing human tumours (Epstein et al., 1965). 
 
1.2.2 EBV Background 
EBV (human herpes virus 4) belongs to the genus lymphocryptovirus (LCV).  EBV 
infection is usually transmitted through salvia contact.  Infection of young children is 
generally asymptomatic, however primary infection in young adults can cause 
infectious mononucleosis.  This delayed infection and resultant infectious 
mononucleosis is more prevalent in developed countries.  In both cases a lifelong latent 
infection of B cells is established, which is present in about 95% of adults (Thompson 
and Kurzrock, 2004). In healthy carriers the pathological effects of the virus are 
controlled by the immune system so infection is asymptomatic and the virus persists.  
Other diseases, including nasopharyngeal carcinoma and Hodgkin’s and non-Hodgkin’s 
 - 15 - 
 
lymphomas, are associated with EBV in patients with compromised immune systems.  
This is covered in more detail in section 1.3.  There are 2 sub-types of EBV; EBV-1 and 
EBV-2.  The major differences between the sub-types are in the nuclear protein genes 
EBNA2, EBNA3A, EBNA3B and EBNA3C which vary between the strains by 16% - 
47%  in protein sequence (Sample et al., 1990). EBV-1 is more efficient at transforming 
B-cells in vitro and is the more prevalent sub-type in most populations.  However the 
incidence of EBV-2 is increased in populations with endemic Burkitt’s lymphoma 
including equatorial Africa and New Guinea (Young et al., 1987). 
 
1.2.3 EBV Structure 
EBV has a double-stranded DNA core within an icosahedral nucleocapsid, surrounded 
by a protein tegument and encased in an outer envelope covered in glycoprotein spikes 
(Figure 1.2).  The glycoprotein spikes include gp350/220, which is required for virus 
entry into B cells. Gp350/220 binds with high affinity to the complement receptor type 
2 (CD21, CR2) on B cells (Nemerow et al., 1987).    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: Basic structure of Epstein Barr virus and other herpes viruses 
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The EBV genome is approximately 172 kbp long and contains over 85 protein encoding 
genes (Thompson and Kurzrock, 2004), NCBI).  The genome contains terminal repeat 
regions (TR) at both ends as well as tandem internal repeat sequences (Kieff and 
Rickinson, 2007).  Upon infection the terminal repeats anneal together in the nucleus of 
the infected cell to form a viral episome.  The genome is maintained as an episome 
during the latent cycle, replicating once during each cell division.  The EBV genome 
contains 3 distinct origins of replication; the origin of plasmid replication, OriP, is 
utilised during episome replication.  During the replicative lytic cycle, the origin of lytic 
replication, oriLyt, is used for rolling circle replication. There are 2 copies of oriLyt in 
most strains of EBV.  The multiple genome DNA molecules are cut into genome 
lengths at the TR and then packaged and released from the cell (Kieff and Rickinson, 
2007).  
 
 
1.2.4 EBV Infection 
Primary infection of EBV commonly occurs through salivary contact (Niederman et al., 
1976) and occurs in the tonsillar area known as the oropharynx.  In the course of 
infection, both lymphocytes and epithelial cells are infected.  However in the process of 
this infection it is unclear whether the initial infection occurs in circulating B-
lymphocytes in the lymphoepithelium of Waldeyers ring or in tonsillar epithelial cells.  
If the virus does not initially infect epithelial cells then the host epithelial membrane 
must be crossed to access B cells, either through physical wounds or leakiness from 
inflammation (Shannon-Lowe and Rowe, 2011).   
 
Lytic replication in oral epithelial cells has been observed in both oral hairy leukoplakia 
lesions from AIDS patients (Greenspan et al., 1985) and more recently in epithelial 
tongue cells in viral carriers (Herrmann et al., 2002).  However patients with B-Cell 
deficient X-linked agammaglobulinemia, who lack mature B-cells, appear to be resistant 
to EBV infection, which implies that the oral epithelial infection requires B-cell 
involvement (Faulkner et al., 1999).  In vitro experiments have shown that infection of 
epithelial cells is 1000 times more efficient when the virus is associated via gp350 to 
CD21 of a B-cell (Shannon-Lowe et al., 2006).  This demonstrates that association of 
EBV with B-cells may be important for both B-cell and epithelial infection (Shannon-
Lowe and Rowe, 2011). 
 - 17 - 
 
 
Attachment of the virus to both B-cells and epithelial cells occurs through interactions 
between different viral glycoproteins and human cell surface proteins.    
 
The EBV gp350/220 membrane glycoprotein attaches to the CD21 receptor on the B 
lymphocyte surface (Nemerow et al., 1985).  This interaction causes cross-linking of 
CD21 and a series of events including tyrosine kinase activation, increased mRNA 
synthesis and expression of IL-6 and surface CD23 (reviewed in (Thompson and 
Kurzrock, 2004). This results in delivery of the now uncoated viral genome to the 
nucleus.  Here the linear DNA circularises into an episome and the latent cycle 
commences (Figure 1.3).    
 
The EBV proteins gH and gL associate and may operate as a ligand to epithelial cells 
(Molesworth et al., 2000), although the receptor has not been identified.  In addition the 
EBV protein BMRF2 is a ligand to several integrins and appears to be important for 
infection in polarized epithelial cells (Tugizov et al., 2003).  Fusion of the viral 
envelope to both cell types requires the core fusion machinery which is composed of 
three viral proteins gH, gL and gB (Spear and Longnecker, 2003).  
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Figure 1.3: Infection of a B lymphocyte by EBV 
The glycoprotein gp350/220 binds to the cell surface receptor CD21 on the B 
lymphocyte surface.  EBV can then penetrate the cell via endocytosis and the viral 
genome circularises in the nucleus.  EBV can then establish a latent infection (A), 
expressing only a few genes including Latent Membrane Proteins (LMPs).  
Alternatively the lytic cycle program (B) leads to the production of new virions. 
This diagram was adapted from http://www2.ujf-grenoble.fr/pharmacie/laboratoires 
/gdrviro/groupedrouet/archive/2003/recherche.html 
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1.2.5 Latency 
 
1.2.6 Establishment of Latency in B cells 
For viral persistence in the host, the viral genome must be maintained in host cells that 
avoid death and evade immune responses while activating cellular proliferation 
pathways (Thompson and Kurzrock, 2004).  The actions of the genes expressed after 
infection increase host cell survival and proliferation. These circumstances could 
contribute to the association of EBV and cancer.  Infected B-lymphocytes are triggered 
to proliferate, entering S-phase 24 - 48 hours post infection (Rowe, 1999). 
 
In a similar manner to other herpesviruses, EBV maintains a lifelong infection in the 
host cell.  One or more episomal copies of the viral genome are maintained in the 
nucleus.  As the host cell replicates, the episomes also replicate once each cell division, 
using the host cell machinery.  This period of the viral lifecycle is called latency.  At 
this stage there is a much restricted pattern of viral gene expression.  The genes 
involved are listed below: 
 
6 EBV Nuclear Antigens (EBNA 1, 2, 3A 3B, 3C and LP) 
3 Latent Membrane Proteins (LMP 1, 2A, 2B) 
2 small non-coding EBV RNAs – (EBER 1 and 2) 
Bam HI-A rightward transcripts - (BARTs)   
27 micro-RNAs (miRNAs) 
(Swaminathan, 2008) 
 
There are 4 distinct patterns of EBV latent gene expression observed in infected 
lymphocytes, with a subset of the genes expressed in different cells and malignancies.  
Quiescent memory B-cells express a latency 0 profile.  The non-protein-coding genes 
are expressed in latency 0 but the 9 protein-coding latent genes are not (Table 1.4).  The 
other 3 expression profiles, latency I, II and III, are identified in cells during different 
disease states as detailed in Table 1.4. 
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 0 I II III 
Cell Type Quiescent    
B-cell 
BL HD 
NPC 
IM 
PTLD 
Promoter  Qp Qp Wp/Cp 
EBNA-1 - + + + 
EBNA-2 - - - + 
EBNA-3A, 3B, 3C - - - + 
EBNA-LP - - - + 
LMPs (LMP2A) + (LMP2A) +  + + 
EBERs + + + + 
BARTs ? + + + 
miRNAs ? + + + 
 
 
Table 1.4: Expression profiles of Latency 0, I, II and III 
Expression profiles are shown for Latency 0 (Quiescent memory B-cells), I (Burkitt’s 
Lymphoma (BL) cells), II (Hodgkin’s Disease (HD) and Nasopharyngeal Carcinoma 
(NPC) cells) and III (Infectious mononucleosis (IM) and post-transplantation 
lymphoproliferative disease (PTLD). Expression (+) of the protein / RNA or not (-) is 
shown.  Expression of BARTs and miRNAs in latency 0 is unknown. 
 
 
1.2.7 EBNAs 
EBNA1 is a phosphoprotein that binds to DNA in a sequence specific way.  It is 
required for replication and maintenance of the viral genome so is key to maintaining 
the latent infection of EBV (Middleton and Sugden, 1994). Viruses lacking a functional 
EBNA1 are unable to establish a latent infection in B-cells (Lee et al., 1999).   
EBNA1 is expressed in all three disease associated latent states, being transcribed by 
the Qp promoter in latency I and II and by the Wp and Cp promoters in latency III 
(Figure 1.5).  At the origin of plasmid replication (OriP) there are 2 EBNA1 binding 
elements, both composed of multiple 18bp EBNA1 binding sites.  The Family of 
Repeats site contains 20 EBNA1 binding sites and the dyad symmetry site contains 4 
(Wysokenski and Yates, 1989).  Binding to these sites initiates plasmid replication. The 
promoter Qp is key to maintaining levels of EBNA1 in the cell and is subject to a 
negative auto-regulation feedback system by EBNA1 binding to 2 downstream binding 
sites (Sample et al., 1992). 
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Figure 1.5: Schematic Diagram of the Latent EBV genome 
Following entry into the nucleus, the linear EBV genome forms an episome through the 
ligation of the terminal repeats (TR). Transcription of the latent membrane proteins 
LMP1, LMP2A and LMP2B are shown as black arrows. LMP2A and LMP2B are 
composed of multiple exons located either side of the TR region.  The green arrowed 
line represents transcription during latency III, when all the EBNAs are transcribed 
from either the Cp or Wp promoter.  The red arrowed line represents transcription from 
Qp during latency I and II encoding EBNA1 only. Purple arrows indicate the two 
clusters of BART miRNAs. (Diagram adapted from (Murray and Young, 2001)) 
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EBNA1 also assists EBV in immune system evasion.  A series of glycine-glycine-
alanine repeat sequences within the protein disrupt ubiquination and proteosomal 
degradation of EBNA1.  This prevents MHC class I antigen presentation of fragments 
of EBNA1 at the cell surface to the immune system. (Levitskaya et al., 1997).      
 
EBNA2, along with EBNA-LP, is one of the first genes detected upon infection of a 
primary B-cell, being detected within 12 to 16 hours of EBV infection (Alfieri et al., 
1991).  It has a key role in B-cell transformation as demonstrated by Cohen and 
colleagues with an EBV strain lacking EBNA2 that was unable to transform B-cells 
(Spear and Longnecker, 2003).   
EBNA2 is an indirect transcriptional activator of both cellular and viral genes.  Initiated 
by the promoter Wp, EBNA2 is a transcriptional activator of the Cp promoter.  The Cp 
promoter is in turn responsible for the expression of most latent EBV proteins (Young 
and Rickinson, 2004).  EBNA2 operates through interaction with transcription factors 
such as the cellular RBP-Jκ (Recombining Binding Protein suppressor of hairless) 
(Waltzer et al., 1994).  In the absence of EBNA2 , Cp activation is repressed through 
RBP-Jκ binding with a co-repressor complex, also including Histone deacetylase 1 
(HDAC1) and the ski-interacting protein (SNW1, SKIP) (Waltzer et al., 1995; Zhou et 
al., 2000).  EBNA2 interacts with the chromatin remodelling protein hSNF5/Ini1, 
disrupting the nucleosome and allowing transcriptional machinery access to the Cp 
promoter.  Cellular genes upregulated by EBNA2 include CD23, a cell surface marker 
of activated B-cells, the proto-oncogene c-myc and the EBV receptor, CD21 (reviewed 
in (Young and Rickinson, 2004)). 
 
The other gene expressed early in EBV infection is EBNA-LP (leader protein or 
EBNA5).  Together EBNA2 and EBNA-LP can push quiescent B-cells from G0 to G1 
of the cell cycle.  This is achieved by inducing cyclin-D2 (Sinclair et al., 1994) and 
possibly through interaction with p53 and Rb (Szekely et al., 1993).   EBNA-LP varies 
in size due to exon skipping, resulting in a variable number of W repeats (reviewed in 
(Rowe, 1999)). 
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The EBNA3 family is comprised of 3 proteins; EBNA3A, EBNA3B and EBNA3C.  
They are encoded by three adjacent genes in the viral genome.  All three are 
transcriptional regulators with EBNA3A and EBNA3C being critical for B-cell 
transformation (Tomkinson et al., 1993).  All three EBNA3 proteins interact with RBP-
Jκ, inhibiting binding to transcriptional targets, including inhibition of the EBV Cp 
promoter (Waltzer et al., 1996).  This has the effect of repressing EBNA2 activity.  In 
addition EBNAC3 interacts with histone deacetylase 1 (HDAC1) along with RBP-Jκ 
which results in chromatin remodelling at Cp (Radkov et al., 1999).  
 
1.2.8 LMPs 
The three latent membrane proteins, LMP1, LMP2A and LMP2B are transmembrane 
proteins.     
LMP1 contains 6 transmembrane domains and a cytoplasmic tail.  It is essential for the 
proliferation of EBV infected B-cells (Kilger et al., 1998).  LMP1 is a constitutively 
active receptor that mimics CD40 in a ligand-independent manner (Gires et al., 1997).  
CD40 is an important cell surface marker for B-cells that have been activated by 
antigen, with roles in proliferation and differentiation.  Two regions in the cytoplasmic 
tail of LMP1 bind to members of the tumour necrosis factor (TNF) receptor activated 
family (TRAFs) and to TNF receptor activated death domain protein (TRADDs).  As 
LMP1 lacks kinase activity these proteins act as adaptor proteins to activate the NFκB 
signalling pathway (Huen et al., 1995).  The transcription factor NFκB has a key 
cellular role in the regulation of cell growth and apoptosis. It can induce expression of 
cytokines including lymphotoxin, an autocrine growth factor for transformed B-cells by 
binding to the respective promoter (Thompson et al., 2003).  In addition LMP1 
influences other signalling pathways, including the JAK/STAT pathway which can be 
activated by LMP1 interacting with JAK3 (Gires et al., 1999).  LMP1 also exhibits the 
ability to inhibit apoptosis through elevation of Bcl-2 levels (Rowe et al., 1994).  
Through a combination of these actions LMP1 is closely implicated in oncogenesis with 
EBV in latency II and III such as Hodgkin’s Disease and Nasopharyngeal carcinoma. 
 
The gene LMP-2 encodes the two proteins, LMP-2A and LMP-2B, which are not 
essential for B-cell immortalisation (Rochford et al., 1997).  The 2 proteins differ in the 
NH2-terminal domain.  Exon 1 LMP-2A contains a 118 amino acid cytoplasmic 
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domain, containing an immunoreceptor tyrosine-based activation motif.  This domain is 
missing from LMP-2B.  This domain of LMP-2A is functional in the prevention of 
activation of the lytic cycle by inhibiting the signal transduction from immunoglobulin 
cross-linking of the B-cell receptor (Fruehling and Longnecker, 1997).  This effect may 
be modulated by LMP-2B, although the exact role of LMP-2B is unclear. 
 
1.2.9 EBERs 
EBER1 and EBER2 are non-polyadenylated, non-coding RNAs of 167 and 172 
nucleotides and are found in all stages of latency (reviewed in (Thompson and 
Kurzrock, 2004).  They are the most abundant RNAs in most EBV cells, often with 
more than 5x106 copies per cell (Lerner et al., 1981).  The EBERs have been shown in 
vitro to bind to the cellular Protein kinase R (PKR) and inhibit its activity in 
translational inhibition and apoptosis (Clarke et al., 1990).  However it is unclear if this 
effect is replicated in vivo, mainly as EBERs are localised to the nucleus and PKR is 
cytoplasmic.  EBERs interact with the autoantigen La and ribosomal protein L22.  La 
enhances the stability or translation of mRNAs and L22 forms part of the large 
ribosomal subunit which binds RNA.  EBER binding to these proteins causes nuclear 
sequestering, however there is not significant depletion of L22 from the ribosomes and 
La levels also remain high (Swaminathan, 2008).  Komano and colleagues have shown 
that both EBERs can confer apoptotic resistance via bcl-2 induction in Burkitt’s 
lymphoma cells, promoting their survival (Komano et al., 1999).  It is possible that 
EBERs act as a transcriptional regulator to protect EBV under in vivo stress conditions 
(Swaminathan, 2008).  The precise role of these RNAs in EBV latency is not yet clear 
but the ubiquitous expression and evolutionary conservation suggest an important 
function.   
 
1.2.10 BARTs 
BamHI-A rightward transcripts (or complementary strand transcripts) are spliced RNAs 
with a common 3’ open reading frame and a poly-adenylation site.  They are present in 
many EBV infections and especially prevalent in NPC cells.  It is unclear if protein 
products of these transcripts exist. Predicted products can modulate both RBP-Jκ and its 
interaction with EBNA-2 and the Notch pathway through RAK (Smith et al., 2000; 
Zhang et al., 2001). 
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1.2.11 miRNAs 
Micro RNAs (miRNAs) are small non-coding RNAs approximately 22 nucleotides 
long. MiRNAs modulate translation by inhibiting translation or promoting degradation 
of mRNAs through incorporation into a RNA-inducing silencing complex (RISC) as 
well as binding directly to complementary sequences in the genome (reviewed in 
(Bartel, 2004)).   
In EBV, miRNAs are encoded in the BamHI A region of the genome (BART miRNAs) 
and from the BamHI H region (BHRF1 miRNAs). Expression or miRNAs varies 
markedly between cell types.  In NPC cells BART miRNAs are strongly expressed, 
while BHRF1 miRNAs are not detected.  Transformed B cells preferentially express 
BHRF1 miRNAs.  In latency III under Cp or Wp promoter activity BHRF miRNAs are 
thought to originate from splicing of the EBNA transcripts (Swaminathan, 2008).  
Possible targets of the EBV miRNAs include IFN-inducible T-cell attracting chemokine 
CXCL-11 which may result in host inhibition of the interferon response (Xia et al., 
2008).  In addition the miRNAs may target at least 2 EBV genes, BALF5 and LMP1 
(Swaminathan, 2008).  
 
1.2.12 Latency Types 
In a healthy EBV carrier there is a low stable proportion of infected B-lymphocytes of 
about 1-50 in 106 cells (Wagner et al., 1992).  These cells are in latency 0 and express a 
highly restricted range of latent viral genes.  In order to achieve this state, a newly 
infected B-lymphocyte must progress through different stages of latent gene expression 
as shown in Figure 1.6.  This mimics the activation of B-cells by antigen, also resulting 
in production of memory B-cells (reviewed in (Thorley-Lawson and Gross, 2004). 
 
After EBV infection or antigen activation, B-cells cluster at the germinal centre of the 
lymph nodes where proliferation and differentiation occur (Macsween and Crawford, 
2003).  Upon initial infection, EBV initiates a latency III or growth pattern of gene 
expression, during which all the latent genes are expressed (Table 1.4).  This induces 
cell proliferation and induction of the B-cell activation markers including CD23.  EBV 
has the ability to transform or immortalise B-lymphocytes so that they continue to 
proliferate, expanding the pool of circulating EBV positive memory B-cells. EBNA-2, 
EBNA-3A, EBNA-3C and LMP1 are essential for transformation. 
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Figure 1.6: Steps in establishment and maintenance of EBV infection in B-cells 
Naive B-cells are infected by EBV and activation of the latency III program activates 
cells to become proliferating lymphoblasts.  In the germinal centre differentiation under 
latency II occurs to produce a memory B-cell.  During replication of the memory B-cell 
a switch to latency I occurs, expressing EBNA1 to enable replication of the viral 
episome. (adapted from (Thorley-Lawson and Gross, 2004))  
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An antigen activated B-cell in the germinal centre is protected from apoptosis by the 
action of antigen-specific helper T-cells. To avoid apoptosis, an EBV infected cell must 
substitute these rescue signals by the action of genes expressed during latency II.  This 
pattern of expression of EBNA1 and the LMPs is also seen in Hodgkin’s disease and 
nasopharyngeal carcinoma.   
On exit from the germinal centre and entry into the peripheral circulation, expression of 
all protein coding genes is shut down.  During the occasional division of an EBV 
positive memory B-cell, a latency I pattern of expression is enacted to express EBNA1 
and allow concerted replication of the episome.  Latency I is also observed in Burkitt’s 
lymphoma cells (Niedobitek et al., 1995).  
 
1.3 EBV Associated diseases 
EBV was first discovered through association with Burkitt’s lymphoma and has since 
been linked with several other diseases and cancers (Figure 1.7).  In order for EBV to be 
oncogenic it must fulfil four criteria; 
i. Maintain viral genome in host cell 
ii. Not destroy the cell 
iii. Prevent cell from becoming a target of the immune system 
iv. Activate cellular growth pathways 
  
A person is vulnerable to EBV associated malignancies when the host immune system 
is suppressed such as in patients with AIDS or immunosuppression following organ 
transplantation. 
 
  
 
  
 
-
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Figure 1.7: Diagram of Cancer development and EBV 
Modified from (http://info.cancerresearchuk.org/cancerstats/causes/infectiousagents/epsteinbarrvirus/) 
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1.3.1 Infectious Mononucleosis 
Infectious mononucleosis (IM) or glandular fever is normally caused by delayed 
primary EBV infection of adolescents and young adults.  It is characterised by fever, 
pharyngeal inflammation and enlarged lymph nodes and spleen.  IM is rare in the 
developing countries as primary infection in these areas occurs almost universally in 
early childhood.   A causative link to EBV was established in 1968 (Henle et al., 1968).   
In IM, as in normal primary infection, EBV infected cells proliferate, progress through 
the germinal centre and mature into memory B-cells.  During IM up to 50% of the 
memory B-cells may be infected with EBV (Hochberg et al., 2004).   
The immune response in IM is characterised by an increased proportion of lymphocytes 
(lymphocytosis), in particular CD8+ cytotoxic T cells.  This enables lysis of  infected B-
cells but is also responsible for IM symptoms due to the release of high levels of 
cytokines including IL2 and INFγ (Foss et al., 1994).  There is a correlation between the 
level of T cell activation and clinical severity of IM (Williams et al., 2004).  During this 
initial phase of infection B-cells display a latency III gene expression profile. This is 
followed by latency II expression, which produces a much lower immune response in 
the patient (Williams and Crawford, 2006). 
 
In most cases symptoms diminish after 4-6 weeks but relapses can occur for up to 12 
months.  During this period the level of EBV+ memory B cells may remain higher than 
in a normal carrier (Vetsika and Callan, 2004).     
 
1.3.2 X-linked lymphoproliferative disease 
X-linked lymphoproliferative disease (XLP) is a rare X-linked genetic condition with a 
mutation in the gene Signalling Lymphocytic Activation Molecule (SLAM) - 
Associated Protein (SAP) (Sayos et al., 1998).  SAP is a cytoplasmic signal 
transduction molecule that is expressed in activated T cells and NK cells.  The 
transmembrane glycoprotein SLAM, which is member of the Ig superfamily, is 
expressed on T, B and dendritic cells.  Levels are upregulated on activated CD4+ and 
CD8+ T cells and binding by specific antibody leads to proliferation of T cells and 
production of cytokines including INFγ (Garcia et al., 2001).  Binding of SAP to SLAM 
inhibits production of INFγ.  An absence of functional SAP results in deregulation of 
the host immune response to viral infection.  XLP patients develop severe and often 
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fatal IM-like responses to EBV infection with an uncontrolled proliferation of cytotoxic 
T cells, resulting in hepatic necrosis and bone marrow failure (reviewed in (Williams 
and Crawford, 2006)).     
1.3.3 Post Transplant Lymphoproliferative disease 
Post Transplant Lymphoproliferative disease (PTLD) is a proliferation of B-
lymphocytes which may occur following organ transplantation.  To ensure immune 
acceptance of the transplanted organ the cytotoxic T cell response of host immune 
system is suppressed by drugs.  The lack of a complete T cell response to EBV infection 
allows abnormal proliferation of EBV+ B lymphocytes, normally expressing a latency 
III type infection (reviewed in (Williams and Crawford, 2006)).  This often presents as a 
single clonal lesion.  The level of immunosuppression the patient receives is a major 
risk factor for PTLD.  As this varies with the type of organ transplanted,  the incidence 
of PTLD varies widely (Williams and Crawford, 2006).  PTLD can occur in up to 33% 
of patients who have received a multi-organ transplant but less than 1% of stem cell 
transplant recipients.  50% of PTLD occurs as a result of primary EBV infection and 
this is more common in children as they are more likely to be EBV naive at 
transplantation (Ho et al., 1985).  A similar tumour is seen in late-stage AIDS patients 
who have lost T cell control due to HIV infection. 
 
1.3.4 Nasopharyngeal carcinoma 
Nasopharyngeal carcinoma (NPC) is a tumour arising from squamous epithelial cells in 
the post-nasal space.  It has a high incidence in South East Asia and a moderate 
incidence in Southern and Northern Africa and Polynesia but is rare elsewhere in the 
world.  There is also an increased prevalence in some populations including the Inuit 
population of North America and Greenland (Jemal et al., 2011).  70% of NPC tumours 
are composed of undifferentiated cells and all these carcinomas are associated with 
EBV, demonstrating a type II latency pattern.  LMP1 is potentially important in NPC 
development as it is expressed in most NPC cells, can inhibit differentiation of 
squamous epithelium and can induce tumours in animal models (reviewed in (Crawford, 
2001)).  Genetic and environmental factors are also considered to be important in NPC 
development (Chang and Adami, 2006). 
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1.3.5 Hodgkin’s Lymphoma 
Hodgkin’s Lymphoma (HL) is characterised by the presence of large multinucleate 
Hodgkin and Reed-Sternberg (HRS) cells.  It is the most common lymphoma in young 
people and there is a 3 fold increased risk of HL with a history of IM (Gutensohn and 
Cole, 1980).  EBV is found in about 50% of HL cases in Western countries with a 
higher association in some developing countries (reviewed in (Crawford, 2001).  The 
EBV genome is found in a subset of HRS cells, which express high levels of LMP1 in a 
latency II pattern.  HRS cells originate from germinal centre B cells with Ig gene 
rearrangements and defective Ig transcription (Marafioti et al., 2000).  The presence of 
high levels of LMP1 may provide additional cellular proliferation and apoptosis 
resistance signals.  The EBV genomes in HRS cells are monoclonal which suggests that 
EBV infection is an early event in development of the tumour (Anagnostopoulos et al., 
1989). Although there is evidence for an oncogenic role for  EBV in HL the details are 
still unclear.       
1.3.6 Burkitt’s Lymphoma 
Burkitt’s lymphoma is an aggressive lymphoma with two types; endemic with EBV 
present and sporadic with an inconsistent association with EBV.  Almost all BL 
tumours arising in Africa are endemic BL containing EBV but only approximately 20% 
of tumours in North America and Europe contain EBV (Crawford, 2001).  Generally the 
EBV genome is found in the form of multiple nuclear episomes and in some instances 
with chromosomal integration.  The genomes are clonal suggesting EBV infection 
occurs early in carcinogenesis.  The only EBV gene expressed is EBNA1, along with 
EBERs, suggesting a latency I profile.  Although the carcinogenic potential of this 
expression is questionable, lymphoid tumours have developed in EBNA1 transgenic 
mice (Wilson et al., 1996) and bcl-2 induction by EBERs may provide an anti-apoptotic 
advantage (Komano et al., 1999). 
BL tumours all demonstrate one of three chromosomal translocations which brings the 
oncogene c-myc under the control of an Ig gene, resulting in constitutive expression.  
BL incidence is geographically associated with malarial regions.  This may be due to 
continuous B-cell activation by chronic malaria infection which leads to a large number 
of EBV+, proliferating B-cells.  This provides greater opportunity for a critical 
oncogenic translocation to occur.  The translocations are different in endemic and non-
endemic BL but it is not known if EBV has any causative effect on endemic 
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translocation (reviewed in (Thompson and Kurzrock, 2004)).   The Akata Burkitt’s 
lymphoma cell line is able to induce tumours in mice.  However if EBV is lost from the 
Akata cell line it is not able to induce these tumours and decreased growth is observed.  
If Akata cells are re-infected with EBV, induction is re-established (Shimizu et al., 
1994).     
1.4 Lytic Cycle 
In common with other herpesviruses, the infection strategy of EBV consists of life-long 
latency in the host, punctuated at intervals by reactivation of the lytic cycle in a small 
proportion of the latently infected cellular population.  This type of replication is needed 
for infection and propagation of the virus.  Lytic reactivation probably occurs in latently 
infected memory B-cells that differentiate further as a response to antigen stimulation 
via binding to B-cell receptor (BCR) or as a result of stress (Amon and Farrell, 2005).  
The lytic cycle proceeds via staged expression of viral proteins, resulting in the 
production of infectious virions that enable the EBV genome to be transmitted to new 
hosts.  The highly regulated reactivation process is initiated by the immediate early (IE) 
gene BZLF1 (Rooney et al., 1989), which expresses Zta (Z, Zebra, EB1).  Zta is 
essential for the reactivation of EBV from latency as cells with a BZLF1 knockout virus 
are unable to reactivate the lytic cycle (Feederle et al., 2000).  In addition transfection 
with short interfering RNA (siRNA) directed against BZLF1 renders cells defective in 
reactivation (Chang et al., 2004).  Zta auto-activates the Zta promoter (Zp) as well as 
the Rta promoter (Rp) of the BRLF1 gene (Feederle et al., 2000).  These two IE 
transcriptional transactivators co-operate to push the transition from latency to lytic 
cycle, triggering a gene expression cascade of over 80 EBV genes (Kenney et al., 1989; 
Takada and Ono, 1989).  The early genes encode proteins responsible for initiating viral 
DNA replication and include the viral DNA polymerase.  This is followed by the 
expression of late genes which encode nucleocapsid and virion structural proteins.  As 
EBV virions are shed from the host cell by budding, the lytic cycle does not necessarily 
lead to lysis of the host cell.  Serological evidence has suggested that prior to the onset 
of NPC, Burkitt’s lymphoma and Hodgkin’s disease, there is reactivation of EBV lytic 
replication (Mueller et al., 1989; Chan et al., 1991) which suggests that the lytic cycle 
may contribute to the development of some EBV-associated diseases (Israel and 
Kenney, 2005). 
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The following section focuses on the structure and function of Zta, the product of the 
immediate early gene BZLF1.  
 
1.4.1 Zta Structure 
Zta is a member of the leucine zipper family of transcription factors (reviewed in 
(Sinclair, 2003).   
Zta is a 245 amino acid protein, comprised of four distinct functional domains; an N-
terminal transactivation domain, a basic DNA contact domain, a coiled-coil (zipper) 
dimerisation domain and a unique C-terminal domain (Figure 1.8A).  The central basic 
and zipper domains form a long α-helix. This 35kDa protein operates as a homodimer in 
vivo.   
 
The crystal structure of Zta bound to DNA has been determined (Petosa et al., 2006) 
(Figure 1.8B).  This reveals that unlike other bZip proteins, the C terminal domain folds 
back in an anti-parallel direction to the α-helix and interacts with the zipper domain.  It 
is probable that this interaction has a stabilising effect on dimerisation and so is 
important for the function of Zta (Petosa et al., 2006; Sinclair, 2006).  The nine extreme 
C terminal amino acids are missing from the crystal structure so the full extent of the 
interaction is yet to be determined.   
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Figure 1.8: The structure of Zta 
A shows a cartoon with  the four domains of Zta, operating as a homodimer and in 
association with DNA (yellow).  B shows the crystal structure of Zta, bound to a ZRE 
(Petosa et al., 2006)  This model does not include the N-terminal transactivation domain 
or the 9 extreme C-terminal residues. 
 
 
 
Leucine zipper family members include C/EBPα, GCN4 and the transforming proteins 
c-fos, c-jun and c-myc.  Alignment of these proteins shows a shared region of structural 
homology, composed of a leucine residue every seven amino acids (Landschulz et al., 
1988). The leucine zipper motif is a super-secondary structure that forms the basis of 
the dimerisation domain for these proteins, which all interact with DNA as homo or 
heterodimers.  The heptad repeat of leucine residues forms a hydrophobic core for a 
coiled-coil structure (O'Shea et al., 1989).  All these transcription factors also contain a 
Transactivation Domain
Basic Domain
Zipper Domain
CT Domain
A
B
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basic DNA contact domain adjacent to the coiled-coil zipper and so are termed bZIP 
proteins.  A third common domain is the transactivation domain.   
 
Although Zta contains coiled-coil zipper, basic DNA binding and transactivation 
domains, it differs from canonical bZIP proteins due to a lack of the heptad repeat of 
leucine residues.  These positions are substituted by other hydrophobic amino acids.  
The resulting strength of the coiled-coil is weaker than in other bZIP proteins (Hicks et 
al., 2001).   
 
1.4.2 Regulation of the BZLF1 promoter (Zp) 
Zta is produced from either a monocistronic 0.8 kb mRNA transcript controlled by the 
BZLF1 promoter or a 2.9 kb transcript controlled by the BRLF1 promoter (Figure 1.9).  
The larger bicistronic transcript contains 2 open reading frames and encodes both Zta 
and Rta proteins (Manet et al., 1989; Sinclair et al., 1991).  BRRF1, an early gene, is 
also located in this region and is transcribed in the opposite direction from a separate 
promoter (Figure 1.9). 
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Figure 1.9: Diagram of the two BZLF1 mRNA transcripts in the EBV genome 
BZLF1 is transcribed from either Zp as a 0.8kb monocistronic mRNA or from Rp as a 
2.9kb bicistronic mRNA, that also encodes BRLF1. The 3 promoters, Zp, Rp and 
BRRF1p within the immediate early gene region are shown. (not drawn to scale) 
Adapted from (Rooney et al., 1989) and www.ncbi.nlm.nih.gov 
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Initial activation of the lytic cycle occurs through expression of Zta through the BZLF1 
promoter Zp.  The EBV lytic cycle can be chemically induced by several methods in 
EBV positive cell lines, including phorbol esters, (e.g. TPA), IgG, transforming growth 
factor β1 (TGFβ1) and HDAC inhibitors.  
 
The B-cell receptor (BCR) is activated via cross-linking of surface IgG which leads to 
an increase in cytosolic calcium concentration, following a release of calcium from the 
endoplasmic reticulum (reviewed in (Scharenberg et al., 2007).  This results in the 
activation and nuclear localisation of cellular transcription factors, inducing Zp to 
express Zta (Daibata et al., 1990; Speck et al., 1997).   
 
Several host cell factors regulate Zp, acting through multiple cis-acting elements (Figure 
1.10A).  There are 4 types of binding elements, ZI, ZII, ZIII and ZV.  ZI sites A-D are 
negative regulatory elements in the absence of a lytic cycle signal (Flemington and 
Speck, 1990c). MEF2D, SP1 and Sp3 bind to the ZI binding sites (Liu et al., 1997a; Liu 
et al., 1997b).  Histone deacetylase complexes are recruited to MEF2D in latently 
infected B-cells, resulting in transcriptional repression (Gruffat et al., 2002).  Under 
some conditions, e.g. TPA addition, the ZI sites can act as positive regulators 
(Flemington and Speck, 1990c).   
 
The ZII site in Zp binds multiple factors including CREB, c-jun, ATF1/2 and C/EBPα 
(Flemington and Speck, 1990c; Wang et al., 1997; Adamson et al., 2000; Wu et al., 
2004).  In contrast to the ZI sites, the ZII site is essential for Zp activation (Flemington 
and Speck, 1990c; Daibata et al., 1994).  However in the presence of Zta, ZII is 
dispensable and Zp is auto-regulated through the Zta binding sites, ZIIIA and ZIIIB 
(Flemington and Speck, 1990a).  This suggests that activation of Zp occurs in two 
stages; firstly transactivation by cellular transcription factors at ZI and ZII results in a 
low level of Zta expression and secondly newly expressed Zta binds to ZIII sites.  This 
results in a higher level of Zta expression and activation of the lytic cycle (Flemington 
and Speck, 1990a).     
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The ZV motif, which is located close to the transcription start site, binds the zinc finger 
protein ZEB and is a strong negative regulator of Zp activation.  Binne et al showed that 
deletion of ZV greatly increased the promoter activation following IgG cross-linking 
(Binne et al., 2002).      
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Figure 1.10: cis-acting elements and transcription factors of IE promoters Zp and 
Rp  
A. The BZLF1 promoter, Zp, contains ZI, ZII and ZIII cis-acting elements.  An 
additional element, ZV, inhibits transcription from the promoter in uninduced cells.  
MEF2D-HDAC, SP1 and Sp3 bind to the ZI binding sites.  The ZII element binds 
multiple factors and is essential for promoter activation in the absence of Zta.  Zp is 
auto-regulated through the 2 ZIII Zta binding sites.   B. The BRLF1 promoter, Rp, 
contains 3 Zta Response Elements (ZREs) as well as Sp1/Sp3 and EGR-1 binding sites.  
Negative regulation can occur through 2 YY1 sites.  
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1.4.3 Regulation of the BRLF1 promoter (Rp) 
The essential second step in reactivation of EBV from latency by Zta is activation of 
another immediate early transcription factor, Rta (Figure 1.10B).  This occurs through 
Zta interaction with three Zta Response Elements (ZREs) in the Rp promoter; ZRE1, 
ZRE2 and ZRE3.  Both ZRE2 and ZRE3 contain CpG motifs, which are very likely to 
be methylated during the latent phase in vivo (Robertson and Ambinder, 1997; Tao and 
Robertson, 2003).  Zta has demonstrated the novel ability to selectively bind methylated 
response elements (Bhende et al., 2004).  CpG containing ZREs may only be 
recognised when methylated or binding is enhanced, while binding to non CpG ZREs is 
not influenced by methylation status.  In addition Rp contains several important 
Sp1/Sp3 binding sites which are required for constitutive activity (Zalani et al., 1992; 
Ragoczy and Miller, 2001).  BCR cross-linking and TPA induction both result in 
increased levels of EGR-1 (Krappmann et al., 2001) and Rp contains two EGR-1 
binding sites (Zalani et al., 1995).  This suggests that EGR-1 may regulate expression of 
Rp.  Negative regulation of Rp occurs through two YY1 binding sites (Zalani et al., 
1997).     
 
1.4.4 Zta as a transcription factor (viral and cellular) 
The α-helical DNA binding domain of Zta comprises the mostly basic amino acids 172 
to 198 (Packham et al., 1990; Petosa et al., 2006).  As Zta is required to form a 
homodimer to bind DNA, the adjacent dimerisation domain is also important for 
binding function (Hicks et al., 2003).   As described in section 1.4.1, Zta differs from 
other bZip proteins due to a lack of leucine residues in the coiled-coil (Kouzarides et al., 
1991) and it possesses a unique CT domain that folds back and stabilises the 
dimerisation domain (Petosa et al., 2006).  This unusual structure of Zta may permit it 
to recognise a wider range of DNA binding sites than other bZIP proteins (Farrell et al., 
1989; Lieberman et al., 1990; Sinclair, 2006).  The shorter dimerisation domain present 
in Zta may allow greater flexibility in the homodimer (Petosa et al., 2006; Schelcher et 
al., 2007).  The residues that directly contact DNA during binding are almost identical 
in c-Fos, c-Jun and Zta and are analogous to the Zta amino acids 182, 185, 186, 189 and 
190 (Glover and Harrison, 1995).  The exception is amino acid 186 which is a serine in 
Zta and an alanine in c-Fos and c-Jun.  Mutation S186A in Zta results in a mutant that 
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cannot bind selected ZRE sites, for example in Rp, but retains binding ability to Ap1 
sites and other ZREs (Francis et al., 1997; Adamson and Kenney, 1998).  This residue is 
important for Zta recognition of a broad range of binding sites.          
 
ZRE motifs are found in the promoters of many early EBV genes (Urier et al., 1989; 
Flemington and Speck, 1990a).  When two or more ZREs are located in a promoter, the 
effect on transactivation is synergistic (Carey et al., 1992).  Zta is also able to facilitate 
a transcription favouring DNA conformation by interacting directly with histone 
acetylating complexes such as CBP and p300 to acetylate chromatin (Adamson and 
Kenney, 1999; Zerby et al., 1999).  Zta interacts with the transcription factor C/EBPα to 
form a stable complex that is capable of activating promoters, including Zp, through 
binding to C/EBPα binding sites (Wu et al., 2004).   
 
ZREs within the human genome are common and Zta can exert a transcriptional effect 
on host cell genes.  Affected genes include c-fos (Flemington and Speck, 1990b), IL-10 
(Mahot et al., 2003), TGF-β (Cayrol and Flemington, 1995), tyrosine kinase TKT (Lu et 
al., 2000) and matrix metalloproteinases 1 and 9 (Yoshizaki et al., 1999; Lu et al., 
2003).  The immunosuppressive cytokines IL-10 and TGFβ may be induced by Zta to 
suppress host cell immune response (Israel and Kenney, 2005).  The function in EBV 
persistence or transmission for other host genes activated by Zta is unclear, but 
potentially could contribute to oncogenesis (Israel and Kenney, 2005). Matrix 
metalloproteinases have been shown to play a role in metastatic spread and IL-10 is a 
growth factor for B cell tumours.  
 
1.4.5 Interaction with Cellular proteins 
Zta interacts directly with a number of cellular proteins, providing another mechanism 
for Zta to modify the cellular environment.  Like many other viruses, EBV influences 
the tumour suppressor protein p53 and this is mediated by Zta.  There have been 
conflicting reports of both activating and inhibitory effects on p53 by Zta (Mauser et al., 
2002b, Dreyfus et al., 2000).  These two distinctive, opposing methods of p53 
regulation appear to be dependent on p53 phosphorylation state, cell type and stage of 
lytic replication (Sato et al., 2010.)  p53 is transiently induced by Zta during the early 
stages of lytic replication resulting in cell cycle arrest (Cayrol and Flemington, 1996b).  
 - 41 - 
 
In the later stages of lytic replication Zta is a component in an ubiquitin ligase complex, 
targeting p53 for degradation and resulting in S-phase conditions (Sato et al., 2009).  
Zta and p53 also interact directly and over-expression of either protein inhibits the 
transactivation ability of the other (Tarakanova et al., 2007).  In a similar way, direct 
interaction between Zta and NFκB p65 results in negative regulation of Zta 
transactivation function (Gutsch et al., 1994).  Other Zta-interacting negative regulators 
include the retinoic acid receptors RXRα and RARα (Pfitzner et al., 1995; Sista et al., 
1995). 
 
 Positive regulation of Zta function occurs through an interaction with the histone 
acetylase and transcriptional co-activator CBP (Adamson and Kenney, 1999).  Zta 
interaction with the N-terminus of CBP occurs through both the transactivation and 
zipper domains of Zta.  The interaction results in the recruitment of  histone acyl 
transferases (HAT), destabilising the nucleosome structure and forming a more open 
chromatin structure for the basal transcription machinery, thus allowing transactivation 
of genes (Adamson and Kenney, 1999).  Interaction between Zta and C/EBPα leads to 
stabilisation and increased levels of C/EBPα.  In turn C/EBPα transactivates the cycle 
dependent kinase inhibitor p21, contributing to G1 cell cycle arrest (Wu et al., 2003; 
Wu et al., 2004).  
 
1.4.6 Zta and EBV replication 
In addition to functioning as a transcription factor, Zta plays a direct role as a replication 
factor, binding directly to the origin of lytic replication (oriLyt) (Schepers et al., 1996).    
 
Expression of Zta and six early genes including the EBV DNA polymerase catalytic 
subunit (BALF5) and polymerase processivity factor (BMRF1) are essential for viral 
genome replication (Fixman et al., 1992).  The other genes encode a helicase/primase 
complex (BBLF2/3, BBLF4, and BSLF1) and a DNA binding protein (BALF2).   
 
The EBV genome contains two highly related oriLyts; Left and Right, located 
approximately opposite each other on a circularised genome, within a duplicated 
segment (DS) of the genome. A separate third replication origin, oriP, is utilised for 
EBV plasmid replication during latent infection (Yates et al., 1984).  Each oriLyt spans 
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approximately 1000bp and they are essentially identical.  oriLyt is comprised of an 
upstream and a downstream component separated by approximately 400bp 
(Hammerschmidt and Sugden, 1988).  The upstream component contains four ZRE 
motifs and binding by Zta to these sites is required for replication from oriLyt (Fixman 
et al., 1992; Schepers et al., 1996).  Both the DNA binding and transactivation domains 
of Zta are required for oriLyt binding (Schepers et al., 1996).  In addition there are three 
ZREs located downstream of the downstream component but these are not essential for 
replication (Schepers et al., 1996).   
The formation of an initiation complex at oriLyt is the first step in lytic replication, 
requiring Zta binding at the upstream ZREs and binding of transcription factors ZBP-89 
and SP1 to the downstream component (Baumann et al., 1999).  Binding of Zta is 
thought to recruit other essential viral components to this complex (Gao et al., 1998), 
(reviewed in (Tsurumi et al., 2005)).  The six essential EBV replication proteins work 
together as the replication machinery at the replication fork.  Replication then proceeds 
in a two stage process, with initial replication generating two copies of the genome with 
fewer supercoils and nucleosomes (Pfuller and Hammerschmidt, 1996).  These genomes 
then provide the template for rolling circle replication, generating large head-to-tail 
DNA concatamers, which are then cleaved into genome length units for virion 
packaging (Cho and Tran, 1993).  The EBV genome is replicated 100-1000 fold during 
this process (Tsurumi et al., 2005). 
 
Zta functions in multiple ways to allow lytic replication of the EBV genome.  As a 
transcription factor, Zta induces the expression of essential EBV replicative enzymes, 
recruits these enzymes to oriLyt and provides the platform for formation of the initiation 
complex.  
 
1.4.7 The Cell Cycle 
During the course of the cell cycle DNA is replicated and division of the parent cell into 
two daughter cells occurs.  This process consists of four main phases: G1, S, G2 and M 
phases (Figure 1.11).  Non-proliferative cells are maintained in a state of quiescence 
termed G0 phase.  G1 phase is characterised by cell growth and preparation for DNA 
replication including the synthesis of required enzymes.  During S phase replication of 
DNA occurs, resulting in a doubling of cellular DNA content.  Following S phase, 
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preparation for cell division occurs during G2.  During M phase or mitosis the DNA and 
cellular components are divided into two daughter cells.   The cell cycle is regulated by 
checkpoints to ensure required conditions and components are available for continuation 
of the next phase and integrity of replicated DNA is maintained (reviewed in 
(Vermeulen et al., 2003)).  The two main checkpoints are G1/S and G2/M.  Progression 
through these checkpoints is regulated by protein phosphorylation by specific protein 
kinases.  These heterodimeric kinases are comprised of a regulatory subunit, called a 
cyclin and a catalytic subunit, called a cyclin dependent kinase (cdk).   
Progression of the cell through the G1/S checkpoint is mainly controlled by the protein 
kinases cdk 4, 6/cyclin D and cdk2/cyclin E.  Together cdk4,6/cyclin D and 
cdk2/cyclinE cause hyper-phosphorylation of Rb, resulting in dissociation from E2F.  
This frees the transcription factor E2F to initiate transcription of key S-phase-promoting 
genes required for DNA replication.  
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Figure 1.11: Cell cycle progression and Zta  
Diagram of the cell cycle and control points of the G1/S checkpoint that are influenced 
by the expression of Zta. Critical cyclin/cdk complexes for progression and DNA 
content is shown for each phase of the cell cycle.  
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1.4.8 EBV, Zta and the Cell Cycle 
EBV lytic replication is inhibited when the host cell enters S-phase so manipulation of 
the cell cycle is important to allow replication of the virus (Takase et al., 1996).  Zta has 
been shown to inhibit progression through the cell cycle via several different 
mechanisms (Figure 1.11).  Zta is able to signal via the cyclin dependent kinase 
inhibitor p21 through either a p53-dependent or independent mechanism.   Zta can cause 
cell cycle arrest at G1 via upregulation of p53.  The increased level of p53 in turn 
activates expression of p21, leading to inhibition of cdk2/cyclin E (Cayrol and 
Flemington, 1996a; Cayrol and Flemington, 1996b).  This results in a reduction of Rb 
phosphorylation and halts cell cycle progression.  In addition Zta is able to upregulate 
p21 and thus promote G1 cell cycle arrest via a p53-independent mechanism (Rodriguez 
et al., 1999).  This requires a stabilising interaction between Zta and C/EBPα and results 
in transcriptional activation of p21 (Wu et al., 2003; Wu et al., 2004).   
Zta-mediated inhibition of cdk4,6/cyclin D occurs when Zta interacts with TGFβ, 
resulting in activation of the cdk inhibitor p27 (Cayrol and Flemington, 1996b; 
Rodriguez et al., 1999).  p27 inhibits formation of cdk4,6/cyclin D, resulting in a 
reduction of Rb phosphorylation.   Zta has also been shown to directly induce 
expression of E2F and cyclin E (Mauser et al., 2002a).  The interaction of Zta with 
several different control points in the G1/S checkpoint is likely to contribute to the cell 
growth arrest function of Zta.    
Kudoh and colleagues have shown that S-phase cdks are required for viral replication 
(Kudoh et al., 2004).  They proposed that the elevation of cyclins E/A and accumulation 
of hyper-phosphorylated Rb is characteristic of post-G1/S cells and that these S-phase-
like conditions are required for EBV DNA replication (Kudoh et al., 2003; Kudoh et al., 
2004).   
The ability of Zta to cause cell cycle arrest is dependent on the cell type (Cayrol and 
Flemington, 1996a; Cayrol and Flemington, 1996b; Flemington, 2001; Mauser et al., 
2002a).  Zta demonstrates the ability to mediate cell cycle arrest at G1/S in HeLa and 
LCL cell lines and in human fibroblasts cells.  However in human keratinocytes and 
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EBV-infected gastric carcinoma cells Zta appears to instead promote cell cycle 
progression (Mauser et al., 2002a).  
In contrast to the lytic cycle, EBV encoded genes in latency have cell cycle promoting 
activity, allowing EBV to cause growth transformation upon infection of naive B 
lymphocytes (reviewed in (Flemington, 2001)). 
Residues within the basic region of Zta have been shown to be important for Zta to 
mediate cell cycle arrest and to reactivate EBV from latency (Kolman et al., 1996). This 
connection raises the possibility that the cell cycle arrest function of Zta is a 
requirement for EBV lytic cycle activation.   
Rta, which is induced by Zta, may also have an effect on the cell cycle through 
interactions with E2F and pRb (Swenson et al., 1999). 
 
1.4.9 Zta and immune response 
Zta has a key role in reducing the host cell immune response to lytic infection by EBV.  
This is exerted through several different mechanisms as detailed below.  
 
Zta is able to inhibit the expression of MHC class I on the cell surface, thus limiting the 
immune presentation of viral antigens (Keating et al., 2002).  IFN-γ is an important 
component in the host response to viral infection, inducing cellular protein with direct 
anti-viral effects (Morrison et al., 2001).  Zta can inhibit the signalling pathway of the 
cytokine IFN-γ, decreasing activation of a number of important downstream IFN-γ 
targets including CIITA, p48 and class II MHC surface expression (Morrison et al., 
2001).  This is achieved by Zta via inhibition of STAT1 tyrosine phosphorylation and 
nuclear localisation.  In addition Zta causes down-regulation of the IFN-γ receptor 
(Morrison et al., 2001).  This may also be key for promoting B cell infection as EBV 
virus produced in cells expressing MHC class II preferentially infect epithelial cells and 
virus produced in MHC class II negative cells preferentially infect B cells (Borza and 
Hutt-Fletcher, 2002). 
   
Promyelocytic leukaemia (PML) bodies are structures in the nucleus that are induced by 
expression of type I and II interferons and are thought to have an antiviral, apoptotic 
function (Bernardi and Pandolfi, 2003).  Several viruses encode proteins that disperse 
PML bodies (Chee et al., 2003) and Zta expression has also been shown to disperse 
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these structures (Adamson and Kenney, 2001).  As sumo-I modification is essential for 
the formation of PML bodies, this may in part be due to competition for sumo-I as Zta 
is sumo-modified at lysine 12 (Adamson and Kenney, 2001).       
 
Zta also inhibits expression of the receptor for tumour necrosis factor (TNF), thus 
repressing TNF cytokine signalling (Bristol et al., 2010).  As part of an immune 
response TNFα induces key inflammatory genes as well as cellular apoptosis.  However 
both these functions are abrogated in the presence of Zta (Morrison and Kenney, 2004). 
 
1.4.10 Lytic cycle Therapies 
The cause of most EBV-associated diseases is the ability of EBV to transform and 
immortalise cells promoting tumour formation, not as a result of lytic reactivation.  
However a novel approach to treat EBV malignancies is therapeutic induction of the 
lytic cycle in tumour cells (Westphal et al., 1999).  This could be achieved by 
introduction of the IE genes.  Delivery of BZLF1 and BRLF1 using adenoviruses in 
nude mice resulted in the inhibition of EBV+ tumour cells (Feng et al., 2002).  Lytically 
infected cells express viral protein kinases that are capable of converting a nucleoside 
analogue to the active form (Moore et al., 2001). This is cytotoxic as the host DNA 
polymerase is inhibited and this effect is transferred to neighbouring cells.  Induction of 
the lytic cycle in tumour cells, in conjunction with administration of the nucleoside 
analogue gancyclovir is a possible treatment for EBV positive tumours (Faller et al., 
2001; Mentzer et al., 2001).   
1.5 Lymphocryptoviruses 
EBV is a member of the lymphocryptovirus (LCV) genus, along with about 50 different 
LCVs that have been identified in both New and Old World primates (Ehlers et al., 
2010).  Many of the LCVs that have been identified in primates are closely related to 
EBV.  The in vivo infection of the related LCVs also closely resembles the natural 
history of EBV infection (Wang et al., 2001).  Asymptomatic, lifelong infection of most 
occurs in infancy and LCV-induced tumours arise in immune-suppressed primates 
(reviewed in (Wang et al., 2001)).  This identifies simian LCVs as a valuable model 
system to provide a better understanding about EBV. 
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1.6 Aims 
 
Aim 1: To investigate the effect of methylated ZREs on Zta binding and function 
including the methylation sensitive Zta mutant C189S 
 
As methylation of some Zta Response Elements is critical for Zta binding and appears 
to play an important role in viral lytic activation, I hypothesize that conformational 
differences between Zta and the methylation sensitive Zta mutant C189S are permissive 
for enhanced binding to ZREs containing a methylated CpG motif. 
 
Aim 2: To compare DNA binding specificity, lytic reactivation and the promotion of 
cell cycle arrest function of RhZta and Zta. 
 
The two related lymphocryptoviruses, EBV and Rhesus Macaque LCV, share a similar 
pathogenesis and repertoire of genes.   I hypothesize that the RhLCV protein ZtaRh is 
functionally equivalent to the EBV protein Zta, in terms of DNA binding specificity, 
lytic reactivation and the promotion of cell cycle arrest.  
 
Aim 3: To investigate how Zta and mutants of Zta interact with various host cell 
proteins.  This includes known interacting partners as well as investigating potentially 
novel Zta interactions. 
 
Interactions with a variety of viral and cellular host proteins are critical for the functions 
of Zta.  Several of these interactions occur through the zipper dimerization domain, 
which is contacted by the CT domain.  I hypothesize that alterations to the extreme CT 
of Zta reduce the ability of Zta to contact some interacting partner proteins.  
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Chapter 2      Materials and Methods 
2.1 Materials 
2.1.1 Plasmids  
Plasmid name Method Source 
pSP64-Z(L243A-F245A) Cloning Generated by Celine Schelcher 
pSP64-Zta F245A Cloning Generated by Celine Schelcher 
pSP64-Zta L243A Cloning Generated by Celine Schelcher 
pSP64-Zta N244A  Cloning Generated by Celine Schelcher 
pBabe -Z(L243A-F245A) In vitro transcription Generated by Questa Karlsson 
pBabe -Zta F245A In vitro transcription Generated by Questa Karlsson 
pBabe -Zta N244A  In vitro transcription Generated by Questa Karlsson 
pBabe-his-ZtaRh  In vitro transcription Generated by Questa Karlsson 
pBabe-his-Zta  In vitro transcription Generated by Questa Karlsson 
pBabe-Zta L243A In vitro transcription Generated by Questa Karlsson 
pcDNA3-Flag-C/EBPα In vitro transcription (Schelcher et al., 2005) 
pSP64- Zta C189S In vitro transcription (Schelcher et al., 2005) 
pSP64-Zta In vitro transcription (Hicks et al., 2003) 
pBluescript-ZtaRh  In vitro transcription 
cloning Generated by Mirjam Meyer 
pGL2- EBV∆ZRE3 Luciferase assay Generated by Questa Karlsson 
pGL2- RhLCV RhRp Luciferase assay Generated by Questa Karlsson 
pGL2-EBV Rp Luciferase assay Generated by Questa Karlsson 
pGL2-Rh+ZRE3 Luciferase assay Generated by Questa Karlsson 
pBABE Puro Transfection of cells (Morgenstern and Land, 1990) 
pBabe-Rh_LNF  Transfection of cells Generated by Questa Karlsson 
pBABE-Zta Transfection of cells (Hicks et al., 2001) 
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Plasmid name Method Source 
pBABE-Zta C189S Transfection of cells (Schelcher et al., 2005) 
pBabe-Zta_I∆∆ Transfection of cells Generated by Questa Karlsson 
pcDNA3 Transfection of cells Invitrogen 
pcDNA3-flag-BGLF4 Transfection of cells (Tarakanova et al., 2007) 
pcDNA3-flag-BMRF1 Transfection of cells Generated by Questa Karlsson 
pcDNA3-flag-NFκB p65 Transfection of cells Generated by Questa Karlsson 
pcDNA3-flag-p53 Transfection of cells Addgene 
pcDNA3-flag-RARα Transfection of cells Generated by Questa Karlsson 
pcDNA3-flag-RXRα Transfection of cells Generated by Questa Karlsson 
pmaxGFP Transfection of cells 
FACS Amaxa 
 
Table 2.1: Plasmids 
 
2.1.2 Oligonucleotides 
N.B. Primer pairs used in site directed mutagenesis (sdm) are reverse complements of 
each other so only one primer sequence is shown.  For EMSA probes the ZRE is shown 
in blue and methylated residues in red. 
 
Name Sequence (5’→3’) Method 
To create EBV 
Rp 
(a)ctgcacaccggacgcgttgtcgtcgggagata
aaagt 
(b)ctgcacaccggctcgagctttaaaaaggccgg
ctgac 
Cloning 
To create his-
ZtaRh 
(a)caccggggatccatgcatcatcatcatcatca
tatggaccccagcttgcctcctg 
(b)caccgggaattcttatataagatcttcatgga
taatgtctgg 
Cloning 
To create 
pcDNA3-flag-
BMRF1 
(a)ctgcacaccggggatccatggattataaagat
gatgatgataaaatggaaaccactcagactctccg 
(b)ctgcacaccgggaattcttaaatgagggggtt
aaaggcctg 
Cloning 
To create 
pcDNA3-flag-
NFκB p65 
(a)ctgcacaccggggatccatggattataaagat
gatgatgataaaatggacgaactgttccccct 
(b)ctgcacaccggaagcttttaggagctgatctg
actcagc 
Cloning 
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Name Sequence (5’→3’) Method 
To create EBV 
Rp 
(a)ctgcacaccggacgcgttgtcgtcgggagata
aaagt 
(b)ctgcacaccggctcgagctttaaaaaggccgg
ctgac 
Cloning 
To create his-
ZtaRh 
(a)caccggggatccatgcatcatcatcatcatca
tatggaccccagcttgcctcctg 
(b)caccgggaattcttatataagatcttcatgga
taatgtctgg 
Cloning 
To create 
pcDNA3-flag-
BMRF1 
(a)ctgcacaccggggatccatggattataaagat
gatgatgataaaatggaaaccactcagactctccg 
(b)ctgcacaccgggaattcttaaatgagggggtt
aaaggcctg 
Cloning 
To create 
pcDNA3-flag-
RARα 
(a)ctgcacaccggggatccatggattataaagat
gatgatgataaaatggccagcaacagcagctcctg
c 
(b)ctgcacaccgggaattctcacggggagtgggt
ggc 
Cloning 
To create 
pcDNA3-flag-
RXRα 
(a)ctgcacaccggctcgagatggattataaagat
gatgatgataaaatggacaccaaacatttcctgcc
g 
(b)ctgcacaccgggaattcctaagtcatttggtg
cggcg 
Cloning 
To create 
RhLCV RhRp  
(a)ctgcacaccggacgcgtcggcgtggggaaata
aaagt 
(b)ctgcacaccggctcgaggacaaaataggctgg
ctgaca 
Cloning 
AP-1 (a) gatccatgactcagaggaaaacatacg (b) cgtatgttttcctctgagtcatggatc EMSA 
oriLyt (ZRE1) (a) ccttaaagtattacacagag (b) ctctgtgtaatactttaagg EMSA 
oriLyt 1 (a)gatctaaggtattgcacagcgccc (b)gatcgggcgctgtgcaatacctta EMSA 
oriLyt 6 (a)gatcggattagtgtgccacggtga (b)gatctcaccgtggcacactaatcc EMSA 
oriLyt 7 (a)gatccgtgctctgactcatatttc (b)gatcgaaatatgagtcagagcacg EMSA 
RhLCV ZRE3 
methylated 
(a)gatccagcacacpgccpggattttgc 
(b)gatcgcaaaatccpggcpgtgtgctg EMSA 
RhLCV ZRE3 
unmethylated 
(a)gatccagcacacgccggattttgc 
(b)gatcgcaaaatccggcgtgtgctg EMSA 
ZRE1 (Rp) (a) gatctcttttatgagccattggca  (b) tgccaatggctcataaaagagatc EMSA 
ZRE2 (Rp) (a) gatcaagcttatgagcgattttat (b) gatcataaaatcgctcataagctt EMSA 
ZRE2 
methylated 
(a) gatcaagcttatgagcpgattttat 
(b) gatcataaaatcpgctcataagctt EMSA 
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Name Sequence (5’→3’) Method 
To create EBV 
Rp 
(a)ctgcacaccggacgcgttgtcgtcgggagata
aaagt 
(b)ctgcacaccggctcgagctttaaaaaggccgg
ctgac 
Cloning 
To create his-
ZtaRh 
(a)caccggggatccatgcatcatcatcatcatca
tatggaccccagcttgcctcctg 
(b)caccgggaattcttatataagatcttcatgga
taatgtctgg 
Cloning 
To create 
pcDNA3-flag-
BMRF1 
(a)ctgcacaccggggatccatggattataaagat
gatgatgataaaatggaaaccactcagactctccg 
(b)ctgcacaccgggaattcttaaatgagggggtt
aaaggcctg 
Cloning 
ZRE3 (Rp) (a) gatctcaaaattcgcgatgctata (b) gatctatagcatcgcgaattttga EMSA 
ZRE3 me(0) (a) gatctcaaaattcgcgatgctata (b) gatctatagcatcgcpgaattttga EMSA 
ZRE3 me(1’) (a) gatctcaaaattcgcpgatgctata (b) gatctatagcatcgcgaattttga EMSA 
ZRE3 me(-1’) (a) gatctcaaaattcpgcgatgctata (b) gatctatagcatcgcgaattttga EMSA 
ZRE3 me(1’, 0)  (a) gatctcaaaattcgcpgatgctata (b) gatctatagcatcgcpgaattttga EMSA 
ZRE3 me(-1’, -
2) 
(a) gatctcaaaattcpgcgatgctata 
(b) gatctatagcatcpgcgaattttga EMSA 
ZRE3 me(-1’, -
2, 1’, 0)  
(a) gatctcaaaattcpgcpgatgctata 
(b) gatctatagcatcpgcpgaattttga EMSA 
ZRE3 me(-2) (a) gatctcaaaattcgcgatgctata (b) gatctatagcatcpgcgaattttga EMSA 
ZREIIIB (a) gtacattagcaatgcctg  (b) caggcattgctaatgtac  EMSA 
BBLF2/3 (a)ctggcatcctccgagtctt  (b)cgagttcatcctgggctt QPCR 
BHLF1 (a) gggacactgcactaccgcca (b) cgccaggaaccccggctg QPCR 
BLLF1 (a)agaatctgggctgggacgtt (b)cgagatacaatgcgacca QPCR 
BRLF1 (a) cagaaagtcttccaagccatcc  (b) caaacagacgcagccatgag  QPCR 
BZLF1 (a) ctatcaggacctgggagggc  (b) cacagcacacaaggcaaagg  QPCR 
L32 (a) caacattggttatgcaagcaaca  (b) tgacgttgtggaccaggaact  QPCR 
LMP1 (a)aagaaggccaaaagctgc (b)ctgttcatcttcgggtgc QPCR 
Β-globin 
Forward 
(a)ggcaaccctaaggtgaaggc 
(b)ggtgagccaggccatcacta QPCR 
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Name Sequence (5’→3’) Method 
To create EBV 
Rp 
(a)ctgcacaccggacgcgttgtcgtcgggagata
aaagt 
(b)ctgcacaccggctcgagctttaaaaaggccgg
ctgac 
Cloning 
To create his-
ZtaRh 
(a)caccggggatccatgcatcatcatcatcatca
tatggaccccagcttgcctcctg 
(b)caccgggaattcttatataagatcttcatgga
taatgtctgg 
Cloning 
To create 
pcDNA3-flag-
BMRF1 
(a)ctgcacaccggggatccatggattataaagat
gatgatgataaaatggaaaccactcagactctccg 
(b)ctgcacaccgggaattcttaaatgagggggtt
aaaggcctg 
Cloning 
EBV 
polymerase 
(BALF5) 
(a)agtccttcttggctagtctgttga 
(b)ctttggcgcggatcctc 
QPCR 
(Gallagher 
et al., 
1999) 
To create BZta 
(a)cgggtggcttccagaaaatgccgggccaggtt
taagaatctgctgcagcactaccgtgaggtggctg
c 
sdm 
To create CTZta 
(a1)gttgactccattatcccccggacaccagata
ttatccacgaggatctcttaaatttctaactcccg 
(a2)ccggacaccagatattatccacgaggatctc
atataactcccgttattgaaaccacgcctgcttc 
sdm 
To create 
pBabe-Rh_LNF  
(a)ccggacaccagacattatccatgaagatcttt
taaatttctaagaattcgccagcacagtggtcgac
cctg 
sdm 
To create 
pBabe-Zta_I∆∆ (a)cacgaggatctcatataattctaactcccg sdm 
To create 
pGL2- 
EBV∆ZRE3 
(a)ctggtttatagcaccgtcaattttgactgca 
 
sdm 
To create pGL2 
-Rh+ZRE3 (a)cgacccagcacatcgcaattttgcctgcaat sdm 
To create 
ZipZta 
(a1)gccgggccaggtttaagaatctgctgcagca
ctaccgtg 
(a2)gccaaatcatctgaaaatgacaggctgcgca
tcctgatgaagcagatgtgcccaagcctggatgtt
gac   
(a3)ccaaatcatctgaaaatgaaaggctgcgcat
cctgatgaagc 
sdm 
 
Table 2.2: Oligonucleotides 
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2.1.3 Buffers 
 
Buffer Composition Method 
Sample loading 
buffer (6X) 
0.25% (w/v) Bromphenol blue, 0.25% (w/v) 
xylene cyanole FF, 40% (w/v) sucrose (Sigma) Agarose gel 
TBE 
 
0.89M Tris-Borate, 20mM Na2EDTA, pH 8.3 
(Fisher) 
Agarose gel 
EMSA 
Calcium Chloride 3M CaCl2 (Promega) 
Calcium 
phosphate 
Transfection 
HBS (2x) 50 mM HEPES, 280 mM NaCl, 1.5 mM Na2HPO4, pH 7.1 (Promega) 
Calcium 
phosphate 
Transfection 
PBS 10mM Tris-Base, 150mM NaCl, 1mM EDTA, pH 7.4 (Sigma) Cell culture 
Freezing solution 85% (v/v) FBS, 15% (v/v) DMSO Cell line storage 
Alkaline 
phosphatise 
buffer (10x) 
25 mM Tris-HCl, 1 mM MgCL2, 0.1 mM ZnC12, 
50% (v/v) glycerol, pH 7.6 (Roche) Cloning 
Ligation buffer 
(10x) 
660 mM Tris-HCl, 50 mM MgCl2, 50 mM DTT, 
10 mM ATP, pH 7.5. (Roche) Cloning 
Restriction 
Enzyme buffer A 
(10x) 
330 mM Tris acetate, 100 mM Mg-acetate, 660 
mM K-acetate, 5mM Dithiothreitol (DTT) 
(Roche) 
Cloning 
Restriction 
Enzyme buffer B 
(10X) 
100 mM Tris-HCl, 1 M NaCl, 50 mM MgCl2, 10 
mM 2-mercaptoethanol pH 8 (Roche) Cloning 
Restriction 
Enzyme buffer H 
(10X) 
0.5 M Tris-HCl, 1 M NaCl, 100 mM MgCl2, 10 
mM Dithioerythritol, pH 7.5 (Roche) Cloning 
EMSA binding 
buffer (5x) 
50mM Tris-HCl (pH 7.5), 5mM MgCl2, 2.5mM 
EDTA, 2.5mM DTT, 250mM NaCl, 20% 
glycerol, 0.25 mg/ml poly (dI-dC).poly(dI-dC) 
(Promega) 
EMSA 
Fixing solution 10% (v/v) acetic acid, 20% (v/v) ethanol EMSA 
SP6 transcription 
buffer (5x) 
400mM HEPES-KOH, 160mM MgCl2, 10mM 
spermidine, 200mM DTT, pH 7.5 (Promega) 
In vitro 
transcription 
TFBI 30mM KAc, 50mM MnCl2, 100mM KCl, 10mM CaCl2.2H20, 15% glycerol (v/v) 
Competent 
bacteria 
TFBII 10mM NaMOPs, 75mM CaCl2, 10mM KCl 15% glycerol 
Competent 
bacteria 
Elution buffer 
(EB) 10mM Tris-Cl, pH 8.5 
Mini-Prep 
Maxi-Prep 
Pfx buffer 
 
50mM Tris-HCl, 50mM KCl, 1mM DTT, 0.1 
mM EDTA, 50% glycerol (v/v), pH 8 
(Invitrogen) 
PCR 
TE buffer 10 mM Tris, 1 mM EDTA, pH 8.0 Probe labelling 
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Buffer Composition Method 
Lysis buffer 10% glycerol, 2mM EDTA, 0.1% NP40, 2mM DTT, 150mM NaCl, 10mM NaF in PBS Pulldowns 
Lysis buffer 
(Qiagen) 
50 mM NaH2PO4, 10 mM imidizole, 0.05% 
Tween 20, pH to 8.0 with NaOH Pulldowns 
Lysis buffer (Zou 
et al, 2007) 
1% NP-40, 10mM imidizole in PBS 
 
Pulldowns 
Wash /Nickel 
binding buffer  20mM imidizole, 0.5% NP-40 in PBS Pulldowns 
Wash buffer 
(Qiagen) 
50 mM NaH2PO4, 300 mM NaCl, 20 mM 
imidizole, 0.05% Tween 20, pH to 8.0 with 
NaOH 
Pulldowns 
Wash buffer (Zou 
et al, 2007) 
1% NP-40, 20mM imidizole in PBS 
 
Pulldowns 
SYBR Green 
Master Mix 
HotStarTaqTM DNA Polymerase, QuantiTect 
SYBR Green PCR Buffer, dNTPs mix including 
dUTP, SYBR Green I, ROX and 5mM MgCl2 
Quantitative 
real time PCR 
Laemmli Protein 
Sample buffer 
2% SDS, 10% glycerol, 5% 2-mercaptoethanol, 
0.002% bromphenol blue, 0.0625 Tris HCl 
(Sigma) 
SDS-PAGE 
MOPS SDS 
running buffer 
(20x) 
1M MOPS (2-(N-morpholino) propane sulfonic 
acid), 1M Tris-Base, 69.3mM SDS, 20.5mM 
EDTA (Invitrogen) 
SDS-PAGE 
Protogel 
resolving buffer 
0.375 M Tris-HCl and 0.1% SDS, pH 8.8 
(National Diagnostics) SDS-PAGE 
Protogel stacking 
buffer 
0.125 M Tris-HCl and 0.1% SDS, pH 6.8 
(National Diagnostics) SDS-PAGE 
Tris-Glycine SDS 
buffer (10x) 
0.25M Tris base, 1.92M glylcine, and 1% (w/v) 
SDS SDS-PAGE 
Ponceau-S 
concentrate 
(10X) 
2% (w/v) Ponceau-S, 30% (v/v) Trichloroacetic 
acid, 30% (v/v) Sulphosaliylic acid (Sigma) 
Western 
blotting 
Blocking solution 
5% dried milk (w/v), 10mM Tri-Base pH 7.4, 
150mM NaCl, 1mM EDTA, 0.1% Tween 20 
(v/v). 
Western 
blotting 
ECL buffer A 250mM luminol, 90mM P-Coumaric acid, 100mM Tris, pH 8.5 
Western 
blotting 
ECL buffer B 1.92% H2O2 (v/v), 100mM Tris, pH 8.5 Western blotting 
PBS-Tween 
 
10mM Tris-Base, 150mM NaCl, 1mM EDTA, 
0.1% Tween 20 (v/v), pH 7.4  
Western 
blotting 
Transfer buffer 
 
0.025M Tris, 0.192M Glycine, 15% methanol 
(v/v) 
Western 
blotting 
 
Table 2.3: Buffers 
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2.1.4 Antibodies 
Type Name Source 
Primary BZ1 mouse monoclonal  Gift from Professor Martin Rowe 
Primary Cdk2 mouse monoclonal  Santa Cruz Biotechnology 
Primary Monoclonal α-Flag M2 mouse Sigma 
Primary α-penta-his  Qiagen 
Primary Bcl2 mouse Santa Cruz Biotechnology 
Secondary ECL α-mouse HRP-linked  GE Healthcare 
Secondary Polyclonal rabbit-α-mouse Ig Dako 
Tertiary Protein A, peroxidase-linked  Amersham 
 
Table 2.4: Antibodies 
 
 
2.1.5 Enzymes 
Name Manufacturer Method 
Alkaline phosphatase  Roche Cloning 
BamHI restriction enzyme Roche Cloning 
Dpn1 restriction enzyme Roche Site directed mutagenesis 
EcoRI restriction enzyme Roche Cloning, linearisation of plasmid DNA 
HindIII restriction enzyme Roche Cloning 
ImProm-II™ Reverse 
Transcriptase Promega cDNA  Synthesis 
Polynucleotide kinase (PNK) Roche DNA labelling 
Pfx DNA polymerase Invitrogen PCR reaction 
RQ1 RNAse-free DNAse Promega In vitro transcription 
RNasin Ribonuclease 
Inhibitor 
Promega In vitro translation 
SP64 RNA polymerase Promega In vitro transcription 
SYBR Green Qiagen Quantitative Real Time PCR 
T4 DNA ligase Roche Ligation 
T7 RNA polymerase Promega In vitro transcription 
 - 56 - 
 
Name Manufacturer Method 
XhoI restriction enzyme Roche Cloning, linearisation of plasmid DNA 
 
Table 2.5: Enzymes 
 
 
2.1.6 Kits 
Name Manufacturer Method 
QIAquick PCR purification kit Qiagen PCR purification 
QIAprep Maxi-Prep Qiagen Maxi-prep 
QIAprep Mini-Prep Qiagen Mini-prep 
RNeasy  Qiagen Total RNA extraction 
ImProm-II™ Reverse 
Transcription System Promega 
Reverse Transcription 
RiboMax Large Scale RNA 
production systems: SP6 and T7 Promega 
in vitro transcription 
Rabbit Reticulocyte Lysate 
System Promega 
in vitro translation 
Profection Mammalian 
Transfection Systems Promega 
Transfection 
Effectene Transfection Kit Qiagen Transfection 
Luciferase Assay System Promega Luciferase Assay 
 
Table 2.6: Kits 
 
2.1.7 Radioactivity  
The radioisotopes [35S] Methionine (in vitro translated protein labelling for EMSA) and 
[γ33P] ATP (EMSA probe labelling) were purchased from Amersham Biosciences. 
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2.2 Methods 
2.2.1 Cell Culture 
2.2.1.1 Cell Lines 
Human epithelial HeLa cells (Jones et al., 1971; Verma and Hansch, 2006) were grown 
in Dulbecco’s modified Eagle’s medium (Invitrogen) containing 10% (v/v) Fetal 
Bovine Serum, 100U/ml penicillin, 100 µg/ml streptomycin and 2mM L-glutamine. 
These cells were utilised to investigate cell arrest as demonstrated by Cayrol and 
Flemington (Cayrol and Flemington, 1996a).  Human embryonic kidney (HEK) 293 
cells were grown in RPMI medium (Invitrogen) containing 10% (v/v) Fetal Bovine 
Serum, 100U/ml penicillin, 100 µg/ml streptomycin and 2mM L-glutamine.  These cells 
were selected as they are easily grown and transfected so are good for protein 
expression experiments.  HEK 293 cells containing the B95-8 EBV strain lacking the 
BZLF1 gene (HEK293-ZKO cells) (Feederle et al., 2000) were grown in RPMI medium 
(Invitrogen) containing 10% (v/v) Fetal Bovine Serum, 100U/ml penicillin, 100 µg/ml 
streptomycin, 2mM L-glutamine and 100 µg/ml hygromycin.  The hygromycin 
maintains selection for the recombinant virus in HEK293-ZKO cells.  Cells were grown 
at 37°C in a humidified 5% CO2 incubator.  These cells provide a system for 
reactivating the EBV lytic cycle via the transfection of a functional Zta or Zta mutant. 
2.2.1.2 Storage and recovery of cell lines 
80% confluent cells were washed in PBS then spun at 283 xg for 5 minutes.  The pellet 
was resuspended in 1/6 original volume freezing solution and 2ml aliquoted to each 
sterile cryogenic tube.  Tubes were frozen in isopropanol cryogenic boxes overnight at -
80°C, before being transferred to liquid nitrogen storage.   
To recover cell lines, tubes were removed from liquid nitrogen and thawed at 37°C.  
Thawed cells were added to 10mls of media, spun at 145 xg for 10mins to remove 
freezing solution, and the pellet was then resuspended in 10 ml media.  Cells were then 
plated in a small flask and placed in incubator at 37°C. 
 
2.2.1.3 Determination of cell count 
A small aliquot of cells were removed from the media and placed in a Neubauer 
Hematocytometer.  Using a light microscope the total number of cells in the four 
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squares was counted.  To determine the number of cells/ml, the following equation was 
used: 
Number of cells/ml = (total cells counted/4) x 10,000  
 
2.2.1.4 Calcium Phosphate Transfection (HeLa cells) 
Calcium phosphate transfection was performed using the Promega Calcium Phosphate 
ProFection Mammalian Transfection System.  3x105 HeLa cells were plated in a 10cm 
plate.  The following day 30µg of plasmid DNA was mixed with 250µl HEPES 2x 
Buffered Saline (HBS) and 250µl H2O. 30µl of 2.5M CaCl2 was added to each tube, 
mixed and incubated at room temperature for 20 minutes.  This was added drop by drop 
to the cells.  Media was changed the next day and cells were harvested after 48 hours 
and washed twice in PBS. 
 
2.2.1.5 Effectene Transfection (HEK293-ZKO and HEK cells) 
Cells were plated in 6-well plates at 4x105 cells per well in 2mls of media.  Transfection 
was done using the Qiagen Effectene Transfection Kit.  0.8µg plasmid DNA was 
combined with 100µl EC buffer and 3.2µl enhancer.  This was vortexed and incubated 
for 5 minutes at room temperature.  4µl of effectene was added, then vortexed and 
incubated for 10 minutes at room temperature. 1ml of RPMI medium was added and the 
mixture was added directly to the well.  Cells were incubated for 48-96 hours before 
harvesting.  Cells were washed twice in PBS and harvested.   
 
2.2.1.6 FACS 
Cells were transfected with a GFP vector along with the experimental expression vector.  
A fraction of cells were analysed by flow cytometry to determine the transfection 
efficiency as shown by the proportion of cells expressing GFP.   
A second fraction of cells were resuspended in 500µl 80% ethanol and incubated at 4°C 
for one hour.  Cells were centrifuged at 145 xg for 5 minutes and the cell pellet was 
resuspended in 200µl propidium iodide (PI) stain.  5µl of RNAseA was added to each 
sample and samples were incubated at room temperature in the dark for 20 minutes.  
The distribution of cells in the cell cycle was determined by flow cytometry to detect 
the amount of fluorescent PI bound to DNA in each cell. 
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2.2.2 Protein Gels 
2.2.2.1 SDS-PAGE 
Cells were washed in PBS and lysed in an equal volume of Laemmli Protein Sample 
buffer (Sigma).  Samples were vortexed for 30 seconds, heated for 10 minutes at 95°C 
and spun at >10,000xg for 10 minutes.  Samples were loaded into a pre-cast 12% Bis-
Tris NuPAGE gel (Invitrogen) or a 12% homemade gel (see below).  Seeblue marker 
(Invitrogen) was loaded into one lane for size determination.  NuPAGE gels were run 
for 50 minutes at 200 volts in MOPS SDS running buffer (Invitrogen).    
 
2.2.2.2 Acrylamide gels  
Gels were made using a BioRad Mini-PROTEAN 3 gel casting system. 
 
Resolving gel mix for 12% gel  
40ml 30% Protogel (37.5:1 Acrylamide to Bisacrylamide) (National Diagnostics) 
26ml Protogel resolving buffer 
34ml H20 
 
Stacking gel mix 
22ml 30% Protogel (37.5:1 Acrylamide to Bisacrylamide) (National Diagnostics) 
25ml Protogel stacking buffer 
53ml H2O 
 
To initiate polymerisation of 10ml of resolving gel mix, 40μl of ammonium persulfate 
and 5μl of TEMED were added.  This was poured into the mould to 1cm below the 
bottom of the wells, layered with butan-1-ol and allowed to polymerise.  20μl of 
ammonium persulfate and 4μl of TEMED to was added to 5ml of stacking gel mix. 
Butan-1-ol was removed from the mould and polymerising stacking gel mix was poured 
in.  The well comb was put in and the gel left to polymerise.  Samples were loaded and 
run for 50 minutes at 200 volts in 1x Tris-Glycine SDS buffer.   
 
2.2.2.3 Western Blotting 
Following electrophoresis, proteins were transferred onto a nitrocellulose membrane in 
a Bio-Rad Transblot tank for 90 minutes at 75V in transfer buffer.  To check proteins 
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had transferred to the membrane, it was incubated with PonceauS red stain (Sigma) for 
one minute with agitation and then rinsed with deionised water to remove background 
staining and reveal protein bands. The membrane was then blocked for 1 hour in 
blocking solution. The blots were incubated overnight with agitation at 4°C with the 
primary antibody. The following day membranes were washed three times in PBS-
Tween for 10 minutes.  A secondary horseradish peroxidase linked antibody was 
selected against the animal in which the primary antibody was generated. Detection was 
performed by incubating the membrane with the secondary antibody for one hour. For 
some blots a three layer western blot was carried out, with rabbit-α-mouse 
immunoglobulins as the secondary antibody and protein A-HRP as the tertiary antibody.  
Membranes were again washed three times for 10 minutes with PBS-Tween after 
antibody incubation. The immune complexes were observed using enzymatic 
chemiluminescence (ECL). 
 
To detect proteins the membrane was incubated with equal amounts of ECL buffer A 
and buffer B for one minute. Buffer was removed and the membrane was covered with 
saran wrap.  A piece of film was exposed to the ECL treated membrane in a cassette and 
developed to reveal antibody specific bands. 
 
2.2.3 In vitro transcription and translation 
2.2.3.1 In vitro transcription 
In vitro transcription was performed using Promega RiboMAX Large Scale RNA 
Production Systems.  Plasmid DNA was linearised using an appropriate restriction 
enzyme prior to the transcription reaction.   
 
Reactions from the SP6 promoter were assembled as follows: 
Component     Volume 
SP6 5x Transcription Buffer     20µl 
rNTPs (100mM)      20µl 
linear plasmid DNA (1µg/µl)     10µl 
Nuclease free H2O      40µl 
SP6 Enzyme mix      10µl 
Total      100µl 
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Reactions were incubated at 37°C for 4 hours. 
 
For genes under control of the T7 promoter, reactions were assembled as follows: 
 
Component    Volume 
RiboMAX Express T7 2x Buffer  10µl 
linear plasmid DNA (1µg/µl)       1µl 
Nuclease free H2O        7µl 
T7 Express Enzyme mix       2µl 
Total      20µl 
 
Reactions were incubated at 37°C for 30 minutes. 
 
In order to remove template DNA RQ1 RNase-free DNAse was added to both reaction 
types at a concentration of 1U/1µg template DNA and incubated at 37°C for 15 
minutes. 
 
2.2.3.2 Phenol-chloroform extraction and ethanol precipitation  
RNA was extracted using phenol-chloroform extraction and ethanol precipitation.  One 
volume of phenol:chloroform:isoamyl alcohol (25:24:1) was added to the sample and 
mixed by vortexing for one minute. Samples were centrifuged at 4°C for two minutes at 
>10,000xg, forming distinct separation between the upper aqueous and lower organic 
phases. The aqueous phase was transferred to a new tube and one volume of 
chloroform:isoamyl alcohol (24:1) was added. The components were mixed and spun as 
previously.  The aqueous phase was transferred to a fresh tube and spun for ten seconds 
at >10,000xg  to sediment any residual chloroform which was removed from the bottom 
of the tube.  0.1 volumes of 3M sodium acetate and 2.5 volumes of ethanol were added 
to the sample. Samples were incubated on ice for five minutes then spun at >10,000xg 
for ten minutes at 4°C. The liquid layer was removed leaving the white RNA pellet at 
the bottom of the tube. The pellet was washed with 70% ethanol then spun as previously 
for 3 minutes.  Any remaining liquid layer was removed and the tubes were air dried for 
five minutes.  RNA was resuspended in H2O to the starting volume and quantified using 
an eppendorf BioPhotometer.   
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2.2.3.3 In vitro translation 
In vitro translation was performed as below using the Promega Rabbit Reticulocyte 
Lysate Translation System (Nuclease-Treated).   
 
 
Component     Volume 
Rabbit Reticulocyte Lysate   35 µl 
Amino acid -minus methionine (1mM)   1 µl 
RNasin Ribonuclease inhibitor (40U/µl)   1 µl 
RNA (1µg/µl)       2 µl 
[35S] methionine       2 µl 
Nuclease free H2O      9 µl 
Total      50 µl 
 
Reactions were incubated at 30°C for 90 minutes. 
 
Negative control reactions containing all components except RNA were also performed.  
  
2µl of each reaction was run with Laemmli sample buffer on a NuPAGE Novex 12% 
Bis-Tris gel (Invitrogen) in MOPS buffer at 200V for 50 minutes.  The gel was fixed in 
fixing solution and dried under vacuum.  Gels were exposed overnight to an Amersham 
Phosphor Storage screen and detected by phosphorimaging using a Molecular 
Dynamics STORM 860 phosphorimager. Relative signal strength was determined using 
ImageQuant software version 5.1 (Molecular Dynamics).  Proteins were diluted with 
negative control reaction to ensure equivalent concentration for subsequent EMSA 
experiments.  
 
2.2.4 Molecular Biology 
2.2.4.1 Polymerase Chain Reaction (PCR) 
Primers were prepared to a 100 μM stock concentration and then to a working 
concentration of 10 μM in nuclease free water.  
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Each PCR reaction was prepared as below: 
10X Pfx Buffer   5.0 μl 
10 mM dNTPs   1.5 μl 
50 mM MgSO4   1.0 μl 
Forward primer (10 μM)  1.5 μl 
Reverse primer (10 μM)  1.5 μl 
Platinum Pfx DNA polymerase 0.5 μl 
Template DNA (1-200ng)  0.5 - 1.5 μl 
dH20     to 50 μl 
 
Reactions were amplified on a Techne TC-512 PCR machine using the cycling 
conditions below: 
 
94°C  2 minutes 
94°C  15 seconds 
50-65°C 30 seconds 
68°C  60 seconds 
4°C  hold 
 
The annealing temperature used varied between 50°C and 65°C, dependent on the 
melting temperature of the primers used, according to the following formula: 
 
Primer melting temperature = 4(G + C) + 2(A + T)°C 
 
Following a PCR reaction, samples were purified using QIAquick columns (Qiagen), 
following the protocol of the QIAquick PCR Purification Kit (Qiagen). DNA was stored 
at -20°C. 
 
 
2.2.4.2 Determination of nucleic acid concentration  
The concentration of DNA and RNA was determined using an Eppendorf 
BioPhotometer by measuring the absorbance of a sample at two wavelengths; 260 and 
280 nm. Distilled water was used as a blank reading and 1 μl sample was added to 49 μl 
distilled water and the absorbance was read at both wavelengths.   
30 - 35 cycles 
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The ratio of 260/280 determines the purity of the sample; a ratio of approximately 2.0 is 
expected for pure RNA and a ratio of approximately 1.8 is expected for pure DNA.  
 
2.2.4.3 Agarose Gel Electrophoresis 
1-2% agarose gels were used to analyse DNA. The percentage agarose (w/v) was 
resuspended in 1X Tris-Borate EDTA (TBE) and heated until the agarose was 
completely dissolved. When partially cool, 1 μl of 1000 X Ethidium bromide per ml of 
solution was added.  The gel was poured into a mould and a comb added to create the 
wells. 1 X loading buffer was added to samples.  A molecular weight marker of either 
PstI or HindIII λ DNA (Sigma) was run alongside samples.  Gels were run in 1 X TBE 
buffer for up to sixty minutes at 100 volts and was visualised under UV light using a 
Uvitech BTS-2.M. 
 
PCR products and digested vectors were extracted from agarose gels using a QIAquick 
Gel Extraction Kit (Qiagen) following the standard protocol. 
 
2.2.4.4 Genomic DNA Extraction 
DNA was extracted from cells using Promega Wizard Genomic DNA extraction kit.  
600µl of Nuclei Lysis solution was added to each cell pellet and pipetted to lyse cells.  
3µl RNaseA (4mg/ml) was added and incubated at 37°C for 30 minutes then cooled to 
room temperature.  200µl Protein Precipitation solution was added, vortexed and chilled 
on ice for 5 minutes.  Samples were centrifuged for 4 minutes at >10,000xg.  DNA was 
precipitated from the supernatant using ethanol precipitation.  DNA was rehydrated in 
100µl H2O. 
 
2.2.4.5 Isolation of total RNA 
RNA extraction was performed using Qiagen RNeasy kit.  Cells were harvested and 
centrifuged at 167xg for 10 minutes.  Pellets were resuspended in 350μl lysis buffer and 
350μl of 70% ethanol was added.  Samples were loaded into a RNeasy column, 
centrifuged at >10,000xg for 15 seconds and flow-through was discarded.  700μl of 
washing buffer was loaded into column, centrifuged at >10,000xg for 15 seconds and 
flow-through was discarded.  A second 500 μl wash using a washing buffer containing 
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ethanol was performed using same centrifugation steps.  This was repeated twice.  RNA 
was eluted into a clean tube using 40μl of RNAse-free water and RNA was stored at -
20°C. 
 
2.2.4.6 cDNA synthesis 
cDNA was synthesised from total RNA extracted from cells using the ImPromII 
Reverse Transcription System (Promega).  1μg of RNA was mixed with 0.5μg of 
Random Primer in 5μl.  This was incubated at 70°C for 5 minutes and placed on ice for 
5 minutes.  The following reverse transcription mixture was assembled: 
 
Component    Volume 
RNA + random primers  5.0 µl 
ImPromII 5x reaction buffer  4.0 µl 
MgCl2 (25mM)   3.2 µl 
dNTPs mix (10mM)   1.0 µl 
RNasin RNAse inhibitor (20U) 0.5 µl 
ImPromII Reverse transcriptase 1.0 µl 
RNase free H2O   To a final volume of 15µl 
 
This was incubated at 25°C for 5 minutes to anneal random primers to RNA.  Extension 
was performed at 42°C for 1 hour.  The enzyme deactivated at 70°C for 15 minutes.  
cDNA samples were stored at -20°C. 
 
2.2.4.7 Quantitative Real-Time PCR (QPCR) 
A standard curve of each primer set was created from an undiluted sample using a 
dilution series of the DNA for each primer set individually. 
Samples were diluted 1/10.  A master-mix with the following components was made 
and dispensed into wells of a 96-well plate:  
 
Component    Volume 
SYBR Green (Qiagen)  12.5 µl 
Forward primer           1.0 µl (10μM) 
Reverse primer           1.0 µl (10μM) 
H2O        9.5 µl 
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1µl of each sample (in duplicate) was added to the master-mix. 
 
The QPCR reaction conditions using an Applied Biosystems 7500 Realtime PCR 
system were:  
50°C     2 minutes 
95°C  10 minutes 
95°C  15 seconds 
60°C      1 minute  
95°C  15 seconds   
60°C      1 minute    
95°C  15 seconds  
 
The QPCR results were analysed using ABI 7500 system SDS software, ensuring 
sample values fell within the standard curves obtained.   
Melting curve analysis was performed for each reaction to ensure contamination, 
mispriming or primer-dimer artefact was not affecting results.   
 
40 cycles 
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Figure 2.7: Diagram of SYBR Green Quantitative Real-time PCR 
cDNA is synthesized from RNA via reverse transcription.  cDNA is denatured 
and specific primers anneal in the prescence of Sybr Green dye.  Sybr Green 
binds to double stranded DNA causing fluorescence.  The level of fluorescence 
is measured during each cycle of amplification, allowing quantification of the 
DNA product. 
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2.2.4.8 Site directed mutagenesis 
Site directed mutagenesis was performed using mismatched primers to introduce the 
desired sequence change.  Primers were designed with the desired mutation in the 
middle of the primer with 10-15 matching bases either side. 
 
Component    Volume 
10x pfx buffer           5.0 µl 
MgSO4 (50mM)        1.0 µl 
dNTPs (10mM)       1.5 µl 
Forward primer       1.5 µl 
Reverse primer       1.5 µl 
Template DNA (50µg/µl)         1.0 µl 
pfx enzyme           1.0 µl 
H2O     37.5 µl 
Total        50.0 µl 
 
PCR conditions: 
Temperature Time 
95°C   5 minutes 
95°C 30 seconds 
55°C   1 minute 
65°C   4 minutes 
68°C   7 minutes 
 
PCR products were incubated with 1µl Dpn1 enzyme for 1 hour at 37°C to specifically 
digest the methylated template DNA. 
 
2.2.4.9 Subcloning 
The vector and DNA insert were digested using the same restriction enzymes for one 
hour at 37°C. The vector reaction was treated with alkaline phosphatase for 1 hour at 
37°C to remove the 5’phosphate group and stop re-ligation of the plasmid DNA. DNA 
insert and vector were run on a 1% agarose gel and purified using the Qiagen gel 
extraction kit. The vector and insert were ligated at a 1:3 ratio, with 1 unit of T4 DNA 
18 cycles 
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ligase and 1µl of ligase buffer (10X) to a final volume of 10µl. The reaction was placed 
at 4°C overnight. Modifications to ligation ratio, enzyme concentration and temperature 
were used when the initial ligation was unsuccessful.  Colonies were picked and 
amplified, and plasmids extracted using Qiagen mini prep kit.  To ensure the presence 
of the insert, the plasmid was digested with the same restriction enzymes and analysed 
by agarose gel electrophoresis.  Samples were sent for sequencing (MWG 
Biotechnology) for confirmation. 
 
2.2.5 Microbiology 
2.2.5.1 Creating Competent Bacteria 
Under aseptic conditions Top 10 bacteria (Invitrogen) were streaked on to an LB agar 
plate and incubated overnight at 37°C. A single colony was picked from the plate and 
grown overnight in 20 ml LB broth without antibiotic at 37°C, shaking at 220 rpm. The 
overnight culture was diluted in 100 ml LB broth and transferred to a 2 L flask, then 
returned to the heated shaker until the optical density at 600 nm wavelength (OD600) 
was in the range of 0.5-0.9. A further 400 ml LB broth was added to the culture and 
grown until the OD600 was 0.6. Cultures were swirled in a water ice bath to cool, and 
then centrifuged at 2683xg for fifteen minutes.  Cells were resuspended in 100 ml TFBI 
buffer then centrifuged at 2683xg for eight minutes.  Pellets were resuspended in 20 ml 
ice cold TFBII buffer. 100 μl aliquots of bacterial cells were frozen at -80°C. 
 
2.2.5.2 Transformation 
1µl of plasmid DNA was added to chemically competent cells (E. coli equivalent to 
Top10), and incubated on ice for 30 minutes. Samples were heat shocked at 42°C for 30 
seconds following by the addition of 250µl of S.O.C. medium (Invitrogen) and 
incubated in a shaker at 220 rpm for 1 hour at 37°C. Bacteria were streaked onto a LB 
agar plate containing 100µg/ml of ampicillin. 
 
Qiagen mini and maxi preps were performed as recommended in the kit.  
 
 - 70 - 
 
2.2.6 Electrophoretic Mobility Shift Assay (EMSA) 
2.2.6.1 Probe labelling  
For EMSA reactions oligos approximately 25 bp long with the 7 bp binding site in the 
centre were utilised.   
The following reaction was performed to generate an end- labelled oligionucleotide: 
 
Component    Volume 
10µM oligionucleotide a  1.0 µl 
33P γATP (25 μCi)   5.0 µl 
PNK enzyme    0.5 µl 
10x PNK buffer   1.0 µl 
Ultrapure H2O    2.5 µl 
 
The reaction was incubated at 37°C for 30 minutes, then heated at 65°C for 10 minutes 
to inactivate the kinase enzyme.   
 
2µl of 10µM unlabelled complementary reverse probe was added.  This was then 
denatured at 95°C for 2 minutes and annealed at 65°C for 10 minutes and 37°C for 30 
minutes. 90µl of TE buffer was added to each reaction and purified using G25 spin 
columns to remove unlabelled nucleotides.  200μl of TE buffer was added to the 
purified probe.  This double stranded, radiolabelled DNA probe was now ready for use 
in EMSA reactions. 
 
2.2.6.2 Electrophoretic Mobility Shift Assay (EMSA)  
The following components were assembled for EMSA reactions: 
 
Component    Volume 
in vitro translated protein  0.5 - 2.0 µl 
5x binding buffer           2.0 µl 
0.1M DTT            0.4 µl 
labelled probe            1.0 µl 
H2O      To final volume of 10µl 
 - 71 - 
 
 
 Reactions were incubated at room temperature for 20 minutes.   
1µl or 0.5µl of protein was respectively used for ½ and ¼ size reactions.  A control 
containing all reaction components, except RNA in the in vitro translation (IVT), 
controls for binding by proteins contained in the Rabbit reticulocyte lysate.  A reaction 
containing no protein was also included.   
 
2µl of 5x Novex TBE Hi-Density Sample Buffer (Invitrogen) was added to each sample 
then run on a Novex 6% DNA retardation gel (Invitrogen) with 0.5x TBE buffer at 
100V for 45 minutes. Gels were fixed in fixing buffer for 1 hour then dried under 
vacuum and exposed to a phosphor storage screen.  Results were visualised using a 
phosphor imager (Molecular Dynamics Storm 860).  Quantitation of band size was used 
to determine the relative binding efficiencies.  It was important to determine that there 
was excess probe in each reaction, seen as bands at the bottom of the gel.  This 
determines that the binding reaction is not limited due to lack of probe. 
 
2.2.6.3 Competition EMSA 
In addition to the components for an EMSA reaction, unlabelled double-stranded test 
competitor probe was created for each probe to be assessed.  50µl of each 10µM probe 
were mixed then denatured at 95°C for 2 minutes and annealed at 65°C for 10 minutes 
and 37°C for 30 minutes.   This unlabelled test competitor probe was diluted to 6x, 10x, 
20x, 50x, 75x and 100x strength of the probes. 
 
A labelled standard probe that was known to produce strong EMSA reactions was 
selected and the following reactions were assembled: 
 
Component      Volume 
5x binding buffer     2.0 µl 
0.1M DTT      0.4 µl 
labelled standard probe    1.0 µl 
unlabelled test competitor probe (6x-100x)  1.0 µl 
in vitro translated protein    0.5 - 2 µl 
H2O        To final volume of 10µl 
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Proteins were added after probes to reactions to ensure equal binding time for each 
probe. 
Reactions were incubated for 20 minutes, then analysed on a single gel as for EMSA 
reactions. 
 
2.2.7 Luciferase Assay 
2.2.7.1 SssI methylation 
10μg of vector was incubated with 50U SssI enzyme, NEB Buffer 2 (to 1x), 1 μl of 
32mM S-adenosylmethionine (SAM) and H20 for 1 hour at 37°C.  The reaction was 
stopped by incubating at 65°C for 20 minutes. Mock-methylation reactions excluding 
enzyme were also performed for each vector as a control.  Reactions were digested with 
the methylation-dependent restriction enzyme BstUI, which is unable to digest CpG 
methylated DNA.  Protection from digestion in this reaction confirmed methylation. 
 
2.2.7.2 Luciferase Assay 
Transfected cells were harvested after 24 hours, washed in PBS and lysed with 900μl of 
1x Luciferase Cell Lysis Reagent (Promega). Cell lysates were collected by 
centrifugation.  20μl of each sample was added in duplicate to a 96 well plate.  50μl of 
Luciferase Assay Reagent was added to each well.  Bioluminescence was measured for 
a 10 second read on a luminometer using Stingray software (Dazdaq).  
 
2.2.8 Pulldowns 
HEK293 cells were co-transfected with vectors containing pBabe his-Zta and flag-
pcDNA3 experimental vector, as well as controls comprised of his-Zta or experimental 
vector with the complementary empty vector (pBabe or flag-pcDNA3).  Cells were 
harvested and lysed with lysis buffer after 48 hours.  Samples were placed on ice for 30 
minutes then underwent three freeze/thaw cycles (freezing with liquid nitrogen and 
thawing at 37°C).  Samples were spun at 380xg for 10 minutes.  HIS-Select Nickel 
Affinity Gel was washed 3 times in wash/Nickel binding (binding) buffer then 
resuspended in binding buffer.  Sample supernatant was incubated with the gel 
overnight rotating at 4°C.  Samples were spun at 380xg, 4°C for 2 minutes.  The 
supernatant was removed and kept for analysis.  The gel was washed three times as 
previously then the starting volume of binding buffer was added.    1 volume of sample 
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buffer was added before denaturing at 95°C for 10 minutes and running on a protein gel.  
Gels were then western blotted with BZ1 and flag antibodies.     
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Chapter 3      Methylation of Zta Response Elements 
3.1 Introduction 
3.1.1 DNA Methylation 
Methylation of DNA is an epigenetic mechanism typically associated with negative 
regulation of gene expression.  It plays a crucial role in modulating expression of both 
cellular and viral genes.  DNA methylation typically occurs at CpG motifs.  DNA 
methyltransferase enzymes convert the cytosine residue on both strands to 5-
methylcytosine (Figure 3.1A). The cytosine methyl donor is S-adenosyl methionine 
(SAM), yielding S-adenosyl homocysteine (SAH) and 5-methylcytosine (Klose and 
Bird, 2006).  As CpG motifs are palindromes, full methylation consists of two 
methylated cytosine residues positioned diagonally on complementary DNA strands 
(Figure 3.1B).  The DNA methyltransferase enzyme DNMT1 acts on hemi-methylated 
DNA to methylate the complementary cytosine, for example during DNA replication, 
thus maintaining full methylation of the CpG site.   
CpG motifs are often arranged in clusters called CpG islands, which are present in the 5' 
regulatory regions of many genes.  These regions are predominantly unmethylated and 
are often sites of transcription initiation (Deaton and Bird, 2011).  Control of gene 
expression via DNA methylation occurs via two mechanisms; inhibition of transcription 
factor binding to DNA recognition sequences that are methylated and methyl-CpG-
binding proteins and associated co-repressors leading to transcriptional silencing and 
chromatin remodelling in areas of DNA methylation (Klose and Bird, 2006).  
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Figure 3.1: CpG methylation 
A. Mechanism of CpG methylation. CpG motifs consist of a cytosine residue followed 
by a guanine residue.  Methylation of the cytosine within a CpG motif is catalyzed by 
DNA methyltransferases which transfer the methyl group from S-adenosyl methionine 
(SAM-CH3) to cytosine. The methylation reaction yields S-adenosyl homocysteine 
(SAH) and 5-methylcytosine.  
B. As a CpG motif is palindromic, a second cytosine is located on the complementary 
DNA strand.   
A is adapted from (Maxwell et al., 2009) 
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3.1.2 Methylation in EBV 
EBV DNA is unmethylated when infecting cells but becomes progressively methylated 
by host cell processes (Kalla et al., 2010), resulting in extensive methylation in latent 
infection (Robertson and Ambinder, 1997).   Methylation of the viral DNA is an 
essential requirement for lytic cycle activation (Kalla et al., 2010).  The EBV genome is 
extensively methylated in both Burkitt’s lymphoma and nasopharyngeal carcinoma (Lo 
and Huang, 2002; Li et al., 2005). DNA methylation is the main control mechanism for 
regulating the promoter switch from Wp to Cp after primary B cell infection  as well as 
being critical to regulation of the latency promoter Cp (Tierney et al., 2000).  This 
occurs via both direct inhibtion of transcription factor binding and recruitment of 
repressor proteins to methylated DNA (reviewed in (Tao and Robertson, 2003)).   
The use of DNA methylation inhibitors such as 5-azacytidine in EBV related tumours 
may permit re-expression of viral genes, allowing recognition and specific killing by the 
immune system or anti-viral drugs ((Tao and Robertson, 2003). 
 
3.1.3 Zta and Methylation 
A key study by Bhende et al (Bhende et al., 2004) established that methylation of ZRE2 
and ZRE3 in the BRLF1 promoter enhanced the interaction with Zta.  This interaction is 
considered crucial for lytic cycle activation.   
The ability of Zta to demonstrate enhanced binding to CpG methylated, sequence 
specific binding sites is highly unusual for a transcription factor (Bhende et al., 2004).  
Recently the transcription factor C/EBPα has been discovered to have enhanced binding 
to a methylated CRE binding site, while the same unmethylated site is preferentially 
bound by CREB (Rishi et al., 2010). Other examples of proteins with the ability to 
distinguish between methylated and unmethylated DNA are proteins without specific 
DNA-binding ability, for example the methyl bindings MeCP2, MDB1, MDB2, MDB4 
and Kaiso (Prokhortchouk et al., 2001; Klose and Bird, 2006)  
In the experiments conducted by Bhende et al (Bhende et al., 2004) only two of the four 
possible CpG sites in Rp ZRE3 were methylated (ZRE3 me(-1’, -2)) (Figure 3.2A). This 
paper did not explain why the probe was not fully methylated as is the condition in vivo. 
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As methylation of ZRE3 increases the ability of Zta to bind, I wanted to further 
investigate if binding was affected by using a fully methylated ZRE3 probe (ZRE3 me(-
1’, -2, 1’, 0)), in place of the probe with two methylated sites (Figure 3.2B).  
 
 
 
 
A
B
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*
-2*
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C
 
 
Figure 3.2: Methylation of ZRE3 EMSA probes 
A. The methylation state used by Bhende et al (Bhende et al., 2004) is shown. The 
binding site is in bold and methylated CpG motifs are marked in red with an asterisk. 
The latent EBV genome is likely to be fully methylated so we investigated the fully 
methylated probe shown in B. C. The structure of the DNA binding site of Zta from 
Petosa et al (Petosa et al., 2006) in association with Zta, shown in green and yellow.  
The red asterixes show the position of the four potential methylation sites as labelled. 
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ZREs can be classified into three classes (Karlsson et al., 2008b).  Class I ZREs 
contains no CpG methylation sites so binding by Zta is not affected by methylation 
status.  Class II ZREs contain a CpG site and Zta can bind to the non-methylated motif, 
however binding is enhanced by methylation.  Class III ZRE motifs contain one or two 
CpG motifs.  Zta is only able to bind to the methylated site and there is no or very poor 
binding in the unmethylated state.  The gene Rta contains three ZREs in the promoter, 
one of each class.  Rp ZRE1 is an example of a class I ZRE, Rp ZRE2 is class II and Rp 
ZRE3 is class III.    
 
The DNA binding redox-sensitivity of Zta is regulated by Cys-189, a cysteine residue, 
located in the basic region (Wang et al., 2005).  A Zta mutant, ZtaC189S, containing a 
serine residue at this key position is unable to activate the lytic cycle (Schelcher et al., 
2005; Wang et al., 2005) (Figure 3.3).    
 
Competition EMSAs can be used to examine the impact of methylation on binding and 
to establish if ZRE3 with no methylation was compromised or completely defective in 
binding.  This method would also examine the individual contribution of each methyl-
cytosine. This could aid modelling of the interaction between Zta and the methylated 
ZRE3 DNA binding site (Figure 3.2C).   
My initial aim in this chapter is to establish if binding to Zta is increased with a fully 
methylated, rather than half-methylated probe.  I will also examine the individual 
contribution of each methyl-cytosine in the ZRE3 binding site and investigate the effect 
of different methylation patterns on the methylation sensitive Zta mutant C189S. 
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Function Zta C189S
Reactivate lytic cycle + -
Viral gene transactivation + -
Binding to ZREs + +/-
Dimer formation + +
Mediate cell cycle arrest + -
A
B
IKRYKNRVASRKSRAKFKQ
Basic Zip CTTransactivation
C
S
Zta C189S
 
 
Figure 3.3: Summary of  Zta C189S functions 
A. The mutant ZtaC189S has a single cysteine residue in the basic region of Zta 
converted to a serine.  This residue potentially has a role in redox sensitivity and is 
highly conserved in BZip proteins. C189S has been shown by Dr Celine Schelcher to be 
deficient in several key functions of Zta (Schelcher et al., 2005) as summarised in B.  
C189S is unable to reactivate the lytic cycle or transactivate the viral genes BRLF1, 
BMLF1 and BMRF1.  Binding to ZRE ZIIIB and methylated ZRE3  was compromised 
while binding to ZRE2 was unaffected.  C189S is able to form dimers as wild type Zta 
but is unable to mediate cell cycle arrest in HeLa cells. 
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3.2 Results 
3.2.1 Competition EMSA 
Electrophoretic Mobility Shift Assay (EMSA) reactions are an in vitro method to assess 
protein-DNA interactions.  The protein and double-stranded DNA probe are combined 
to allow binding, before submitting for gel electrophoresis.  If binding has occurred 
between the protein and DNA probe, the resulting protein-DNA complex will travel 
more slowly during electrophoresis.  This causes a visible band shift, when compared to 
unbound protein and probe, confirming that binding occurred.   
 
Competition EMSA experiments utilise the EMSA method to ascertain relative binding 
affinity of a protein for different binding sites (Figure 3.4).  A non-labelled test 
competitor probe and a labelled standard probe compete for binding to the protein.  A 
standard DNA oligo, known to bind efficiently to the protein, is radio-labelled then 
annealed to an unlabelled complementary oligo.  This created a double-stranded, 
labelled EMSA probe which is used in a binding reaction with non-labelled, double-
stranded test competitor probe and in vitro translated Zta protein.  If the test competitor 
probe binds efficiently to the protein, less of the labelled standard will be able to bind, 
resulting in weaker EMSA bands.  EMSA reactions are run on a non-denaturing gel, 
fixed, dried and quantitated using a phosphorimager. 
For the following experiments the standard probe used was methylated ZRE2.  This was 
chosen as it is has a high affinity for Zta binding.  The sequence of the ZRE2 oligo is 
GATCATAAAATC*GCTCATAAGCTT, containing the underlined ZRE2 binding site 
and methylated during oligo synthesis as indicated with an asterix.  This approximate 
length of oligo is used to provide surrounding sequence to facilitate binding to the 
specific site in the centre of the probe but is short enough to limit the possibility of  
other potential binding sites.  This was radio-labelled with 33P γATP before annealing to 
create a labelled, double-stranded probe. 
A constant amount of labelled standard probe was used in each reaction with an 
increasing amount of unlabelled ZRE3 test competitor probe (6x, 10x, 20x, 50x, 75x 
and 100x excess). 
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Figure 3.4: Schematic of Competition EMSA method 
A probe that is known to bind well to Zta was radiolabelled with [33P].  In the following 
experiments ZRE2 (GATCATAAAATCGCTCATAAGCTT) was used. A constant 
amount of this competitor probe was added with unlabelled test probe (ZRE3) to 
unlabelled in vitro translated Zta protein in an EMSA binding reaction.  If the test probe 
is unable to bind efficiently to Zta there is no competition to the labelled probe, 
resulting in a strong EMSA band, as seen in the left panel.  However if the test probe is 
a strong binding partner for Zta, less binding to the competitor probe will occur, giving 
a weak EMSA band as seen on the right.   
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In the initial experiment I compared binding efficiency of  a ZRE3 probe methylated at 
two positions (ZRE3 me(-1’, -2)), as used by Bhende et al (Bhende et al., 2004), to 
unmethylated ZRE3 probe (Figure 3.5A) or fully methylated ZRE3 probe (ZRE3 me(-
1’, -2, 1’, 0)) (Figure 3.5B).  All experiments were duplicated. 
The graphs in Figure 3.5C show the percentage of labelled standard probe that is 
competed from binding to Zta at increasing excesses of unlabelled test competitor 
probe.  As little as 20x excess of ZRE3 me(-1’, -2) was able to compete with the 
labelled probe for Zta binding. In contrast even 100x excess unmethylated ZRE3 probe 
was unable to compete. This demonstrates that methylation is absolutely required for 
Zta to bind to ZRE3.   
Fully methylated ZRE3 me(-1’, -2, 1’, 0) was slightly better at competing for Zta 
binding than ZRE3 me(-1’, -2).  At 20x excess ZRE3 me(-1’, -2, 1’, 0) competed 16% 
better.  This data suggests that full methylation of ZRE3 generates a stronger binding 
site for Zta than the version previously tested, however this would need to be repeated.  
As the fully methylated site is most likely to represent the situation in vivo, it reinforces 
the relevance of methylation-dependent binding to this site. 
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Figure 3.5: Competition EMSA of Rp ZRE3 methylation 
Competition EMSAs were performed using increasing amounts of unlabelled ZRE3 
competitor probe (6, 10, 20, 50, 75 and 100x excess). A constant amount of labelled 
probe ([33P] labelled ZRE2 - GATCATAAAATCGCTCATAAGCTT) was included in 
each EMSA reaction. Unlabelled in vitro translated Zta was generated in Promega 
Rabbit Reticulocyte Lysate.  EMSA reactions were separated on SDS-PAGE gels which 
were then fixed, dried and quantitated using a phosphoimager. The left hand side of 
each gel uses the unlabelled ZRE3 methylated probe (me –1’, -2) as shown on the far 
left.  The right hand side of each gel uses an unlabelled ZRE3 probe with the 
methylation status shown to the right of the gel. Panel A shows competition with ZRE3 
unmethylated. Panel B tests ZRE3 with all 4 possible sites methylated (ZRE3 me(-1’, -
2, 0, 1’)). Translation reaction omitting RNA (IVT) is a control in lane 1 and reaction 
with no competitor probe (NC) is lane 2. Both experiments were duplicated and 
quantitated in the graphs in C.  The graphs show the average percentage of the labelled 
probe that is competed from binding at varying excesses of unlabelled probe. 
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3.2.2 Contribution of Individual Methylation Sites 
I used the same technique to investigate the individual contribution of each of the four 
methylation sites within ZRE3.  Oligos with a single methylation of each of the four 
possible CpG cysteines were ordered (Sigma).  Each singly methylated ZRE3 oligo was 
used to create a double-stranded unlabelled EMSA probe.  The four probes, ZRE3 me(-
2), ZRE3 me(-1’), ZRE3 me(0) and ZRE3 me(1’), were used for competition EMSA 
using the labelled ZRE2 probe as a standard competitor.  All four test probes were 
individually able to compete for binding (Figure 3.6).  The strongest binding was 
demonstrated by the probe ZRE3 me(1’) (Figure 3.6D).  At 75x excess to the standard 
probe, the detected binding of the standard probe was reduced by 82%.  This probe was 
not appreciably different at binding Zta from the half-methylated probe, ZRE3((-1’, -2), 
used in the Bhende at al experiments (Bhende et al., 2004).  The other three methylation 
sites showed considerably lower levels of binding than ZRE3((-1’, -2).  However all 
three single sites were able to reduce standard binding at 75x excess.  ZRE3 me(-2) was 
able to reduce standard binding by 32% (Figure 3.6A),   ZRE3 me(0) produced a 15% 
reduction in binding (Figure 3.6C) and ZRE3 me(-1’) reduced binding by 5% at 75x 
excess (Figure 3.6B).  All experiments were duplicated. 
3.2.3 ZtaC189S 
The methylation sensitive mutant, ZtaC189S, may be important as a selective tool in 
understanding the importance of methylation dependent binding by Zta.  I decided to 
quantify the reduced binding demonstrated by ZtaC189S using competition EMSA. 
As shown in Figure 3.7A, ZtaC189S and Zta bind equally to the unmethylated version 
of ZRE2.  However binding of ZtaC189S to methylated ZRE2 is reduced by 50% 
(Figure 3.7B), compared with Zta.  This result was significantly different using a Mann-
Whitney U test (U=16, n1 = n2 = 4, P=0.02857).  Neither protein showed detectable 
binding to unmethylated ZRE3 in these assays.  Binding to methylated ZRE3 was 
greatly compromised for ZtaC189S with both ZRE3 me(-1’, -2) (25%) and me(-1’, -2, 
0, 1’) (21%) (Figure 3.7 C,D).  Both results were significant using a a Mann-Whitney U 
test (U=16, n1 = n2 = 4, p=0.02857).  Experiments were repeated four times. 
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Figure 3.6: Individual contribution of ZRE3 methylation sites 
Competition EMSAs were performed and analysed as in Figure 3.5. Each of the four 
individual potential methylation sites in Rp ZRE3 were methylated in turn as shown to 
the right of each gel;  (A) ZRE3 me(-2), (B) ZRE3 me(-1’), (C) ZRE3 me(0), and (D) 
ZRE3 me(1’).  Competition was compared to ZRE3 me(-1’, -2). 
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Figure 3.7: Comparison of Zta and ZtaC189S  binding to Rp ZRE2 and ZRE3 
EMSAs were performed on in vitro translated proteins Zta and ZtaC189S for 
unmethylated (A) and methylated (B) Rp ZRE2 and half (C) and fully (D) methylated 
Rp ZRE3. Input protein is shown at the top. Probe alone is in lane 1 and translation 
reaction omitting RNA (IVT) as a control is in lane 2. Experiments were repeated 4 
times and the average percentage of Zta binding is shown.   
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3.2.4 Modelling 
The crystal structure of Zta bound to an AP1 site (Petosa et al., 2006) was the basis of 
structural modelling of Zta bound to methylated ZRE2 and ZRE3 performed by Carlos 
Petosa and colleagues at EMBL, Grenoble.  Figure 3.8A describes the nomenclature 
used in these models, the two DNA half sites are designated left and right and the CpG 
motifs are 1 and 2.  The difference in the modelling of ZRE2 and ZRE3 is in right DNA 
half-site as the 2 base-pair difference (+1 and +2) occurs at this position.   The models 
provide an explanation for three key experimental observations; the lack of affinity for 
unmethylated ZRE3, enhanced binding to methylated ZRE2 and ZRE3 and loss of 
affinity for methylated ZRE3 by mutant C189S. 
 Firstly the binding affinity of Zta for unmethylated ZRE3 is greatly diminished in 
comparison to ZRE2 or AP1.  In the crystal structure Zta makes base-specific 
interactions with Asn-182 and Arg-190 (Petosa et al., 2006). Arg-190 interacts in an 
asymmetrical manner that is conserved for the ZRE sites. Asn-182 contacts via 
basepairs ±2 in AP1.  ZRE2 is divergent at -2 and ZRE3 at +2 and -2 (Figure 3.8A).  
This means that the Asn-182 contact is disrupted in the left DNA half-site for ZRE2 and 
is completely disrupted for ZRE3.  It is probable that the additional disruption of this 
interaction with ZRE3 accounts for the loss of affinity Zta has for this site.    
 
The modelling can also explain the enhanced binding to ZRE2 and ZRE3 in the 
methylated state.  Methylation of motif 1 introduces a direct contact between Cytosine1’ 
methyl group and Ser-186Left  (Petosa et al., 2006) and is further enhanced by a 
hydrophobic contact between Cys-189Left and the cytosine-2 methyl group (Karlsson et 
al., 2008a) (Figure 3.8D).  Ser-186Left  and Cys-189Left simultaneously interact with the 
two methyl groups that comprise motif 1.  These are the 2 methyl groups (1’ and -2) 
that I demonstrated to be able to compete most effectively for Zta binding.  The position 
of the DNA and protein helices are not equivalent for both motifs.  CpG motif 2 is 
offset by 1 bp relative to the bZIP helix and in contrast to motif 1, interacts with both 
left and right bZIP helices.  The aromatic ring of cytosine-1’ has a π-cation interaction 
with the guanidino group of Arg-190Left  (Figure 3.8B).   
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Figure 3.8: Structural model of Zta bound to meZRE3 
Modelling of Zta-meZRE3 by Carlos Petosa at EMBL, Grenoble 
(Karlsson et al., 2008a).  
A. Alignment of Zta recognition sequences. The numbering convention is shown for 
basepair positions (bold italics) and individual nucleotides (plain font). Cytosines 
modified by methylation are indicated by a dot. B. Model of the Zta-meZRE3 
complex viewed along the pseudodyad. The methylation sensitive C189 residue (red 
asterisk) and bidentate hydrogen bond interactions between R190Left and Guanine0’ 
(dotted black lines) are indicated. Cytosine methyl groups are semi-transparent. C. 
Orthogonal view. The hydrophobic contact between Cytosine
1’
 and S186
Left
 (broken 
blue line) and hydrogen bond network involving S186Left, N182Left and Guanine2’ 
(dotted black lines) are shown. D. Schematic summary of contacts. van der Waals 
contacts involving the CpG methyl groups and Zta residues are shown as red and black 
broken lines. 
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As the methyl group is electron-donating, methylation of this residue would increase the 
negative charge in the π-electron system, thus enhancing the interaction.  In addition 
there is an extra van der Waals contact with the arginine side-chain (Karlsson et al., 
2008a).  The methyl group of cytosine0 interacts with Ser-186Right and Arg-190Right 
(Figure 3.8C). The models suggest contact between Zta and each of the four CpG 
methyl groups.  This agrees with my competition EMSA experimental evidence of a 
contribution to binding from each of the methyl groups.     
 
The C189S mutation dramatically reduces binding to methylated ZRE3.  The modelling 
postulates that the methylation sensitivity of CpG motif 1 by C189Left is due to a direct 
contact between the thiol group of C189Left and the methyl group of cytosine-2 (Figure 
3.9). This interaction would be destabilized by substitution of the hydrophobic cysteine 
to a more polar serine residue.  This methyl group and thus interaction is common to 
both ZRE2 and ZRE3.  This explains the decreased binding affinity as assessed by 
EMSA for ZtaC189S for methylated ZRE2 and ZRE3 (Figure 3.7).  As the thiol-methyl 
contact is only present in methylated sites this also could explain why ZtaC189S has no 
effect on binding in unmethylated ZRE2.  In motif 2, which is not present in ZRE2, the 
C189S residue is not close enough to form a direct bond with any cytosine methyl 
group. However the modelling puts C189Right in van der Waals contact with the methyl 
group of thymidine-2’ (Figure 3.9D).  It is probable this bond would be disrupted by 
mutation to C189S in the same way as the symmetrically equivalent bond between 
cysteine-2 methyl group and C189Left. This would mean that ZtaC189S destabilizes 
bonds with both half-sites in methylated ZRE3 and could explain the greatly impaired 
binding of ZtaC189S to meZRE3. 
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Figure 3.9: Interactions mediated by CpG motifs and C189 and S186 residues 
Interactions involvingCpG motif 1 (A) and motif 2 (B) are shown in approximately the 
same orientation.  Hydrophobic contacts are shown in dashed blue lines and hydrogen 
bonds as dotted black lines. Motif 1 contacts the left bZIP helix (green) only, while 
motif 2 contacts the Left and Right (yellow) helices of Zta.  Thiol-methyl group 
contacts mediated by C189 in the left (C) and right (D) helices.  Cys-189Left  contacts 
the methyl group of cytosine
-2
 while Cys-189
Right
 contacts the methyl group of Thy
-2’
.  
(Karlsson et al., 2008a) 
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3.3 Discussion 
Zta was the first transcription factor identified to have the ability to preferentially bind 
to and activate methylated promoters.  This appears to be crucial in the function of the 
virus as it allows a mechanism to escape the otherwise inhibitory effects of viral and 
potentially host genome methylation.  In order to understand the mechanism behind this 
key ability of Zta it is necessary to elucidate the interactions between the protein and the 
methylated DNA binding site.    
As the key previous experiments by Bhende et al. (Bhende et al., 2004) had utilised a 
promoter that was only partially methylated, initially I sought to clarify binding of Zta 
to the fully methylated promoter that would be found in vivo. In accordance with the 
Bhende study (Bhende et al., 2004), Zta binding to unmethylated ZRE3 was not 
detectable.  Full methylation of  ZRE3 me(-1’, -2, 1’, 0) created a site that was 16% 
better at binding Zta than the partially methylated ZRE3 me(-1’, -2).  This suggests that 
methylation at positions 1’ and 0 has some additional contribution to creating a stronger 
Zta binding site.   
Further examination of the individual contribution of all 4 methylation sites revealed 
that all competed for binding to varying degree, suggesting that all 4 methylated sites 
contribute to the interaction with Zta.  The order of site strength is meC1’ > meC-2 > 
meC0 ≥ meC-1’.  This reveals that the contribution to binding is strongest from CpG 
motif 1 that is common to both ZRE2 and ZRE3 (Figure 3.8A).  The contribution to 
binding is weaker from CpG motif 2, which is unique to ZRE3.  The modelling 
performed by Carlo Petosa and colleagues (Karlsson et al., 2008a) suggests that 
residues of Zta make contact with each of the 4 methyl groups which is consistent with 
my results of the competition binding by each individually methylated cytosine.  CpG 
motif 1 and CpG motif 2 are predicted to have different stereochemical environments 
although stronger binding by motif 1 was not explained. 
 
C189S is unable to bind to RpZRE3 in vivo, while DNA binding to Rp ZRE1 and ZRE2 
is maintained (Karlsson et al., 2008a). This selective inhibition of DNA binding implies 
that Zta interaction through ZRE3 is a critical step in activation of Rp. In vitro it was 
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demonstrated that C189S is defective in binding to methylated ZRE3 (Karlsson et al., 
2008a), highlighting this as the potential basis of the inability of C189S to activate Rp 
and resultant blockage of the lytic cycle. 
The Zta mutant C189S is compromised for binding to methylated ZRE3 and to a lesser 
extent ZRE2, while retaining wild-type level binding to unmethylated sites including 
ZRE1.  This makes C189S valuable as a selective tool for linking the relevance of 
methylation specific Zta binding to the in vivo disruption of latency.  ZtaC189S is 
unable to activate the expression of BRLF1 in Burkitt’s lymphoma derived Raji cells 
(Karlsson et al., 2008a), suggesting that binding to meZRE3 is essential for activation 
from the Rp promoter in these cells.  This supports the theory that recognition of 
methylated ZREs is a critical step for lytic reactivation of latent EBV in B-lymphocytes.  
A previous study by Wang et al demonstrated ZtaC189S produced only a slight 
disruption to reactivation of BRLF1 (Wang et al., 2005) in epithelial BZLF1-KO-293 
cells.  However in vivo lytic reactivation predominantly occurs in B-lymphocytes and 
the difference in activation by ZtaC189S may be a result of cellular differences in 
transcription factors or chromatin structure.  Raji cells also display a higher level of 
methylation than BZLF1-KO-293 and some other epithelial cells (Bhende et al., 2005).   
The modelling of Zta interacting with meZRE3 predicted that C189 would be sensitive 
to methylation of CpG motif 1 via a thiol-methyl group contact (figure 3.9C).  When 
C189 is substituted with an A or S, this thiol-methyl contact is lost and decreased DNA-
binding ability is observed (Figure 3.7).  C189 also appears important in the redox 
sensitivity of Zta DNA-binding.  Nitrosylation of C189 has been postulated as a 
mechanism for down-regulation of EBV reactivation by nitric oxide (Wang et al., 
2005).  This may be a link between other ways of regulating Zta and Rp activation and 
methylation.     
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Chapter 4     Promoter Functions of Zta and ZtaRh 
4.1 Introduction 
4.1.1 Lymphocryptoviruses 
EBV is a member of the lymphocryptovirus (LCV) genus, along with about 50 different 
LCVs that have been identified in both New and Old World primates (Ehlers et al., 
2010).  Almost every species of non-human primate is naturally infected by their own 
LCV which are closely related to EBV.  Phylogenetic trees have indicated synchronous 
evolution of viruses and hosts (Ehlers et al., 2010).  LCV genomes are organised in a 
collinear fashion with the EBV genome (Wang et al., 2001).  In general an identical 
repertoire of genes is present in each LCV, with greater conservation amongst lytic 
genes than latent genes (Wang et al., 2001).  Even genes with weaker homology 
between EBV and other LCVs such as EBNA 3A, 3B and 3C are functionally 
conserved, as are repeat structures (Wang et al., 2001).  The in vivo infection of the 
related LCVs also closely resembles the natural history of EBV infection (Wang et al., 
2001).  Asymptomatic, lifelong infection of most occurs in infancy and LCV-induced 
tumours arise in immune-suppressed primates (reviewed in (Wang et al., 2001)).  These 
similarities in epidemiology and pathogenesis identify simian LCVs as a valuable model 
system to provide a better understanding about EBV.  Despite the presence of LCVs in 
all Old World primates, initially it was not thought that New World primates were 
similarly infected as there was an absence of cross-reactive antibodies to EBV infected 
B cells.  This would have meant that LCV infection arose late in primate evolution, 
approximately 25 million years ago after the divergence of New and Old World 
primates (Wang, 2005).  The discovery of an LCV  infecting New World common 
marmosets by Cho et al (Cho et al., 2001) and evidence of related LCVs in most or all 
New World species (Ehlers et al., 2003) means that the appearance of EBV-related 
viruses occurred much earlier in primate evolution, at approximately 40 million years 
ago.    
 
4.1.2 Rhesus lymphocryptovirus 
The complete nucleotide sequence of the rhesus macaque LCV, Cercopithecine herpes 
virus 15 (Ce-HV15, RhLCV) has been sequenced (Rivailler et al., 2002).  Every EBV 
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gene is represented by a homologue in the same relative position in the RhLCV 
genome. This identical repertoire of genes has 65% overall similarity with EBV, with 
75.6% similarity in open reading frames.  This provides support at a genetic level for 
use of RhLCV as a model system to study the pathogenesis of EBV.  Proteins appear to 
be functionally conserved but display a range of amino acid similarity ranging from 
29.4% for EBNA3A to 96.9% for uracyl DNA glucosidase. Latent genes are less well 
conserved than lytic genes (Wang, 2005). Conservation between the host human and 
Rhesus macaque genomes is approximately 93% in alignable sequence (Gibbs et al., 
2007). 
 
Although they are relatively well conserved, LCVs appear to be mostly host species 
restricted.  RhLCV is unable to immortalize human B-cells and EBV is unable to 
immortalize cells from rhesus macaques (Moghaddam et al., 1998).  This restriction 
occurs at a later stage than viral entry and may be due to a crucial interaction with a host 
protein. However immortalization between some closely related species is possible, for 
example baboon LCV can immortalise rhesus monkey B cells (Moghaddam et al., 
1998). 
 
RhLCV has already proved valuable as a model species.  For example it is not possible 
to study the very early stages of primary EBV infection in vivo before the onset of any 
symptoms.  However RhLCV naïve rhesus macaques can be orally inoculated with the 
virus,  allowing investigation into the very early stages of infection (Moghaddam et al., 
1997) with wild-type or mutant virus.  Another valuable use of RhLCV is infection in 
immunocompromised animals, such as those infected with a simian-human chimeric 
immunodeficiency virus (SHIV).  Infection of rhesus macaques with SHIV results in an 
immunodeficiency similar to human HIV infection (Reimann et al., 1996).  This allows 
investigation of specific factors that contribute to disease development in LCV infected 
individuals such as components of the host immune response that control the infection 
and alterations in LCV-infected cells.  Potentially the results from experiments like this 
could provide strategies to prevent or treat EBV-associated cancer and disease in 
immunocompromised people.    
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Further investigation into the similarities and differences between EBV and the related 
LCVs could provide valuable information to improve the use of viruses such as RhLCV 
as a model system for EBV.  In addition the other LCVs provide a tool to increase our 
understanding of how EBV works.  
 
My initial aims are to examine the site specific DNA binding function of ZtaRh to 
investigate how it operates as transcription factor.  This will include identification of 
potential ZREs within the RhLCV genome as well as utilisation of a promoter assay to 
assess functionality. 
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4.2 Results 
4.2.1 Alignment of Zta and ZtaRh 
The RhLCV protein ZtaRh is a homologue to EBV Zta.  ZtaRh is a 247 amino acid 
protein, arranged into the same 4 domains as Zta.  Overall ZtaRh displays 71.3% 
similarity to Zta at the protein level (Figure 4.1).  The two proteins share 63% identity 
in the N-terminal transactivation domain and only 11% of the differences are 
conservative amino acid substitutions. The C-terminal third of the protein shows a 
higher degree of similarity (83%) with a total of only 11 amino acid differences in the 
basic, coiled-coil and CT regions.  In contrast to the transactivation domain, 89% of the 
differences are conservative amino acid changes.   
The ability and specificity of the ZtaRh interaction with DNA was questioned because 
there are two amino acid differences in the basic (DNA contact) region (K192R and 
Q195N) and the region immediately adjacent to the bZIP region of ZtaEBV has been 
shown to influence the DNA-binding specificity of Zta.  
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Figure 4.1: Amino acid alignment of Zta and ZtaRh proteins 
The residues highlighted in blue are conservative differences and non-conservative differences are highlighted in red.  The amino acid numbering 
of the Zta protein is bracketed to the left of the alignment.  The transactivation, DNA binding, Zipper and CT domains are indicated below the 
residues.  The alignment was originally done using Invitrogen Vector NTI. 
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4.2.2 Electrophoretic Mobility Shift Assay (EMSA) 
The ability of ZtaRh to bind known Zta Response Elements (ZREs) was examined 
through Electrophoretic Mobility Shift Assays (EMSAs).   
Radio-labelled Zta and ZtaRh proteins were produced from expression vectors using in 
vitro transcription and rabbit reticulocyte in vitro translation.  The RhLCV Zta had been 
cloned by a previous member of the Sinclair lab, Mirjam Mayer.  [35S] Methionine was 
incorporated into the proteins during translation to allow detection on a phosphor 
imager.   
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Double-stranded 33P end-labelled probes were created for six ZRE sequences that Zta is 
known to bind (Figure 4.2).  
 
Figure 4.2: EMSA probe sequences 
The sequences of the 8 ZRE probes used in the EMSA experiments are shown, aligned 
by the highlighted core binding sequence. The red cytosine bases are methylated.  
Probes were labelled with 33P  then annealed to the reverse complement oligo.   
 
 
These probe sequences are all derived from ZREs within promoters or the lytic origin of 
replication (oriLyt) from the EBV genome (Table 4.3).  The probes ZRE1, ZRE2 and 
ZRE3 are from the promoter of the EBV gene BRLF1.  ZRE2 contains one CpG 
methylation site and ZRE3 contains two methylation sites.  These probes were tested 
separately in the methylated and unmethylated forms. The AP1, ZREIIIB, ZRE1 and 
ZRE2 sites are fully conserved in the RhLCV genome.  The ZRE used for the oriLyt 
probe differs by 1 base in RhLCV and ZRE3 is divergent at 4 bases as shown in Table 
4.3.   
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ZRE probe EBV location EBV sequence RhLCV
AP1 BMRF1 promoter TGACTCA conserved
oriLyt ori Lyt 1 TTACACA TTGCACA
ZREIIIB BZLF1 promoter TTAGCAA conserved
ZRE1 BRLF1 promoter TGAGCCA conserved
ZRE2 BRLF1 promoter TCGCTCA conserved
ZRE3 BRLF1 promoter TTCGCGA TCCGGCG
 
Table 4.3: Location and conservation of EMSA probe ZREs 
Five of the six ZRE sequences used in initial EMSA experiments are located within 
three different EBV promoters.  oriLyt is derived from the ZRE oriLyt1 within the 
oriLyt-left region.  The sequences of AP1, ZREIIIB, ZRE1 and ZRE2 are fully 
conserved in RhLCV.  The divergent RhLCV sequences of oriLyt and ZRE3 are shown.   
 
 
For these experiments oligos were methylated at CpG sites during synthesis (Sigma) as 
indicated in Figure 4.2.  Equivalent amounts of each protein were used in EMSA 
reactions for each probe.  A negative control (IVT), containing all the translation 
components except the RNA, was used to determine if proteins in the rabbit reticulocyte 
bind to the specific DNA probe used.  Following quantitation of DNA-probe complexes 
with phospho image analysis, the binding efficiency relative to Zta was calculated 
(Figures 4.4, 4.5, 4.6).  It was important to establish that there was excess probe in each 
reaction, seen as bands at the bottom of the gel.  This determines that the binding 
reaction is not limited due to lack of probe.  All experiments were duplicated.   
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Figure 4.4: Binding by Zta and ZtaRh to AP1 ZRE 
Zta and ZtaRh protein was radiolabelled with [35S] met during in vitro translation with 
Promega Rabbit Reticulocyte Lysate, separated by SDS-PAGE and visualised using a 
phosphoimager. Equivalent amounts of protein (A) were used in all EMSA analysis (B) 
with [33P]-labelled AP1 DNA probe (GATCCATGACTCAGAGGAAAACATACG).  Black 
arrows indicate DNA/protein complexes. A strong second lower band (indicated with 
lower black arrow) was consistently seen in ZtaRh lanes.  The red arrow shows 
unbound free probe.   Experiments were performed in duplicate and in full (2μl protein) 
and half (1μl protein) size reactions and average values are shown.  Probe alone is in 
lane 1 and translation reaction omitting RNA (IVT) as a control is in lane 2. Images 
were scanned on a phosphoimager (Molecular Dynamics Storm 860).  Band size was 
quantitated with Imagequant software (Molecular Dynamics) to determine binding 
efficiency relative to full size Zta (C). For ZtaRh samples the two bands indicated with 
arrows were quantitated and binding efficiency calculated from the combined value.
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Figure 4.5: ori Lyt, ZREIIIB and ZRE1 EMSAs 
EMSA gels and relative binding efficiency graphs for (A) ori Lyt (probe- 
CCTTAAAGTATTACACAGAG), (B) ZREIIIB (probe- GTACATTAGCAATGCCTG) and 
(C) ZRE1 (probe- GATCTCTTTTATGAGCCATTGGCA). Reactions were performed as 
in Figure 4.4. 
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Figure 4.6: ZRE2 and ZRE3 EMSAs 
EMSA gels and relative binding efficiency graphs 
for  (A) ZRE2 methylated (probe-
GATCATAAAATCGCTCATAAGCTT), (B) ZRE2 
unmethylated and (C) ZRE3 methylated (probe-
GATCTATAGCATCGCGAATTTTGA) and (D) ZRE3 
unmethylated.  As there was no binding to ZRE3 
unmeth these reactions and gels were performed 
alongside other probes as a control.  Full and half 
size reactions were performed as in Figure 4.4.  In 
the probe sequence the red cytosine is methylated.  
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Neither protein was able to bind to the unmethylated ZRE3 probe so no numerical data 
was obtained from this experiment.  The binding ability of Zta and ZtaRh to the probes 
tested was similar (Figure 4.7) with the greatest difference in binding of ZtaRh to ZRE3 
methylated which was reduced by 26%.   
This demonstrates that the repertoire of DNA binding sites that ZtaRh is capable of 
binding to overlaps with that of Zta.   
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Figure 4.7: Similar binding ability of Zta and ZtaRh to 8 ZRE probes 
Summary graph showing the average relative binding of Zta and ZtaRh to 8 EMSA 
ZRE probes.  This graph summarises the data shown in Figures 4.4, 4.5 and 4.6.  There 
was no binding for either protein to ZRE3 unmethylated.  Experiments were duplicated 
and the average value shown. 
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4.2.3 ZREs in RhLCV oriLyt 
As the binding ability of the proteins appears to be conserved between the two species, I 
next compared the conservation of ZRE sites within the EBV and RhLCV genomes. 
The left and right origins of lytic replication (oriLyt) are conserved with 88-90% 
identity for both regions.  Figure 4.8 shows an alignment of the oriLyt Left for EBV and 
RhLCV with the seven ZREs in this region highlighted.  4 of the ZREs are completely 
conserved with a sequence difference in the remaining three; oriLyt 1, 6 and 7.  RhLCV 
oriLyt 1 and 6 both differ from EBV by a single base, while oriLyt 7 has two 
differences.  Results are very similar for oriLyt Right which is located in the Rh LCV 
genome at 138,134 - 139,200 bp.   
 
I designed EMSA probes for oriLyt 1, oriLyt 6 and oriLyt 7 using the RhLCV sequence 
as shown in Figure 4.9A.   I compared binding with the EBV and LCV Zta proteins 
using duplicate EMSAs as previously.  The data suggests binding by ZtaRh to oriLyt 6 
and oriLyt 7 was reduced by 50% and 40% respectively (Figure 4.9), however further 
experimental replications would need to be performed to quantify these obsevations. 
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Figure 4.8: Alignment of the oriLyt-Left region of the EBV and RhLCV genomes 
EBV nucleotide sequence is in black and RhLCV sequence is in red.  Sequence differences are highlighted in blue. The seven Zta Response 
Elements, oriLyt 1-7, are boxed in yellow and numbered.  The EBV genomic numbering is shown in brackets.   In the RhLCV genome this 
sequence is located at 34339-35331 bp.  This oriLyt region shows an 88.3% identity between the two genomes. 
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Figure 4.9: Binding by Zta and ZtaRh to three ZREs from RhLCV ori Lyt 
Alignment of the ori Lyt region from EBV and RhLCV showed a difference in three 
ZREs; ori Lyt 1, 6 and 7 (A).  EMSA probes were created using the RhLCV sequence.  
EMSAs were  performed as in Figure 4.4 using Zta and ZtaRh proteins for oriLyt 1 (B), 
ori Lyt 6 (C) and ori Lyt 7 (D).  Example gels and the relative binding graphs are 
shown.  All experiments were duplicated and the average value shown.  
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4.2.4 ZREs in RhLCV BRLF1 promoter 
The promoter of the EBV BRLF1 (Rp) gene contains three ZREs and encodes the 
protein Rta.  These were included in the initial EMSA experiments and ZtaRh was able 
to bind to all three EBV sites.  EBV Rp ZRE2 contains a single CpG methylation site 
and ZRE3 contains two.  As binding to these three ZRE sequences is conserved, I 
aligned the sequences for EBV Rp and  RhLCV Rp (Figure 4.10) to see if the sequences 
are retained in the RhLCV genome.  This revealed that ZRE1 and ZRE2 are completely 
conserved, however ZRE3 is not.  Through sequence alignment the sequence in the 
equivalent position is CGCCGGA.  This sequence only has 3 bases in the same position 
(highlighted) as the EBV sequence, TCGCGAA.  The RhLCV sequence also has 2 CpG 
motifs but they are in a different configuration.  The RhLCV Rp sequence is located in 
the RHLCV genome at 88050 – 88446bp and the sequence identity is 85%.  In order to 
establish if the RhLCV site could potentially operate as a ZRE, I created an EMSA 
probe of the sequence (RhLCV ZRE3) in both methylated and unmethylated versions 
(Figure 4.11).  EMSAs were performed as previously.  Neither Zta nor ZtaRh were able 
to bind to methylated or unmethylated RhLCV ZRE3, suggesting it is non-functional.  
Analysis of the RhLCV promoter with a Microsoft Word macro to search for known 
ZREs from a database compiled by Kirsty Flower in the Sinclair lab revealed that there 
are no other known functional ZRE sites within the RhLCV promoter (Flower et al., 
2011). 
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Figure 4.10: Alignment of BRLF1 gene promoter from EBV and RhLCV 
EBV nucleotide sequence is in black and RhLCV sequence is in red. Sequence differences are highlighted in blue.  The transcription start site is 
marked with an arrow.   The three Zta Response Elements; ZRE1, ZRE2 and ZRE3, are boxed in yellow and numbered.  The EBV genomic 
numbering is shown in brackets.  The RhLCV sequence is located in the genome at 88050 – 88446bp.  There is 85% sequence identity between 
the two viruses in this region.   
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Figure 4.11: Zta and ZtaRh are unable to bind to ZRE3 from RhLCV Rta 
promoter 
An aligned comparison of the region around ZRE3 is shown for both viruses (A). 
Potential methylation sites are indicated with asterixes. Methylated and unmethylated 
EMSA probes were created using the RhLCV sequence.  EMSAs were performed (B) as 
in Figure 4.4.   No binding was seen for either protein.  The left hand panel shows the 
expected position of bound, labelled Zta in a positive control.    
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4.2.5 Determination of methylation dependent promoter efficiency 
In order to compare the effectiveness of RhLCV Rp with the equivalent promoter from 
EBV and to establish the importance of the ZRE3 site in the context of the whole 
promoter region, I performed a luciferase assay.  This allows quantification of 
transcriptional activity from a promoter using luciferase as a reporter gene.  It involves 
inserting the promoter of interest into an expression vector, directly upstream of the 
luciferase gene.  This brings the luciferase gene under control of the promoter being 
studied and allows ready detection of gene expression.   
 
I cloned the Rp from each virus into the vector pGL2 (Promega).  The pGL2 vector 
encodes the firefly (Photinus pyralis) luciferase gene.  Expression of the gene through 
promoter activation results in the oxidation of a luciferin, coelenterazine, by luciferase 
to produce a luminescent protein, coelenteramide.  This can then be quantitated using a 
luminometer.  This assay would enable a comparison of the relative strength of the 
promoters from EBV and RhLCV.  Inserting a functional ZRE3 into the Rh promoter 
would help ascertain if there is a possible function for this site in RhLCV.     
 
4.2.5.1 Cloning EBV and RhLCV Rp 
The aim was to clone the promoters of EBV BRLF1 (Rp) and RhLCV BRLF1 (RhRp) 
immediately upstream from the luciferase gene in the pGL2 vector.  This makes it 
possible to readily measure gene expression by detection of luciferase. I designed PCR 
primers to amplify approximately 1000bp encoding the promoter region of EBV Rp and 
RhLCV RhRp.  Originally I incorporated restriction enzyme cutting sites for MluI and 
XhoI at the primer ends to enable cloning into the multiple cloning region of the pGL2 
vector.   EBV Rp was amplified using PCR using Rp-CAT as a template.  Rp-CAT is a 
plasmid containing the promoter region of BRLF1 coupled to the chloramphenicol 
acetyltransferase (CAT) gene (Sinclair et al., 1991). The PCR template DNA for RhRp 
was Cosmid LV28, containing RhLCV DNA from 70,760 to 111,969 bp in the 
SuperCos vector (a gift from Prof. Fred Wang).   
Both Rp fragments were successfully amplified (Figure 4.12A), restriction digested 
with MluI and XhoI and purified from agarose gel using QIAquick gel extraction 
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(Qiagen).  The pGL2 vector was also digested and purified in the same way. However 
multiple attempts at ligating the fragments into the digested pGL2 vector failed.  
I then repeated the PCR reactions and digested newly amplified, purified products with 
XhoI alone.  The pGL2 vector was sequentially digested with the blunt cutter SmaI (in 
place of MluI) then XhoI.  After overnight ligation reactions, products were transformed 
into chemically competent E. coli cells and grown on agar plates.  Colonies were picked 
and grown before plasmid DNA was extracted using a Qiagen Miniprep kit.  Successful 
cloning of EBV Rp was detected by the presence of 3 restriction bands (sizes 277bp, 
462bp and 217bp) when cut with HindIII.   Cutting cloned RhRp with SmaI produced a 
band of 395bp.  Vectors were sequenced to confirm cloning of the appropriate region 
was successful.  The pGL2 vectors now contain Rp from EBV or RhLCV (Figure 
4.12B).   
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Figure 4.12: Cloning EBV Rp and RhLCV Rp and ZRE3 mutants 
The promoter regions of EBV Rp and RhLCV Rp were amplified using PCR (A). 
Products were restriction digested using SmaI and XhoI and ligated into Promega pGL2 
vector (B) which contains the gene for firefly luciferase (luc).  
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Mutagenesis to knock out EBV ZRE3 
I designed mis-matched primers (Figure 4.13A) to convert ZRE3 in EBV Rp into a non-
functional site using site-directed mutagenesis, creating the vector EBV∆ZRE3.  This 
was undertaken successfully as shown by sequencing of the mutant in Figure 4.13C. 
The mutant sequence (CCGTCAA)is the same sequence used by Bhende et al (Bhende et 
al., 2004) in their investigations into Rp. 
    
Mutagenesis to insert functional ZRE3 into Rh 
Through sequence alignment the equivalent position of ZRE3 in RhLCV Rp (Figure 
4.10) was identified. Site-directed mutagenesis was used to introduce a ZRE3 site into 
this position (Figure 4.13B) to create the vector Rh+ZRE3.  Rh+ZRE3 was sequenced 
to verify the mutations were accurate (Figure 4.13D).   
 
Cloning his-tagged ZtaRh into pBabe 
ZtaRh is not detected by the BZ1 antibody used to identify Zta in western blots, so I 
subcloned ZtaRh and Zta into pBabe vectors, incorporating a 6x-histidine (his) tag.  I 
designed a forward PCR primer for each gene including 6 repeats of the sequence CAT, 
preceded by ATG.  This encodes for a 5’ tag of 6 histidine residues which can be 
detected by a his-Tag antibody.  The his-tagged Zta gene was able to reactivate EBV 
from latency to an equivalent level as non-his-tagged Zta. 
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Figure 4.13: Site directed mutagenesis of Rp luciferase vector 
Site directed mutagenesis (sdm) was performed on EBV Rp to render ZRE3 non-
functional (A).  The bases shown in red were altered in the sdm reaction to create 
EBV∆ZRE3.  Sdm was performed on the RhLCV Rp vector to insert an EBV ZRE3 
into in the aligned sequence position (B), creating Rh+ZRE3. Vectors were sequenced to 
confirm changes (C and D).  ZRE sites are highlighted in yellow and altered bases in 
EBV∆ZRE3 (C) and Rh+ZRE3 (D) are highlighted in orange.  Rh+ZRE3 was 
sequenced in reverse and the complement sequence is shown below. 
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4.2.5.2 Methylation of vectors 
In order to assess the effect of methylation on promoter efficiency, I had to create 
methylated versions of each vector.  This was achieved using the CpG 
Methyltransferase M.SssI (NEB). This enzyme methylates the cytosine residue in all 
double-stranded CpG motifs. 10μg of each vector (EBVRp, RhRp, EBV∆ZRE3 and 
Rh+ZRE3) was incubated with 50U SssI enzyme, NEB Buffer 2 (to 1x), 1 μl of 32mM 
S-adenosylmethionine (SAM) and H20.  After 1 hour at 37°C, the reaction was stopped 
by incubating at 65°C for 20 minutes. Each vector was also mock-methylated in 
reactions excluding enzyme.  Reactions were digested with the methylation-dependent 
restriction enzyme BstUI, which is unable to digest CpG methylated DNA.  Protection 
from digestion in this reaction confirmed methylation (Figure 4.14).  
 
Figure 4.14: Methylation of  Rta Promoter Vectors 
pGL2  luciferase vectors containing EBV Rp, RhLCV Rp, EBV∆ZRE3 and Rh+ZRE3 
were methylated and mock-methylated (no enzyme) with SssI methylase.  Reactions 
were then cut with the methylation dependent BstUI restriction enzyme and run on 
agarose gels to confirm methylation.  The left panel shows digested unmethylated (U) 
DNA and methylated (M) EBV∆ZRE3 which was protected from digestion.  The right 
panel has 2 unmethylated controls and methylated EBV (E) Rp, RhLCV (R) Rp and 
Rh+ZRE3.     
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4.2.5.3 Luciferase assay  
HEK293 cells were co-transfected with pBabe Zta, pBabe ZtaRh or empty pBabe and 
methylated or non-methylated pGL2 containing EBV Rta promoter (EBVRp), RhLCV 
Rta Promoter (RhRp), EBVRp with non-functional ZRE3 (EBVΔZRE3) or RhRp with 
EBV ZRE3 (Rh+ZRE3).    Cells were harvested and lysed after 24 hours growth and 
bioluminescence was measured on a luminometer. The entire experiment was 
duplicated.   
Western blots for expression of cdk2 were performed as a loading control (Figure 
4.15A).  Samples were also analysed for Zta and ZtaRh levels with western blots using 
an α-his antibody (Figure 4.15B).  Equivalent levels of protein were observed.   
 
Figure 4.15: Western blots for luciferase assay 
A western blot of cdk2 is shown as a loading control (A). α-his antibody detected his-
Zta and his-ZtaRh for methylated and unmethylated samples used in the luciferase assay 
(B).  
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Figure 4.16 shows the relative luminescence levels detected for unmethylated 
promoters.  As can be seen in the graph neither Zta or ZtaRh were able to activate any 
of the four unmethylated promoters.  As luciferase levels for these samples are not 
above the levels of empty pBabe vector, it can set the background for activation from 
methylated promoters.  This also clearly demonstrates that both EBVRp and RhRp are 
not capable of enabling transcription in the absence of methylation.  It can be seen in 
Figure 4.16 that the background level of activation varied widely from 2 to 20.  This 
variability could arise from differences in transfection efficiency, cell viability or 
pipetting and should be considered when interpreting results from this method. 
    
The methylated versions of these promoters were activated by the addition of Zta or 
ZtaRh as shown in Figure 4.17.  EBVRp was activated by both Zta and ZtaRh.  The 
resulting luciferase level after activation by Zta is 3 fold higher than from activation by 
ZtaRh.  The wild-type RhRp promoter is also activated by both proteins, although it is a 
weaker promoter in this system with 4 fold lower luciferase levels from Zta and 5 fold 
less from ZtaRh.  Despite the loss of a functional methylation dependent ZRE3 within 
the RhRp, the promoter is still methylation dependent when activated by Zta or ZtaRh. 
 
The loss of a functional ZRE3 site in EBV∆ZRE3 reduced the activation by both Zta 
and ZtaRh.  There was a 32% reduction in activation by Zta from EBVΔZRE3 
compared to the EBVRp which contains an intact ZRE3 site.  This is a smaller effect 
than was observed by Bhende et al (Bhende et al., 2004).  The reduction in activation 
for ZtaRh from EBVΔZRE3 is slightly more pronounced at 53%.  This data indicates 
that both proteins contribute to the activation of the promoter through binding at ZRE3.   
 
Addition of a functional ZRE3 site into the RhRp promoter was not sufficient for either 
protein to increase the activation from the wild-type RhRp promoter.  The lack of a  
ZRE3 element in RhRp does not appear to account for the lower level of activation in 
comparison to EBVRp.   ZtaRh was considerably weaker at activating all 4 promoters in 
comparison to Zta, using this system.  Reducing the experimental variability and further 
experiments would provide greater evidence of the influence of the individual promoter 
elements on expression levels.
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Figure 4.16: Rta Promoter luciferase assay with unmethylated promoters 
HEK293 cells were co-transfected with pBabe vector encoding Zta, ZtaRh or empty and 
unmethylated pGL2 vectors containing EBV Rta Promotor (EBVRp), RhLCV Rta 
Promotor (RhRp), EBVRp with nonfunctional ZRE3 (EBVΔZRE3) or RhRp with EBV 
ZRE3 (Rh+ZRE3).  Cells were harvested and lysed after 24 hours and the luciferase 
level was detected by a luminometer.  Experiments were performed in duplicate and 
average values are shown.
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Figure 4.17: Rta Promoter luciferase assay with methylated promoters 
HEK293 cells were co-transfected with pBabe vector encoding Zta, ZtaRh or empty and 
methylated pGL2 vectors containing EBV Rta Promotor (EBVRp), RhLCV Rta 
Promotor (RhRp), EBVRp with nonfunctional ZRE3 (EBVΔZRE3) or RhRp with EBV 
ZRE3 (Rh+ZRE3).  Cells were harvested and lysed after 24 hours and the luciferase 
level was detected by a luminometer.  Experiments were performed in duplicate and 
average values are shown. 
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4.3 Discussion 
Zta is relatively well conserved between RhLCV and EBV.  There is a smaller degree of 
conservation in the N-terminal transactivation domain of the protein.  As this region is 
assumed to interact with host proteins to transactivate transcription, species specific 
differences in host proteins may have driven selection for these differences.   
 
There are 2 amino acid changes located in the basic DNA contact domain of ZtaRh.  As 
this region influences the specificity of Zta DNA-binding, binding of ZtaRh was 
investigated.   
 
EMSA DNA-binding experiments revealed there were no differences in binding by Zta 
and ZtaRh to any of the six DNA probes analysed or to 2 methylated variants.  This 
included 2 sites, ori Lyt and Rp ZRE3, which are not conserved in the RhLCV genome.  
Despite the changes in ZtaRh sequence and some relevant differences in the target 
binding sites, the range of sites that ZtaRh can bind overlaps with binding by Zta.    
Analysis of ZREs in the EBV and RhLCV genomes revealed some differences between 
the two viruses.  There were alterations in three (oriLyt 1, 6 and 7) of the seven ZREs in 
the left oriLyt.  When oriLyt 1, 6 and 7 from RhLCV oriLyt were utilised as EMSA 
probes, both Zta and ZtaRh were able to bind with with considerable strength, although 
ZtaRh was weaker.   
 
The Rp promoter elements ZRE1 and ZRE2 were conserved but ZRE3 differed at 4 
bases.  The ZtaRh Rp ZRE3 site still has 2 methylation sites although the conformation 
is different.  When used as an EMSA probe, neither Zta nor ZtaRh were able to bind to 
methylated or unmethylated versions of RhLCV Rp ZRE3.  Analysis of the RhLCV Rp 
promoter found no additional known functional ZRE sites.  For EBV, activation via 
ZRE3 is required for activation of Rp, as demonstrated by the Zta mutant C189S 
(Karlsson et al., 2008a).  Without a functional ZRE3, RhLCV must act in a different 
way to activate Rp.   
 
The Rp promoters from EBV and RhLCV were cloned into a luciferase expression 
vector and 2 mutant variants of the promoters were created.  The first mutant was EBV 
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Rp containing a non-functional ZRE3 and the second mutant was RhLCV Rp with the 
insertion of a functional EBV ZRE3 in the equivalent position.  Each vector was 
methylated and analysed in both the unmethylated and methylated forms using an 
luciferase assay in HEK293 with Zta and ZtaRh.  The resultant bio-luminescence was 
analysed to reveal the magnitude of activation.   Neither Zta nor ZtaRh were able to 
activate any of the four unmethylated promoters.  Both methylated wild-type EBVRp 
and RhRp were activated by both proteins, although EBVRp was a stronger promoter.  
This suggests that methylation is of critical importance for activation from both 
promoters in these cells.  Removal of ZRE3 from EBVRp resulted in weaker binding 
for Zta and ZtaRh.  This indicates that both proteins contribute to activation of EBVRp 
through ZRE3.  This observation for Zta is in agreement with (Bhende et al., 2004). 
However the addition of a functional ZRE3 into RhRp did not result in higher levels of 
activation than from wild-type RhRp for either protein.  In all experiments ZtaRh was 3-
4 times weaker than Zta in promoter activation.  As there was a high level of variability 
in the background luciferase levels, further experiments could provide stronger evidence 
for the influence of individual elements on promoter activation.   
 
These results suggest that in these cells for EBV methylation of ZRE3 is dominant for 
promoter activation.  However for RhLCV, methylation is important but this does not 
occur via ZRE3.  As ZRE2 contains the only other methylation site within a ZRE in this 
promoter, it is possible that methylation of ZRE2 plays a more critical role in RhLCV.  
These experiments were completed in human cells and experiments performed with 
ZtaRh in the natural Rhesus monkey host cells, with the different complement of host 
cell proteins present would produce a result that is more informative for ZtaRh.  There 
is currently no suitable Rh cell line in existence. 
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Chapter 5      Lytic Reactivation and Cell Cycle 
5.1 Introduction 
The previous chapter has shown that ZtaRh is functional for DNA binding.  This 
chapter assesses whether ZtaRh is also able to perform other important functions of Zta, 
namely lytic reactivation and enabling cell cycle arrest.  Any divergence of ZtaRh from 
the normal functions of Zta may help to further characterise key regions of this 
important protein. 
 
5.1.1 Lytic Reactivation 
One of the key functions of Zta is reactivation of EBV from latency.  The transcriptional 
activation function of Zta is critical for this lytic reactivation function.  As part of this 
process Zta is required for both lytic cycle gene expression and DNA replication (Zhang 
et al., 1996). 
The ability to reactivate EBV from latency can be assessed using HEK 293 ZKO cells 
(Feederle et al., 2000). These cells are stably transfected with the EBV genome 
containing a defective BZLF1 gene. Transfection with a vector capable of expressing 
functional Zta results in activation of the lytic cycle and consequent replication of the 
EBV genome as shown in Figure 5.1.  The level of lytic activation can then be assessed 
using QPCR.   
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Figure 5.1: Schematic of lytic reactivation experiment 
An expression vector containing the BZLF1 gene encoding Zta is transfected into 
HEK293-ZKO cells (A).  These are human embryonic kidney cells stably transfected 
with the EBV genome containing a defective copy of the BZLF1 gene. B.  Zta protein 
produced by the incoming vector is able to activate the lytic cycle of EBV.  This 
produces DNA which is then extracted along with host cell DNA and analysed using 
QPCR.   
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5.1.2 Zta and the cell cycle 
Zta has the ability to modulate the environment of the host cell to provide optimum 
conditions for EBV replication during the lytic cycle .  This includes the ability to cause 
cell cycle arrest in some cell types (Figure 1.11).  The benefit of this activity to the virus 
during the lytic cycle is likely to be two-fold.  Firstly as EBV relies on the expression of 
some cellular genes for viral DNA replication, arrest ensures that these proteins are 
available.  Secondly mitosis is prevented until the viral lytic cycle has been completed.   
This allows the virus to escape competition with the host genome for cellular 
components required for DNA replication. 
 
5.1.3 RhLCV and the cell cycle 
It is probable that an equivalent mechanism of cell cycle arrest occurs in rhesus LCV.  
In order to investigate this, ZtaRh was tested in a cell cycle assay. This could also 
highlight any contribution to functionality of amino acid differences between the two 
homologues.  Ideally experiments would be conducted in both rhesus cells and human 
cells, however as rhesus cells were not available, experiments were conducted in human 
HeLa cells. 
 
This chapter aims to assess whether ZtaRh is capable of performing two important 
functions of Zta, lytic reactivation and enabling cell cycle arrest.   
 
5.2 Results 
5.2.1 Lytic reactivation 
The ability of ZtaRh to reactivate EBV from latency, as determined by increased EBV 
genome levels, was assessed using his-tagged Zta and ZtaRh.  HEK293 ZKO cells were 
transfected with his-tagged Zta, ZtaRh or empty vector (pBabe).  Cells were incubated 
for 96 hours to enable EBV genome replication to occur before harvesting.  A sample of 
cells was used for western blotting to determine the presence of Zta and ZtaRh using an 
anti-His Tag antibody.  This control determined that equivalent levels of each protein 
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was expressed (Figure 5.2A).  In addition a western blot for the gene blc2 served as a 
loading control for each sample.  However apoptosis status may vary for different 
experimental samples, resulting in variable expression levels of bcl2.  This means that 
bcl2 was not an appropriate loading control to use for this experiment.  The genomic 
DNA was extracted from the remaining cells.  In order to assess if EBV DNA 
abundance was equivalent, the amount of EBV genome present was assessed using 
quantitative real time PCR (QPCR) using primers within the EBV DNA polymerase 
gene (Schelcher et al., 2005) (Figure 5.2B).  For each sample the level of human 
genome present was measured using QPCR with primers for the human gene β-globin 
as detailed in Table 2.2.  The relative expression of β-globin was used to standardise the 
samples for DNA level. The experiments are duplicated.  Transfection with Zta resulted 
in increased EBV genome levels.  However after transfection with ZtaRh the amount of 
EBV genome detected was only 23% of that Zta transfection (Figure 5.2).  The EBV 
genome levels following transfection with ZtaRh are very low and barely higher than 
seen as background detection following transfection with the empty pBabe vector.  As 
the loading control used was inappropriate these experiments should be repeated with 
another control to ensure accurate results.  However it appears that expression of the 
EBV genome is greatly reduced or absent following transfection with ZtaRh in 
comparison to Zta.    
As regions in the C-terminal domains of Zta have previously been shown to be 
important in lytic reactivation (Taylor et al., 1991; Schelcher et al., 2005) it was of 
interest to see if differences in this portion of Zta and ZtaRh could account for the loss 
of reactivation ability of ZtaRh.  The three C-terminal domains of Zta contain 11 amino 
acids differences from ZtaRh (Figure 5.3A).  The possible contribution of these 
divergent residues in the reduced lytic reactivation ability of ZtaRh was assessed 
through the creation of three domain swap mutants (Figure 5.3B-D).  
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Figure 5.2: Reactivation of lytic cycle by Zta and ZtaRh 
HEK293-BZLF1-KO cells were transfected with his-tagged Zta, ZtaRh or empty vector 
(pBabe).  Cells were harvested after 96 hours and genomic DNA was extracted. Western 
blots confirm that approximately equal amounts of protein were present (A). Molecular 
weight markers are shown on the left.  A Western Blot of bcl2 is shown as a loading 
control. Quantitative Real Time PCR (QPCR) was used to detect the presence of the 
EBV genome and beta-globin (B).  Results were standardised by the amount of beta-
globin present.  Experiments were duplicated and average value shown.  
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Figure 5.3: Zta and ZtaRh alignment and Domain swap mutants 
A. An alignment of the three terminal domains of Zta and ZtaRh from amino acids 177-245. Differences between the 2 proteins are highlighted in 
green and the functional domains are indicated below.  Mutants of Zta were constructed with each domain in turn containing ZtaRh sequence.  
The sequence of  the basic region domain swap mutant (BZta) is shown in B, the coiled coil mutant (ZipZta) in C and the CT region mutant 
(CTZta) in D.  Amino acids altered to match ZtaRh are highlighted in red and remaining differences are in green. The entire transactivation 
domain of these mutants is encoded by Zta.
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5.2.2 Creation of domain swap mutants 
The basic region of Zta (aa 177 - 195) differs from ZtaRh at two residues, Lys-192 and 
Gln-195.   Both substitutions are conservative; positively charged Lys-192 is substituted 
in ZtaRh for positively charged Arg and polar Gln-195 is substituted by polar Asn. A 
mismatched primer pair for site-directed mutagenesis (sdm) was designed to introduce 
the mutations K192R and Q195N (Figure 5.4).  The template for amplification was his-
tagged Zta in the pBabe vector.  The vector was sequenced to confirm creation of the 
domain swap mutant BZta (Figure 5.4 C). 
 
Creation of zipper domain swap mutant, ZipZta.  
The coiled coil or zipper domain of Zta (aa 196 - 219) contains 4 residues that vary 
from ZtaRh.   There are 3 conservative substitutions, acidic Asp-212 to acidic Glu, 
hydrophobic Leu-216 to hydrophobic Ile and hydrophobic Leu-218 to hydrophobic Met. 
Position 206 is changed from hydrophobic Ala to hydrophilic Ser.  However A206S is a 
polymorphism that occurs naturally as a variant of EBV (Grunewald et al., 1998) and 
does not alter dimerisation stability or DNA binding (Hicks et al., 2001).  Two 
sequential rounds of sdm were required to create firstly L216I and L218M, then the 
mutation D212E (Figure 5.5A,B) was added.  Attempts to mutate Ala-206 to Ser failed.  
As this is a polymorphic site, it was decided to leave this residue as Ala in the mutant.  
ZipZta contains the amino acid changes L216I, L218M and D212E (Figure 5.5 C,D). 
 
Creation of CT domain swap mutant, CTZta.  
The extreme C-terminus of ZtaRh lacks the final two amino acids, Asn-244 and Phe-
245 found in Zta.  The terminal residue of ZtaRh is Leu-243, while Zta contains an Ile 
at position 243. This means that the final amino acid in Zta is Phe compared with Leu in 
ZtaRh. The terminal domain contains 2 additional conservative differences between Zta 
and ZtaRh, V237I and L238I (Figure 5.6A). Two cycles of sdm were undertaken to 
create the domain swap mutant CTZta (Figure 5.6B-D).  All mutants were sequenced to 
confirm the changes. 
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Figure 5.4: Basic Region Domain Swap 
A. The nucleotide sequence of the three C-terminal domains of Zta. The Basic domain is in blue with the two codons causing an amino acid 
difference in ZtaRh highlighted.  The bases that will be mutated to encode the ZtaRh residue are shown in red.  B. The sequence of the site 
directed mutagenesis (sdm) forward primer with the alterations highlighted.  The reverse primer is the reverse complement of this sequence. The 
template for the sdm was Zta in a pBabe vector.  A chromatogram of the mutated DNA is shown in C with altered bases indicated with a red 
asterisk. D. The amino acid sequence encoded by the domain swap mutant BZta.  
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Figure 5.5: Coiled Coil Domain Swap 
A. The nucleotide sequence of the three C-terminal domains of Zta. The coiled coil or zipper domain is in green with the five codons causing an 
amino acid difference in ZtaRh highlighted.  A206 is not mutated as this site is polymorphic.  The bases that will be mutated to encode the ZtaRh 
residue are shown in red. B. The sequences of the two sequential sdm forward primers are shown, with the alterations highlighted. In primer Zip2 
the blue bases were mutated in the previous stage of sdm. C. A chromatogram of the mutated DNA is shown with altered bases indicated with a 
red asterisk. D. The amino acid sequence encoded by the domain swap mutant ZipZta. 
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Figure 5.6: CT Domain Swap 
A. The nucleotide sequence of the three C-terminal domains of Zta. The CT domain is in purple with the six codons causing an amino acid 
difference to ZtaRh highlighted. The bases that will be mutated to encode the ZtaRh residue are shown in red.  B. The sequences of the two 
sequential sdm forward primers with the alterations highlighted. In primer CT2 the blue bases were mutated in the previous stage of sdm.  A stop 
codon was introduced to delete residues 244 and 245. Sdm  was done using pBabe Zta as template. A chromatogram of the mutated DNA is 
shown in C with altered bases indicated with a red asterisk and the stop codon labelled ter. D. The amino acid sequence encoded by the domain 
swap mutant CTZta. 
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5.2.3 EBV reactivation by domain swap mutants 
In order to attempt to localise the loss of reactivation ability to one or more regions of 
the ZtaRh protein, lytic reactivation assays were undertaken using the three domain 
swap mutants.  Experiments were performed as previously for ZtaRh.  BZta, ZipZta and 
CTZta were analysed in comparison to Zta and empty pBabe.  Western blots using his 
antibody were performed to confirm that equivalent levels of protein were present in 
each sample (Figure 5.7A).  The gene bcl2 was used as a loading control, although as 
this gene is associated with apoptosis it was not an appropriate control.  All three of the 
domain swap mutants were able to reactivate the lytic cycle to some degree, although 
none were equivalent to Zta reactivation (Figure 5.7B).  BZta reactivation was reduced 
by 24% in comparison to Zta.  There was a greater inhibition of lytic reactivation shown 
by the other two mutants.  Transfection by the mutant ZipZta resulted in a 60% decrease 
in detected EBV genome.  CTZta transfection demonstrated a 78% reduction in EBV 
genome in comparison to wild type Zta and is only marginally above the background 
level shown by transfection with the empty vector pBabe.  The loss of lytic reactivation 
effect was stronger towards the CT end of the protein; indeed reactivation by both 
CTZta and ZtaRh was very weak or may be background noise.  This data suggests that 
differences in the basic, zipper and CT regions of Zta and ZtaRh do have an effect on 
the ability of the protein to reactivate EBV from latency, however further experiments 
and use of a different loading control may further elucidate the levels of activation 
achieved by each variant.  
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Figure 5.7: Reactivation of lytic cycle by Zta and ZtaRh domain swap mutants 
Three domain swap mutants containing ZtaRh domains in a Zta background, BZta, 
ZipZta and CTZta were utilised to reactivate the lytic cycle in Hek293-ZKO cells. 
Western blots confirm that approximately equal amounts of protein were present (A). 
Transfection and QPCR were carried out as described in Figure 5.2 and levels of EBV 
genome detected  are shown in B. Experiments were duplicated and average value 
shown.  
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5.2.4 Analysis of extreme CT mutants 
One of the key differences between the CT regions of the two proteins is that ZtaRh 
lacks the two terminal amino acids (NF).  As the most substantial reduction in lytic 
reactivation was observed in the CT region, a closer analysis of mutants in this area may 
further clarify the importance of individual residues for this function.  Celine Schelcher 
had previously constructed three mutants of Zta with each of the three extreme CT 
amino acids converted to alanine (L243A (ANF), N244A (LAF) and F245A (LNA)) 
and one with all three changed to AAA (LNF243-245AAA (AAA)) (Figure 5.8A).   
I sub-cloned these LNF mutants from an SP64 vector into pBabe as a way to further 
analyse the effect of this CT region on lytic reactivation ability.  The same EBV 
reactivation experiment was repeated using the LNF mutants. BZ1 western blots to 
reveal expressed protein levels showed that the Zta was expressed at equivalent levels 
for the Zta sample and all mutants with the exception of ANF, which was approximately 
half that of the other proteins (Figure 5.8B).   
In the mutant AAA, with all three extreme CT amino acids altered, the ability for lytic 
cycle reactivation was abrogated, as expression of the EBV genome was below that of 
background (pBabe) (Figure 5.8C).  This suggests that these three terminal amino acids 
may fully account for the reduction in lytic cycle reactivation of ZtaRh.  Although the 
strongest effect appears to be from ANF, Zta was expressed at a lower level in both 
experiments for this protein, as can be seen on the western blot, so activation may be 
under-represented.  Both AAA and ANF EBV genome levels are lower than that of 
empty pBabe, suggesting that these mutants have complete loss of lytic reactivation 
ability. As the expression of the EBV genome for AAA and ANF is below that of the 
pBabe control containing no EBV genome, this represents a variation in the 
experimental system that should be addressed in further experiments.  The level of EBV 
genome detected in cells transfected with ANF was reduced by 93.6% compared to Zta, 
LAF by 37.5 %, LNA by 70.9 % and AAA by 89.3 %.  
These lytic reactivation assays suggest that the extreme CT region of Zta is essential for 
lytic reactivation, however further experiments should be conducted to allow significant 
data to be generated.  This would also determine if the results showing a lower level of 
EBV genome activation than the empty pBabe vector are accurate. 
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Figure 5.8: Reactivation of lytic cycle by Zta and C-terminal LNF mutants  
pBabe expression vectors containing Zta and mutants with substitutions to alanine of 1 
or all 3 of the terminal amino acids LNF (A), created by Celine Schelcher, were 
transfected into HEK293-ZKO cells. Western blots used BZ1 antibody to detect Zta and 
mutants and cdk2 as a loading control (B). The level of Zta protein detected by BZ1 
antibody for ANF was approximately half the rest of the samples. QPCR was performed 
on the genomic DNA to determine levels of EBV genome present (C). Transfection and 
QPCR were carried out as described in Figure 5.2. Experiments were duplicated and the 
average value is shown. 
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5.2.5 Regulation of the Cell Cycle by Zta and RhZta 
 
In the next series of experiments the effect of ZtaRh on the cell cycle was assessed.  Zta 
has the ability cause cell cycle arrest in some cell types including HeLa cells (Cayrol 
and Flemington, 1996b).  This occurs through several mechanisms as detailed in section 
1.4.8. I wanted to investigate if the ability of Zta to cause cell cycle arrest is shared with 
RhZta.   
  
HeLa cells were co-transfected with GFP vector and Zta, ZtaRh or empty vector 
(pBabe) expression vectors. Cells were harvested after 48 hours and a sample of cells 
was used for western blot analysis using an anti-his antibody. This was to determine that 
an equivalent level of protein expression of Zta or ZtaRh is observed in each sample.  
Prior to establishment of cell cycle status, a sample of cells were prepared for analysis 
of transfection efficiency for each experiment.  Cells were resuspended in PBS and 
analysed with a flow cytometer.  In order to calculate transfection efficiency, healthy 
cells were gated and the proportion that were positive for GFP was determined (Figure 
5.9).  Cells that are expressing GFP are assumed to also be successfully transfected with 
the experimental expression vector.   
A third fraction of cells was fixed in 80% ethanol and stained with propidium iodide.  
The cell cycle profile was determined for these cells by flow cytometry analysis.  As 
propidium iodide binds stoichiometrically to DNA, cells are selected according to DNA 
content and thus are categorised to cell cycle phase; G1/G0, S or G2/M (Figure 5.10)   
 
The transfection efficiency in the initial experiment was between 61% and 67% (Figure 
5.9).   Transfection efficiency remained consistently at that approximate level for all 
experiments.  Cells that were transfected with Zta showed on average a 12.6% increase 
in the G1 cell population over cells transfected with empty pBabe (Figure 5.11).  
However cells transfected with ZtaRh had only a 2.6% increase in G1 cells.  The results 
are significantly different using a Mann-Whitney U test (U=16, n1 = n2 = 4, 
P=0.02857). The experiment was repeated 4 times.  The western blots in Figure 5.11 
confirm that an equivalent amount of his-tagged protein was expressed for Zta and 
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ZtaRh. ZtaRh shows an almost complete inability to promote cell cycle arrest in HeLa 
cells. 
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Figure 5.9: Transfection Efficiency as determined by FACS analysis 
HeLa cells were untransfected (A) or transfected using Calcium Phosphate with pBabe 
(B), Zta (C) or ZtaRh (D), along with 250ng of GFP vector.  A sample of cells harvested 
after 48 hours were tested for transfection efficiency using flow cytometry.  Healthy 
cells were gated (left panels) and then selected for presence of GFP, giving a 
transfection efficiency percentage (right panel). 
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Figure 5.10: Cell cycle analysis of Zta and ZtaRh 
HeLa cells transfected with pBabe vector (A), Zta (B) or ZtaRh (C) were treated with 
RNAse and stained with propidium iodide (PI). Flow cytometry (FACS) was used to 
detect the fluorescence from PI bound to DNA to show the distribution of cells in 
G1/G0, S and G2/M of the cell cycle. The average number of cells in G1/G0 is shown to 
the right of each graph. 
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Figure 5.11: ZtaRh is compromised in Human Cell Cycle arrest function 
The graph shows the average increase in G1 cells compared to cells transfected with 
pBabe alone, as detected by FACS analysis. This experiment was repeated 4 times. The 
results are significantly different with a Mann-Whitney U test (U=16, n1 = n2 = 4, 
P=0.02857).  The western blot using his-antibody shows the presence of the his-tagged 
proteins. Cdk2 is shown as a loading control.   
 
 
 In order to localise this loss of cell cycle arrest function that ZtaRh displayed, the same 
experiments were repeated using the domain swap mutants, BZta, ZipZta and CTZta, 
described in Figure 5.3.  There was no change from Zta in the increase in G1 cells in 
cells transfected with BZta or ZipZta (Figure 5.12).  There was a slight reduction in cell 
cycle arrest function seen in the mutant CTZta (7.1% compared with 11.9% for Zta).  
However this does not account for the entire reduction seen with cells transfected with 
ZtaRh.   
 
The cell cycle assay was repeated using the extreme CT LNF mutants, to reveal if the 
reduction in cell cycle arrest function seen in the mutant CTZta could be localised.  
However the level of reduction observed with each of the three mutants was slight 
(Figure 5.13). 
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Figure 5.12: Cell cycle analysis of Zta and domain swap mutants 
HeLa cells were transfected with pBabe vector, Zta, BZta, ZipZta and CTZta and cell 
cycle assays were performed as in Figure 5.10.  Experiments were duplicated and 
average value shown. Western blot shown his-Zta and mutants detected by α-his 
antibody and cdk2 as a loading control are shown. 
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Figure 5.13: Ability of extreme C-terminal Zta mutants to cause cell cycle arrest 
Four substitution mutants of the three C-terminal amino acids of Zta, as described in 
Figure 5.8 were used to transfect HeLa cells. The cell cycle arrest assay was performed 
as in Figure 5.11.  Western blots showing Zta detection by BZ1 and cdk2 as a loading 
control are shown below the graph.
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The loss of lytic reactivation ability of ZtaRh could not be accounted for by the same 
mechanism as the reduced ability of ZtaRh to cause cell cycle arrest as the extreme CT 
region is not implicated in the latter function.  In order to further characterise the loss of 
lytic reactivation I developed a series of QPCR probes to span the lytic reactivation 
cascade.  This could reveal when in this cascade of activation the extreme CT of Zta is 
critical for the process and give an insight into the possible mechanism. 
5.2.6 Analysis of lytic cycle cascade 
Replication of EBV genes in the lytic cycle occurs in a cascade of sequential gene 
activation (Figure 5.14).  This commences with the immediate early transcription 
factors Zta and Rta, which transactivate their own promoters as well as early genes.  
The early genes transcribe proteins involved in viral DNA replication, resulting in the 
creation of linear viral genomes.  Late genes are involved in the packaging of this viral 
DNA into complete virions.  Further information about the mechanism responsible for 
the loss of reactivation by CT mutants of Zta could be uncovered by revealing the stage 
at which lytic reactivation is compromised.   
The immediate early genes BZLF1 and BRLF1, early genes BBLF2/3, BHLF1 and 
EBV DNA polymerase (BALF5) and the late gene BLLF1 were selected for further 
QPCR analysis.  QPCR primers were designed for BBLF2/3, BHLF1 and BLLF1 and 
also for the latent gene LMP1.  I attempted to design primers that crossed splice sites to 
ensure that the quantitative PCR would analyse cDNA only and not background 
genomic DNA. However this was not possible for all genes.  Primers for BBLF2/3, 
LMP1, Zta and Rta do cross splice sites but other primer pairs do not.   
HEK 293 ZKO cells were transfected with Zta, ZtaRh or empty vector (pBabe) and 
harvested as in the earlier experiments.  RNA was extracted and treated with RQ1 
DNase to degrade genomic DNA that could contaminate the QPCR.  cDNA was 
produced from the DNase-treated RNA.  This was analysed using QPCR to determine 
the level of gene expression for BRLF1, BBLF2/3, EBV polymerase, BHLF1, BLLF1 
and LMP1 (Figure 5.15A). Expression levels were normalised to the host ribosomal 
protein L32.  Rta was expressed by ZtaRh to 45% the level of activation by Zta.  ZtaRh 
shows markedly reduced relative levels of expression for all 3 early genes (12-20% of 
activation by Zta).   
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Figure 5.14: Cascade of lytic gene activation 
EBV replication in the lytic cycle proceeds through a cascade of sequential gene 
activation.  Initially the immediate early transcription factors BZLF1 and BRLF1 are 
expressed, transactivating their own promoters and early genes.  Early genes are 
involved in the replication of viral DNA , creating linear viral genomes. Late genes 
transcribe proteins including viral capsid, membrane and tegument proteins for 
packaging this DNA into complete virions. Genes highlighted in red were used for RT-
PCR to determine at which stage of  lytic activation ZtaAAA is defective. 
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Figure 5.15:  RT-PCR of Zta and ZtaRh for selected EBV genes 
HEK293-BZLF1ko Cells were transfected with 0.8μg of DNA (Zta, ZtaRh or empty vector (pBabe)) and harvested after 48 hours.  Total RNA 
was extracted, DNase treated and cDNA was synthesized.  Western blots using α-his tag and cdk2 antibodies confirmed equivalent expression of 
pBabe (pB), Zta (Z) and ZtaRh (RhZ) proteins and provided a loading control (A).  1 μl of each diluted cDNA sample was used in a real time 
PCR reaction with 0.5 μM of each primer and 12.5 μl SYBR Green mastermix (Qiagen).  Each sample was standardised for cDNA amount using 
the housekeeping gene L32.  The ability of each protein to activate gene expression was assessed using primers for Rta, BBLF2/3, BALF5 (EBV 
pol), BHLF1, BLLF1 and LMP1 (B).  Values have been normalised to Zta expression for each gene.  The experiment has been duplicated and 
average value shown. 
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The experiment was repeated using DNase treated RNA from HEK 293 ZKO cells 
transfected with Zta, ZtaAAA or empty vector (pBabe).  A western blot for BZLF1 
confirmed that equivalent levels of protein were expressed and a western blot for cdk2 
was performed as a loading control (Figure 5.16A).   
 
ZtaAAA demonstrated a different distribution of expression for these selected genes 
(Figure 5.16B).  AAA demonstrated higher levels of expression for BZLF1 (60% 
higher), BRLF1 (135%) and the early gene BBLF2/3 (187%) than Zta.  However for the 
other two early genes, EBV pol and BHLF1 and the late gene BLLF1, expression had 
dropped to approximately similar levels to ZtaRh (16%, 26% and 27% respectively).  
This indicates that the reduced expression from ZtaRh is via an additional mechanism 
affecting activation of Rta.  For the latent gene LMP1 expression through ZtaRh 
activation was reduced to 54% of the level of Zta, while expression by AAA is 
approximately similar to Zta.
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Figure 5.16: RT-PCR of Zta and ZtaAAA for selected EBV genes 
HEK293-BZLF1ko Cells were transfected with 0.8μg of DNA (Zta, ZtaAAA or empty vector (pBabe) and harvested after 48 hours.  Experiments 
were performed as in Figure 5.15.   A BZ1 western blot showing equivalent expression of Zta (Z) and ZtaAAA  (AAA) is shown and a cdk2 
western blot is a loading control (A). The ability of each protein to activate gene expression was assessed using primers for Zta, Rta, BBLF2/3, 
BALF5 (EBV pol), BHLF1, BLLF1 and LMP1 (B).  Values have been normalised to Zta expression for each gene.  The experiment has been 
duplicated and average value ahown. 
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ZtaRh displayed poor activation and EBV replication.  This could be caused by the 
changes in the transactivation domain or in combination with differences to Zta in the 
three C terminal domains.  As ZtaAAA is only defective in expression of two early 
(BHLF1 and BALF5) and one late gene (BLLF1), it is possible that the extreme CT of 
ZtaRh has also contributed to decreased expression of these genes. In order to examine 
this two new mutants were designed; Rh_LNF and Zta_I∆∆ as shown in Figure 5.17A.  
Rh_LNF is comprised of ZtaRh sequence with the terminal Ile-247 replaced with Leu, 
Asn and Phe, the three terminal amino acids of Zta.  Conversely Zta_I∆∆  is comprised 
of Zta sequence with the three terminal residues (LNF) replaced with Ile.  Both mutants 
were created using mis-matched primers with PCR site-directed mutagenesis (Figure 
5.17B-C).  Mutants were sequenced to confirm changes.   
 
Zta_I∆∆ does not appear to mimic the pattern of gene expression shown by ZtaRh 
(Figure 5.18).  This suggests that the low expression seen in cells transfected with 
ZtaRh is not caused by the extreme CT of the ZtaRh gene.  This is supported by the 
mutant Rh_LNF which does show expression at an almost equivalent level to ZtaRh.  
The only exception was higher expression of Rta in cells transfected with Rh_LNF 
(131% of Zta cell expression, compared with 45% in ZtaRh cells).  The reduced 
expression of EBV polymerase, BHLF1 and BLLF1 seen with ZtaRh was not seen with 
Zta_I∆∆.  Considerably higher expression was seen for Zta, Rta, BBLF2/3 and EBV 
polymerase with Zta_I∆∆ than with Zta. As the differences in these proteins are 
restricted to the extreme CT, this further suggests that this region may be important to 
the function of Zta.  This in turn may have a role in influencing the expression of 
multiple genes.  As experiments were only duplicated, further replicates would have to 
be performed to provide results with any measure of significance. A summary of the 
expression for each protein is shown in Table 5.19.   
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Figure 5.17: Construction of extreme CT mutants 
A. Site directed mutagenesis was used to create two mutants that differ from Zta or 
ZtaRh only in the extreme CT residues. Zta_I∆∆ is Zta sequence with the terminal LNF 
replaced with I from Rh.  The sdm primers and the sequence chromatogram are shown 
with the changed residues highlighted (B). Rh_LNF is ZtaRh sequence with the 
terminal I replaced with LNF from Zta (C). 
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Figure 5.18: RT-PCR of Zta, Rh_LNF and Zta_I∆∆ for selected EBV genes 
HEK293-BZLF1ko Cells were transfected with 0.8μg of DNA (Zta, Rh_LNF, Zta_I∆∆ or empty vector (pBabe))  and harvested after 48 hours. 
Western blots using α-his tag and cdk2 antibodies confirmed equivalent expression of pBabe (pB), Zta (Z), Rh_LNF (R_L) and Zta_I∆∆ (Z_I) 
proteins and provided a loading control (A). cDNA was produced and RT-PCR was performed as in figure 5.15 .  The ability of each protein to 
activate gene expression was assessed using primers for Zta, Rta, BBLF2/3, BALF5 (EBV pol), BHLF1, BLLF1 and LMP1 (B).  Values have 
been normalised to Zta expression for each gene.  The experiment has been duplicated and average value shown. 
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Table 5.19: Expression of  EBV genes in cells transfected with ZtaRh and mutants in 
comparison with Zta cells.  
Quantitative PCR was used to determine expression of EBV in cells transfected with 
Zta, ZtaRh, ZtaAAA, Rh_LNF or Zta_IΔΔ as described in Figure 5.16 and 5.18.  
Expression is shown realative to Zta transfected cells.  ++ indicates greater than 1 fold 
increase over expression by Zta.  -- indicates greater than 1 fold decrease over 
expression by Zta.  0 indicates no difference in expression levels. 
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5.3 Discussion 
ZtaRh has been shown to be defective in several key functions of Zta.  ZtaRh was 
almost totally deficient in causing lytic reactivation in HEK 293 ZKO cells and in 
activating cell cycle arrest in HeLa cells.  In addition ZtaRh was deficient in causing 
expression of selected early and late EBV genes.  ZtaRh is not compromised in DNA 
binding so the loss of these other functions is via a different mechanism.  ZtaRh differs 
markedly from Zta in the N-terminal transactivation and contains some more modest 
differences in the three C-terminal regions (Figure 5.3).    The CT region has been 
shown previously to be important in lytic reactivation so I examined the contribution of 
differences between Zta and ZtaRh using three domain swap mutants.  This showed that 
there was a small influence from the basic region and a stronger effect from differences 
in the zipper and CT regions.  Use of four CT terminal mutants showed that mutation of 
Zta L243 to alanine (ANF mutant) was sufficient to lose lytic reactivation function.  In 
addition a mutant with the three terminal amino acids, LNF, converted to AAA, 
ZtaAAA (AAA) was entirely compromised for this function.  Examination of the 
domain swap and extreme CT mutants in a cell cycle assay revealed that despite a small 
decrease in cell cycle arrest from ZtaCT, the loss of this function maps outside of these 
domains.  This means that differences in the transactivation domain most probably 
account for the loss of the cell cycle arrest function in ZtaRh.   
To understand the mechanism of reactivation loss, it was of interest to determine at 
which stage of lytic reactivation ZtaRh and ZtaAAA are defective.  ZtaRh showed 
reduced expression of Rta to 50% of the level shown by Zta, and was at very low levels 
for all early and late genes.  In comparison ZtaAAA showed strong expression of Rta 
and the early gene BBLF2/3 with expression loss of the other early and late genes.  This 
suggests an additional mechanism for some of the loss of activity by ZtaRh which 
affects Rta activation.  The mutant Zta_I∆∆ showed that this is an effect from part of the 
protein prior to the CT region, probably the transactivation domain.  Conversion of the 
ZtaRh terminal to LNF (Rh_LNF), mimicking Zta, restored replication of Rta to the 
same level as Zta.  This shows that the reduced levels of Rta were not responsible for 
the loss of replication of genes later in the lytic reactivation cascade. In addition the 
latent gene LMP1 was expressed at wild-type levels with Rh_LNF, showing that the 
terminal three amino acids have no influence on transcription of this gene.  
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It is reasonable to assume that as RhLCV is a functional virus, ZtaRh would be a 
functional replication factor when operating on the right genome in the right cells.  As 
yet little is known about the specific mechanisms of RhLCV and differences in protein 
co-factors, cellular environment and DNA sequence are likely to be critical for the 
optimal functioning of ZtaRh in rhesus cells and account for the loss of function 
observed in human cells.   
The data presented in this chapter shows that the last three amino acids of Zta are 
critical for key functions of the protein.  The extreme CT is conserved in all isolates of 
EBV suggesting the functional importance of this region (Grunewald et al., 1998; Hicks 
et al., 2001).  The exact conformation of this region of Zta is not yet known as the 
terminal nine amino acids are missing from the current crystal structure (Petosa et al., 
2006).  The preceding nine amino acids in the resolved Zta structure, D228-D236,  have 
been shown to fold back, making stabilising contacts with the zipper domain for 
dimerisation (Petosa et al., 2006).  These interactions have been shown to be critical for 
DNA replication, but not for promoter transactivation (McDonald et al., 2009).  Cross-
linking experiments have indicated that the extreme CT residues continue this contact 
with the zipper region (Schelcher et al., 2007)(Figure 5.20).  This is one possible 
mechanism by which the ZtaAAA mutant has such an impact on functions of Zta. As 
DNA binding is not obviously compromised in ZtaRh, the mechanism of reactivation 
loss may be due to a disruption in interactions with one or more proteins. The first 
example of a specific function to be ascribed to the extreme CT of Zta is the interaction 
of 53BP1 and Zta (Bailey et al., 2009).  Interaction between 53BP1 and Zta is greatly 
diminished with a deletion mutant of the three terminal amino acids, LNF.  
Additionally, Bailey and colleagues demonstrated that the knockdown of 53BP1 
expression reduced EBV replication, which indicates that the association between Zta 
and 53BP1 is involved in the viral replication cycle (Bailey et al., 2009). 
ZtaRh contains a cysteine at the equivalent position to C189 of Zta.  It would be 
interesting to investigate if a serine mutation at this position in ZtaRh would also result 
in methylation sensitive binding and if there would be any change in lytic reactivation.  
As ZtaRh is defective in lytic reactivation of EBV, this would have to be investigated in 
a cell-line containing CeHV-15, which we currently do not have.     
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Figure 5.20: Schematic diagram of Zta structure 
This schematic diagram of Zta is based on the crystal structure of Zta, as determined by 
Petosa and colleagues (Petosa et al., 2006) which ends at D236.  The distal CT region of 
Zta interacts with the zipper region (A).  The wavy black line shows the extreme 
terminal CT region of unknown structure.  Experimental cross-linking evidence shows 
that the extreme CT of Zta also makes contact with the zipper region (B) (Schelcher et 
al., 2007) 
( Diagram adapted from (Schelcher et al., 2007) 
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Chapter 6      The impact of Zta on host cell proteins 
6.1 Introduction 
6.1.1 Zta Interactions 
Zta interacts with a variety of different cellular and viral proteins.  Many interactions 
occur through the transactivation domain, but several are dependent on the zipper 
dimerisation domain.  As the CT region has contact with this domain, it is possible that 
alterations to the CT region may have an influence on the ability of Zta to form these 
contacts.  It would be interesting to investigate how mutants of Zta in the CT region 
would affect the following Zta interactions, both in vitro and in vivo.  If differences 
between Zta and ZtaRh influenced these interactions, it would be informative on the 
role of Zta in human cells. 
 
6.1.2 Protein Interactions 
A potential mechanism for the loss of function of Zta when mutated at the CT would be 
if interaction with an important protein was disrupted by alterations to the extreme CT 
region of Zta.  This interaction could be with either a viral or cellular protein.  This will 
be investigated in two stages.  Initially known binding partners of Zta could be tested in 
vitro and in vivo for disruption to binding with alterations to this region.     
CBP 
CREB-binding protein (CBP) is a histone acetylase and a co-activator of transcription.  
CBP has been shown through an immunoprecipitation assay to positively regulate Zta 
transactivation (Adamson and Kenney, 1999).  The acetylation of histones by CBP 
leads to a weakened association between the histones and DNA, resulting in a more 
open chromatin structure and better access for the basal DNA transcription machinery.  
Meanwhile Zta decreases the transactivation function for the transcription factor CREB.  
This may occur through competitive CBP binding between Zta and CREB (Adamson 
and Kenney, 1999).  As a transcriptional activator, Zta may direct histone acetylase 
activity to target promoters, possibly through its interaction with CBP.  Interaction with 
Zta occurs in two regions of CBP and requires the transactivation as well as zipper 
region of Zta (Adamson and Kenney, 1999). 
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C/EBPα 
Zta interacts with another bZIP protein, CCAAT/enhancer binding protein α (C/EBPα), 
which acts as a positive regulator of Zta. The protein is stabilised by Zta interaction 
leading to increased levels of C/EBPα (Wu et al., 2003).  This results in induction of the 
cyclin dependent kinase inhibitor p21, ultimately resulting in G1 cell cycle arrest (Wu et 
al., 2003).  This interaction requires the basic domain of Zta and some residues from the 
zipper.   
NFκB p65 subunit 
The p65 subunit of NFκB has been shown to negatively regulate Zta transactivation 
both in vitro using GST fusion proteins and in vivo with co-immunoprecipitation 
(Gutsch et al., 1994).  As NFκB p65 inhibits Zta from transactivating viral genes, this 
may be a mechanism for maintaining viral latency (Gutsch et al., 1994).  This 
interaction occurs in the zipper dimerisation domain of Zta.    
RARα and RXRα 
The retinoic acid receptors (RARα and RXRα) repress activation by Zta of the viral 
gene BMRF1 (Sista et al., 1993).  The interaction between RXRα and Zta occurs 
through the zipper domain (Sista et al., 1995).  
p53 
p53 is a key protein in the cellular response to viral infection, both by inducing 
apoptosis and inducing a type I interferon response.  Interaction between Zta and p53 
occurs in vitro and in vivo and each protein is capable of inhibiting the other (Zhang et 
al., 1994).  Zhang et al proposed that the balance of p53 and Zta in latently infected 
cells may be important in regulation of lytic cycle activation. If Zta is activated and 
overcomes inhibition by p53, it may in turn inhibit p53-dependent transactivation.  The 
zipper domain of Zta is required for contact with p53 (Zhang et al., 1994). 
BGLF4 
BGLF4 is a serine/threonine protein kinase and is the only protein kinase encoded by 
EBV (Smith and Smith, 1989). 
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 A study by Asai and colleagues has shown that BGLF4 mediated phosphorylation of 
Zta leads to formation of a stable BGLF4-Zta complex (Asai et al., 2009).  BGLF4 
downregulates transactivation by Zta from its own promoter.  The site of 
phosphorylation that is necessary for interaction is Ser-209 in the zipper region of Zta 
(Asai et al., 2009). 
BMRF1 
The viral polymerase processivity factor (BMRF1) interacts directly with Zta and this 
has been shown to affect lytic reactivation (Zhang et al., 1996).  
 
6.1.3 Expression array 
Another approach to question how Zta impacts host cell proteins is to examine the 
effects of Zta on host gene expression using quantitative PCR.  This could reveal novel 
genes that Zta is able to influence as well as explore the effects of Zta mutants.  The 
results of a QPCR array are presented, which analysed the expression of 600 human 
genes from the cDNA of HEK293 cells, transfected with either Zta or the mutant 
ZtaAAA.  
This chapter aims to investigate how the binding of Zta to known interacting proteins is 
affected by different mutations.  In addition I aim to identify potentially new changes to 
the host cell as a result of Zta expression by use of a QPCR array.   
 
6.2 Results 
6.2.1 Protein Co-expression 
Initially two viral genes and six human genes encoding proteins that interact with Zta 
outside of the transactivation domain were selected to investigate interactions with Zta 
and mutants.    They were the viral genes BMRF1 and BGLF4 and human genes CBP, 
C/EBPα, NFκB p65, p53, RARα and RXRα (Table 6.1).  The target vector for cloning 
was pcDNA3.  This vector was chosen as it is suitable for use in bacterial or 
mammalian expression systems.  The addition of a flag-tag in the cloning primers was 
included to allow detection of cloned proteins via a flag antibody.
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Protein Critical Zta Residues  WB size (kDa) References 
p53 200-227 53 (Zhang et al., 1994; Mauser et al., 2002b) 
C/EBPα 124-134, 204 45 (Watt and Molloy, 1988; Wu et al., 2003) 
RARα 179-245 45 (Sista et al., 1993; Pfitzner et al., 1995; Sista et al., 1995) 
RXRα 140-227, 200-227 53 (Sista et al., 1993; Pfitzner et al., 1995; Sista et al., 1995) 
NF-κβp65 200-227 65 (Gutsch et al., 1994; Hong et al., 1997) 
BMRF1 138-245, 200, 214/218 48 (Schepers et al., 1996) 
BGLF4 209 54 (Asai et al., 2006; Asai et al., 2009) 
 
 
Table 6.1: Proteins known to interact with Zta targeted for cloning 
The table shows 5 human and 2 EBV genes known to bind to Zta.  The region of Zta that is critical for interaction is shown. C/EBPα was cloned 
by Celine Schelcher and BGLF4 was given by Dr Tarakanova (Tarakanova et al., 2007).  The expected molecular size on a western blot (WB) is 
shown in kDa.  
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6.2.1.1 Cloning of viral genes 
Primers for cloning BMRF1 were designed to amplify by PCR the 1212bp coding 
region, as well as incorporating a flag-tag at the 5’ end of the gene and restriction 
enzyme sites at both ends to enable ligation into the pcDNA3 vector.   The BMRF1 
gene was amplified in a PCR reaction using these primers, with cDNA from LCL cells 
as a template.  Digested, purified PCR product was ligated into digested pcDNA3 to 
create flag BMRF1 pcDNA3 (Figure 6.2A).  The vector was also digested again and run 
on agarose to check insertion of the cloned gene (Figure 6.2B).  All evidence suggested 
the gene had been correctly cloned however sequencing of the final vector revealed a 
deletion of 3 basepairs (ΔATT) in the flag-tag (Figure 6.2C).  As primers were ordered 
with the full flag-tag sequence, this could have been either an error in the synthesis of 
the primer or an enzymatic error during PCR.  Complementary primers containing the 
correct sequence were ordered and used in a site directed mutagenesis reaction to 
correct the flag-tag error.  This correction was confirmed by sequencing (Figure 6.2C). 
A vector containing flag-tagged BGLF4 was kindly given by Tarakanova (Tarakanova 
et al., 2007).   
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Figure 6.2: Cloning of  BMRF1 
A shows a vector map of pcDNA3 with cloned EBV gene BMRF1 containing a flag-
tag.  BMRF1 was PCR cloned using cDNA  from LCL cells.  Primers contained a flag 
tag and PCR product was digested with BamHI and Eco RI and ligated into digested 
pcDNA3 vector.  Product was digested and run on an agarose gel to check insertion (B).  
The vector was sequenced to confirm (C).  There was an error (∆ATT) in the flag-tag 
which was corrected using site-directed mutagenesis.   
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6.2.1.2 Cloning of human genes 
C/EBPα had already been cloned by a previous member of the Sinclair lab, Celine 
Schelcher in pcDNA3 with a flag-tag.  
PCR primers were designed for each of the remaining five human genes; CBP, NFκB 
p65, p53, RaRα and RxRα.  For the gene CBP it was not possible to amplify the entire 
gene as it encodes for a very large protein (2405 amino acids long). As Zta interacts 
with two domains of this protein (Adamson and Kenney, 1999; Zerby et al., 1999), 
primers were designed to amplify these two domains separately.  CBP target domain 1 
is comprised of amino acids 301 -585 and domain 2 is amino acids 1680 - 1915.  
PCR reactions using cDNA obtained from Ak31 and LCL3 cells were performed to 
amplify these five human genes.  Initially PCR bands were obtained only for p53.  The 
other 5 PCR reactions produced no discernable products.  Optimisation of reactions, 
including reducing the specificity of the reaction by lowering the annealing temperature, 
utilising a touchdown PCR protocol and re-designing primers resulted in PCR bands for 
NFκB p65, CBP1 and CBP2.  However all products were both weak and contained 
multiple unspecific bands.  No products were obtained under any condition of RXRα or 
RARα.  After purification, multiple attempts at ligating the purified, digested PCR 
products of NFκB p65, CBP1 and CBP2 into the digested pcDNA3 failed and no cloned 
genes were created.   
The probable reason for the lack of success at amplifying the target genes was cDNA 
template that was not of adequate quality.  Use of commercially available human cDNA 
template for PCR cloning may have produced improved results.  Ligation of the target 
genes into pcDNA3 was probably not successful because of the low concentration and 
poor quality of the PCR products.   
In order to continue with the planned pulldown experiments Image Clones of NFκB 
p65, RXRα and RARα were purchased from Invitrogen.  These were amplified in PCR 
reactions using the primers designed for the initial failed amplifications.  Strong PCR 
products were obtained for all three genes, confirming the initial amplification problems 
stemmed from a poor quality template or low levels of mRNA expression in that cell 
type.  PCR products were digested and ligated into digested pcDNA3 (Figure 6.3A).   
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Figure 6.3: Cloning of NFκB p65, RARα and RXRα. 
Initial attempts to clone NFκB p65, RARα and RXRα from cDNA failed.  Image Clones 
containing these genes were bought from Invitrogen.   These were amplified by PCR 
using primers containing restriction enzyme sites and the flag-tag.  PCR products were 
digested and ligated into digested pcDNA3. Product was digested and run on an agarose 
gel to check insertion (A).   Vectors were sequenced to confirm (B). 
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Ligation was again quite problematic and required several rounds of optimisation, 
however it was ultimately successful for all three genes.  Vectors were sequenced to 
confirm the correct sequence had been cloned (Figure 6.3B).  A pcDNA3 vector 
containing a flag-tagged version of p53 was bought from Addgene.  The required 
domains of CBP were not found to be commercially available so this gene was excluded 
at this stage.   
Expression vectors containing the flag-tagged viral genes BMRF1 and BGLF4 and 
human genes C/EBPα, NFκB p65, p53, RXRα and RARα were now available for 
investigating the interactions with Zta and mutants.   
 
6.2.1.3 in vivo expression of proteins 
Expression of these proteins in cell culture was tested by transfecting HEK293 cells 
with each vector DNA.  After 72 hours cells were harvested and lysate was run on 
protein gels.  Detection of flag-tagged proteins was done using western blotting with the 
flag M2 antibody.  Strong expression was seen for BGLF4, BMRF1, C/EBPα and NFκB 
p65 (Figure 6.4A).  Longer exposure of the blot also revealed weaker expression of 
RARα (Figure 6.4B). Expression of p53 and RXRα was not detected. Subsequent 
experiments resulted in p53 expression, however RXRα expression was not achieved. 
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Figure 6.4: Expression of proteins 
HEK293 cells were transfected with 3.5μg of vector DNA using effectene (Qiagen).  
Cells were harvested and lysed after 72 hours and lysate was  run on a protein gel.  
Proteins were detected using western blotting with flag M2 antibody (Sigma) (A).  
Longer exposure of right-hand lanes (B) show expression of RARα (indicated by 
arrow).  RXRα and p53 were not detected.   Expected band sizes are shown in Table 6.1. 
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As expression of BGLF4 was strong, this gene was selected to test the pulldown 
procedure.  HEK293 cells were co-transfected with vectors containing his-Zta and 
BGLF4 (Zta/BGLF), as well as controls comprised of his-Zta or BGLF4 along with the 
complementary empty vector (pBabe or flag-pcDNA3).  Cells were harvested and lysed 
after 48 hours.  Supernatant was incubated with HIS-Select Nickel Affinity Gel (Sigma) 
overnight.  These nickel-linked agarose beads bind to his-tagged proteins, i.e. his-Zta, 
thus also capturing any associated proteins.  The agarose is washed multiple times and 
then mixed with sample buffer, denatured at 95°C and run on a protein gel.  Gels were 
then western blotted with BZ1 and flag antibodies.    Figure 6.5A shows that BZ1 bands 
were detected for both Zta and Zta/BGLF4.  This is as expected as both should be 
captured by the Ni agarose.  However in the α-flag western blot, bands were visible for 
Zta/BGLF4 and BGLF4 alone.  As this does not contain a his-tag, it should not have 
been captured by the Ni agarose.  This shows that there has been non-specific binding to 
the agarose so the experiment does not provide valid results.  
 
 
Figure 6.5: BGLF4 pulldown 
HEK293 cells were transfected with 5 ng of vector containing Zta or BGLF4 with 
empty vector or Zta and BGLF4.  After 48 hours cells were lysed and freeze thawed 
three times.  250 μl of supernatant was added  to 180 μl of Ni-NTA Agarose (Qiagen) 
and bound overnight at 4°C or at room temperature (RT).  After washing agarose was 
mixed 1:1 with  Laemmli Sample buffer and run on a protein gel.  This was western 
blotted with BZ1 and α-flag antibodies 
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This same experiment was repeated with CEBP/α, with the same inconclusive results.  
The lysis and wash buffers used originally are shown in Table 6.6 as Sinclair lab. As 
suggested by Qiagen, I tried increasing the imidizole concentration to provide more 
stringent washing conditions and also added 5mM of DTT as a reducing agent.  Neither 
strategy was successful so I identified two alternative pairs of buffers as detailed in 
Table 6.6 that had been used successfully in similar experiments; Qiagen (Protocol 15: 
Buffers for purification from mammalian cells using Ni-NTA agarose beads) and Zou 
(Zou et al., 2007).  Neither pair of buffers was successful in reducing the non-specific 
binding.  In addition incubation time was adjusted and experiments were performed at 
4°C, however the non-specific binding remained.    
A reverse approach was tried using EZview Red Anti-FLAG M2 Affinity Gel (Sigma), 
in order to select proteins via the flag-tag instead and determine if this also pulled down 
Zta.  However the same problem with sticky proteins was encountered so again valid 
results were unobtainable.   
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Table 6.6: Buffer conditions used for Ni-affinity gel pulldown experiments 
Three different combinations of lysis and wash buffers were tried for the his-pulldown 
of Zta-interacting proteins. The Qiagen buffers are from www.quiagen.co.uk (Protocol 
15: Buffers for purification from mammalian cells using Ni-NTA agarose beads) and the 
Zou buffers from Zou et al (Zou et al., 2007). Buffers also all contained complete 
protease inhibitors (EDTA free)(Roche). 
 
6.2.1.4 Co-expression observations 
Although the pulldown experiments failed to produce the wanted results, some 
interesting observations were obtained when proteins were co-expressed with Zta.  Co-
expression with C/EBPα resulted in a double band for Zta.  The band is larger than Zta 
and is visible in Figure 6.7B.  Co-expression of Zta and p53 resulted in degradation of 
Zta over time.  After 72 hours detection of Zta is barely discernable (Figure 6.7D). 
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Figure 6.7: Expression of Zta at time points following cotransfection  
HEK293 cells were co-transfected using effectene with pcDNA3-flag vector (A), 
C/EBPα (B), NFkB p65 (C) or p53 (D) +/- pBabe Zta.  Cells were harvested after 24, 48 
and 72 hours.  Protein gels were western blotted with BZ1 and αflag antibodies.  
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In order to see if the mutant ZtaAAA would have a similar effect on C/EBPα and p53 as 
Zta, I performed co-transfection experiments using ZtaAAA. Western blots with α-flag 
antibody detected equivalent levels of each protein when co-transfected with Zta or 
ZtaAAA (Figure 6.8A).  As expected only non-specific bands were seen in the α-flag 
western blot from transfection of Zta or ZtaAAA with empty pcDNA3 vector.  Blotting 
with BZ1 antibody revealed that expression of Zta and ZtaAAA were equivalent in the 
control samples (Figure 6.8B).   
Zta co-transfected with C/EBPα showed the larger additional band, however it was 
completely absent in the ZtaAAA / C/EBPα sample.  The level of Zta protein detected 
by BZ1 antibody in the Zta / p53 sample was visible but drastically reduced from the 
levels seen in the control samples.  In ZtaAAA / p53, the level of protein detected was 
again reduced from the controls, however it was considerably stronger than seen for Zta.  
This raises the possibility that the mutation of the three terminal amino acids of Zta to 
AAA may provide protection against degradation when co-expressed with p53. 
 
Figure 6.8: Expression of C/EBPα and p53 with ZtaAAA 
Zta (Z) or ZtaAAA (A) expression vectors were co-transfected into HEK293 cells with 
vectors for flag-tagged C/EBPα (C), p53 (P) or empty PCDNA3 vector (-).  Cells were 
harvested after 48 hours and western blots with α-flag (A) and BZ1 (B) antibodies were 
performed.    
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6.2.1.5 Protein half-life 
In order to further determine what is happening in the co-expression of these proteins, a 
protein half-life experiment was performed (figure 6.9).  HEK293 cells were co-
transfected with empty flag-pcDNA3, C/EBPα, NFκB p65 or p53 +/- pBabe Zta.  48 
hours later cycloheximide was added to cells and cells were then harvested at 0, 4, 8 and 
24 hours.  Cycloheximide is an inhibitor of eukaryotic protein biosynthesis that works 
via blocking translational elongation.  
The results revealed that expression of Zta when transfected along with empty flag-
pcDNA vector, as detected by BZ1 antibody on western blots, is stable for 8 hours after 
cycloheximide addition (Figure 6.9A).  Expression then drops dramatically by 24 hours.  
However when Zta is co-expressed with C/EBPα, an additional band larger than the 
expected 35kDa band for Zta is clearly visible (Figure 6.9B).  C/EBPα also appears to 
have a stabilising effect on Zta as the protein is still strongly expressed after 24 hours.  
The level of C/EBPα is also unchanged at 24 hours.   
In contrast co-expression of Zta and p53 results in a dramatic reduction of Zta 
expression within 2 hours of cycloheximide addition (Figure 6.9C).  This degradation 
was co-ordinated with a reduction in p53 expression.  
The levels of Zta when co-expressed with NFκB p65 are not considerably changed from 
expression of Zta alone (Figure 6.9D).  NFκB p65 expression is approximately halved 
by 2 hours and gradually reduces after that. 
Although the associations of Zta and its known binding partners were not able to be 
assessed in pulldown experiments, co-expression with some proteins provided 
interesting results.  The additional band produced during co-expression of Zta and 
C/EBPα and the degradation of Zta when expressed with p53 show there is a direct or 
indirect association between these proteins.  In contrast expression with C/EBPα did not 
result in an additional protein band for ZtaAAA, and the p53 associated degradation of 
ZtaAAA was much reduced from Zta levels.  This shows that the three CT amino acids 
of Zta, that are key to many functions of Zta, also have an influence on these protein 
interactions.   
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Figure 6.9: Expression of Zta at time points following cotransfection and 
cycloheximide  
HEK293 cells were co-transfected using effectene with pcDNA3-flag vector (A), 
C/EBPα (B), p53 (C) or NFkB p65 (D) or +/- pBabe Zta.  After 48 hours 100μg of 
cycloheximide was added to each well.  Cells were harvested at 0, 4, 8 and 24 hours.  
Cells were counted using a hematocytometer and 1x106 cells were lysed at each time 
point and loaded on a protein gel. Protein gels were western blotted with BZ1 and α-flag 
antibodies. 
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6.2.2 QPCR cancer array  
A second approach was adopted to assess the effect of Zta on host cell proteins, using a 
QPCR expression array with probes for 600 genes with an association with cancer.  By 
comparing changes to the expression of host genes in cells transfected with Zta, 
ZtaAAA or a control empty vector, host genes that are influenced by Zta or ZtaAAA 
may be revealed. In addition acyclovir was used to treat some Zta-transfected cells.  
Acyclovir is a nucleoside analogue with far greater affinity for viral polymerase than 
cellular polymerase.  Acyclovir is phosphorylated by EBV encoded thymidine kinase 
then by cellular kinases to generate acyclovir triphospate, an active acyclo-GTP.  
Incorporation of acyclovir triphosphate into a growing DNA chain results in termination 
of elongation, resulting in the inhibition of viral DNA replication (Lin et al., 1984).  
These acyclovir-treated cells would therefore be restricted from expressing late lytic 
cycle genes.  Different patterns of host cell gene expression observed in these cells 
could be attributed to early EBV lytic events.    
 
6.2.2.1 Method 
HEK293-ZKO cells were transfected with a vector encoding Zta, ZtaAAA or empty 
vector (pBabe) as summarised in figure 6.10.  Cells were harvested after 48 hours and 
RNA was extracted.  This time point was selected as infectious viral particles are 
present 48 hours after transfection. In addition a duplicate set of Zta transfected cells 
was treated with 100 ug/ml acyclovir following transfection.  Two separate 
experimental sets of total RNA were sent to the Biotrove laboratory (now part of 
Applied Biosystems) as biological replicates.  There it was converted to cDNA with a 
high capacity cDNA RT kit (Applied Biosystems).  The cDNA was used at a 
concentration of 100ng/μl for 32 cycles of Quantitative PCR.  This was performed using 
an OpenArray technology which is a nanolitre fluidics platform.  A microscope slide 
sized plate with 3,072 holes is coated with hydrophilic and hydrophobic coatings.  
Reagents and samples for the QPCR reactions are retained in the holes via surface 
tension.  The primers used were for 595 human genes with an association with cancer as 
shown in Table 6.11.  This comprises the Biotrove Cancer OpenArray.  The Cancer 
OpenArray panel includes genes associated with DNA repair, angiogenesis and cell 
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adhesion.  It also contains genes that are differentially expressed in early cancer and 
metastatic disease involved in apoptosis, cell cycle, kinases and transcription factors. 
 
RT-PCR
Q-PCR
Transfection Lysis
Acyclovir 
Treatment
Sinclair Lab Biotrove Lab
RNA
 
 
Figure 6.10: QPCR Cancer OpenArray Flow Chart 
HEK293-ZKO cells were transfected with a vector encoding Zta, ZtaAAA or empty 
vector (pBabe).  One duplicate set of Zta-transfected cells were treated with 100 ug/ml 
acyclovir.  Cells were harvested after 48 hours and RNA was extracted using RNeasy kit 
(Qiagen).  This was sent to the Biotrove Laboratory where it was converted to cDNA 
with high capacity cDNA RT kit (Applied Biosystems).  The DNA was used at 100 
ng/ul for 32 cycles of Quantitative PCR (QPCR) using primers for 595 human genes 
with an association with cancer included in the Biotrove (now Applied Biosystems) 
Cancer OpenArray.  All experiments were performed with biological replicates.  
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FBN1 
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FBP1 
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FGF3 
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FGFR1 
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MNDA 
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MS4A7 
MSH2 
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MYB 
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SACS 
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SEMA3C 
SEMA4D 
SEPP1 
SERPINE1 
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SFN 
SFPQ 
SFRS7 
SHB 
SIAH2 
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SLC16A1 
SLC1A4 
SLC20A1 
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SMAD1 
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SMPD1 
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SND1 
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SOD1 
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TIMP1 
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TMEFF1 
TMEM45A 
TNF 
TNFRSF10B 
TNFRSF1A 
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TNK1 
TNK2 
TOB1 
TP53 
TP53BP2 
TP53I3 
TPBG 
TPT1 
TRADD 
TRAM1 
TRIP13 
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TUBA1B 
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TYK2 
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VIL2 
VIM 
WEE1 
WISP1 
WNT1 
WNT2 
WNT2B 
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Table 6.11: Table of Genes used in QPCR  
Primers for these 595 genes were used in QPCR  for the Cancer OpenArray  
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To verify the expression of Zta and EBV genes, I also analysed the samples with 
quantitative PCR for Zta and EBV DNA polymerase genes (Figure 6.12).  Results were 
standardised to the expression of the housekeeping ribosomal gene L32.  Zta, Zta + 
acyclovir and ZtaAAA all showed similar levels of expression of Zta.  Expression of 
EBV DNA polymerase was greatly reduced for Zta +acyclovir and ZtaAAA.  
Application of acyclovir in cell culture is expected to result in a decreased mRNA levels 
for EBV polymerase (Halder et al., 2009).  As ZtaAAA is defective in lytic reactivation, 
low levels of EBV polymerase expression were also expected.   
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Figure 6.12: Expression of Zta and EBV polymerase in Biotrove samples 
The four samples sent for analysis with the Biotrove Cancer OpenArray were analysed 
using QPCR for expression of Zta and EBV polymerase.  The average result is shown.  
Results were standardised to the expression of the housekeeping ribosomal gene L32. 
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6.2.2.2 Analysis 
 
The results provided by Biotrove were in the form of two replicate CT values for each 
gene from the QPCR analysis.  I converted these values to ΔCT for each sample by 
normalisation to 4 housekeeping control genes selected and previously validated by 
Biotrove, that were analysed on the same array, for each sample.  These housekeeping 
genes were Actin B, GAPDH, keratin 18 and keratin 19.   
I calculated the average of each data point from the two measured QPCR values.  This 
average value was used to determine the ΔΔCT for each comparison pair e.g. ΔΔCT 
Zta/pBabe.  This figure then allows the calculation of the Fold Difference (FD) for the 
comparison pair. 
An error in the analysis by Biotrove provided 46 samples with CT values of 26.00.  
These results were in fact invalid and subsequently these genes had to be removed from 
the analysis.  In total there were 532 genes from the array with data for all samples.   
6.2.2.3 Results 
I plotted scattergraphs of the comparison pairs to give an overview of the data.  These 
are shown in Figure 6.13.  In panel A, values for Zta compared to pBabe are shown.  
The majority of the data points are distributed closely to the diagonal line of FD=0, 
indicating low fold differences.  Several outlying values with a high fold difference are 
highlighted.  The highest fold difference for this comparison is for the gene PSMD2 
(FD = 147.7), followed by CD70 (FD = 26.86) and Notch2 with a FD of 14.7.  A similar 
pattern is observed in panel B for the comparison of ZtaAAA/pBabe.  The highest value 
for this pairing is again PSMD2 (FD = 106.3).  The data in panel C for Zta/ZtaAAA is 
clustered more tightly around the central line, indicating in general less difference 
between the two samples.  The highest fold difference was seen for CD70 (FD = 24.05). 
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 Figure 6.13: Scattergraphs of average ΔCT for Zta and ZtaAAA. 
QPCR was performed using the Biotrove Cancer OpenArray.  Scattergraphs showing a 
comparison of gene expression levels, using  ΔCT, are shown for Zta and pBabe (A), 
ZtaAAA and pBabe (B) and Zta and ZtaAAA (C). Some outlying results are highlighted 
in each graph and the Fold Difference (FD) in expression for these genes are shown to 
the right of the graphs.    
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Table 6.14 gives a summary of the 37 genes with a FD in expression greater than 4 
between cells transfected with Zta vs. pBabe.  This threshold was selected as with only 
duplicate samples in the analysis, I wanted to focus on large differences as these are 
more likely to be real than small differences.  31 of the genes showed higher expression 
in Zta (yellow in Table 6.14) while the remaining 6 were expressed at reduced levels in 
Zta transfected cells.  
The FD for genes with a greater than 4 fold difference between ZtaAAA and pBabe are 
shown in Table 6.15.  There are 51 differentially expressed genes, and all but 1 were 
expressed at a higher level in cells transfected with ZtaAAA.   
There were very few differences in expression between Zta and ZtaAAA.  Only 5 genes, 
CD70, MTDH, NFKB2, SOCS1 and ID1, had a difference in expression greater than 4 
fold (Table 6.15B).  Figure 6.16 shows the 21 genes in common between Zta and 
ZtaAAA that have expression with a greater than 4 FD from pBabe.   
The results from cells transfected with empty pBabe in comparison with cells 
transfected with Zta then treated with acyclovir (acZta) are shown in the scattergraph in 
Figure 6.17.  The highest ranking gene in this experiment is CKS2 with a FD of 9.73.  
Expression was highest for this gene in acZta.   There were only 7 genes with a fold 
difference in expression greater than 4 for these two samples and a summary of these is 
shown in Table 6.18.   
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Gene FD Gene FD
PSMD2 147.74 NDC80 5.25
CD70 26.86 IGF1 5.13
NOTCH2 14.74 TNF 5.12
CP 13.43 CA9 5.04
WNT2 12.05 HMBS 5.01
LCK 9.71 E2F3 5.01
SKIL 9.55 PLK2 4.90
MATN3 9.49 CDKN2A 4.89
FOS 9.41 PKM2 4.58
PFDN4 9.00 PKMYT1 4.40
SOCS1 8.10 CDK10 4.39
TPT1 7.71 ITGB3 4.36
DCN 7.22 WISP1 4.31
DCC 6.54 MYD88 4.30
CDKN2B 6.47 CYP19A1 4.27
TNK1 6.46 TNFRSF1B 4.14
PDGFA 6.18 MME 4.12
RAI2 5.29 ABCG2 4.04
CDK2 5.27
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6.14: Genes with a greater than 2 fold difference in expression in cells 
transfected with Zta vs pBabe. 
QPCR analysis was performed by Biotrove on RNA from cells transfected with Zta and 
pBabe (empty vector) as described in figure 6.10.  My analysis of the QPCR results 
showed that 37 genes had a greater than 4 fold difference (FD) in expression.  Genes 
highlighted in yellow had higher expression in Zta cells and blue highlighted genes had 
higher expression in pBabe cells.    
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A
B
Gene FD Gene FD Gene FD
PSMD2 106.27 ERBB4 6.81 MATN3 4.81
SOCS1 41.64 SERPINE1 6.68 MT3 4.81
NOTCH2 39.98 TIMP3 6.68 TNFRSF1B 4.74
PFDN4 15.17 RAD50 6.56 RAP1A 4.68
TPT1 12.16 CEACAM5 6.15 STK3 4.59
SKIL 12.12 BRCA2 6.01 DEPDC1 4.58
CDK2 10.51 COX6C 5.63 KIF21A 4.56
CP 9.68 ITGA3 5.60 CA9 4.54
PDGFA 9.41 CHPT1 5.60 TGFBR2 4.32
FOS 9.00 ASPM 5.50 MLF1IP 4.31
MTDH 8.84 TNK1 5.38 FGD6 4.30
NDC80 8.22 ATF4 5.33 KIF14 4.29
CDKN2B 7.75 TNF 5.23 FAS 4.27
E2F3 7.74 HMGN2 5.05 PIK3CA 4.04
ARHGAP5 7.08 ITGB3 5.03 NMU 4.03
MYD88 6.98 DCN 4.98 REL 4.02
BAG3 6.83 PTGS1 4.92 RARB 4.00
Gene FD
CD70 24.05
MTDH 4.05
NFKB2 4.87
SOCS1 5.14
ID1 8.25
 
Table 6.15: Genes with a greater than 2 fold difference in expression 
QPCR analysis was performed on RNA from cells transfected with Zta, pBabe (empty 
vector) and ZtaAAA as described in figure 6.10.  51 genes had a greater than 4 fold 
difference (FD) in expression for ZtaAAA and pBabe (A).  Genes highlighted in yellow 
had higher expression in ZtaAAA cells and blue genes had higher expression in pBabe 
cells.   B shows the 5 genes with more than 4 fold expression difference between Zta 
and ZtaAAA.  Expression was higher in Zta cells for blue and higher for ZtaAAA in 
yellow. 
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Figure 6.16: Genes with altered expression in Zta/pBabe and ZtaAAA/pBabe 
21 genes had fold differences greater than 4 in both Zta/pBabe and ZtaAAA/pBabe.  
One gene showed higher expression in cells transfected with pBabe and is shown in 
blue.  The fold difference for Zta/acZta is shown when greater than 4.    
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Figure 6.17: Scattergraphs of average ΔCT for Zta and acZta 
QPCR was performed using the Biotrove Cancer OpenArray.  Scattergraphs showing a 
comparison of gene expression levels, using  ΔCT, are shown for acyclovir treated Zta 
(acZta) and pBabe (A) and Zta and acZta (B). Some outlying results are highlighted in 
each graph and the Fold Difference (FD) in expression for these genes are shown to the 
right of the graphs.    
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Table 6.18: Differentially expressed genes for acZta and pBabe 
QPCR analysis was performed on RNA from cells transfected with Zta then treated with 
acyclovir and pBabe (empty vector).  7 genes had a greater than 4 fold difference (FD) 
in expression for Zta treated with acyclovir (acZta) and pBabe.  Genes highlighted in 
yellow had higher expression in acZta cells and blue genes had higher expression in 
pBabe cells.    
Gene FD
CKS2 9.73
AKR1C2 6.21
CD34 5.92
NMBR 4.88
TRIP13 4.82
COX7A2 4.08
ETV1 4.04
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Figure 6.17B shows the scattergraph of Zta vs. acZta.  The shape of this graph differs 
from the other scattergraphs in that the majority of points are located closer to the ∆CT 
acZta axis, indicating that expression for most genes was higher in the untreated cells.  
There were 6 genes, PSMD2, CD34, AKR1C2, ETV1, ITGB3, and TGFB1 with a fold 
difference greater than 30.  Of the 132 genes differentially expressed at greater than 4 
fold between Zta and acZta, only 4 were expressed at a higher level in acZta.  These are 
detailed in Table 16.19. 
 
It would be expected that expression profiles of ZtaAAA and acZta would be similar as 
ZtaAAA is defective in lytic reactivation and acZta is prevented from expressing late 
lytic genes.  However there were a considerable number of differences between the two 
data sets.  The scattergraph for this comparison is shown in Figure 6.20.  Similarly to 
Zta/acZta, lower levels of expression were detected for most genes in the acyclovir 
treated cells. In total 136 genes were expressed at greater than 4 FD between ZtaAAA 
and acZta.  These genes are shown in Table 6.21.  Of these 136 genes only 5 (PSMD2, 
SERPINE1, IGFBP4, TIMP3 and CDKN2A) were expressed at higher levels in acZta 
cells.   
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Gene FD Gene FD Gene FD Gene FD
PSMD2 156.39 MRPL13 10.99 HSPA5 7.01 PCTK2 5.10
CD34 45.92 CRHR1 10.87 YES1 6.90 EGLN1 5.10
AKR1C2 45.44 PDGFRA 10.71 CDKN2A 6.76 MLF1IP 5.09
ETV1 36.81 UCHL5 10.69 FAS 6.69 BRCA2 5.05
ITGB3 34.13 ERBB3 10.57 STK3 6.63 CD59 4.99
TGFBI 30.23 RAI2 10.52 TNF 6.62 RALBP1 4.95
NOTCH2 27.40 TPT1 10.45 ITGA3 6.36 REL 4.93
NMBR 26.47 SOCS3 10.27 KIF14 6.31 PRNP 4.79
WNT2 26.34 MYB 9.61 MYLK 6.27 GTF2I 4.76
TGFB2 26.12 MAPK13 9.48 CDK10 6.18 KRAS 4.66
BTK 25.56 PDGFB 9.27 ABCB1 6.13 MUC1 4.65
GPR126 25.26 APC 9.24 SEMA3C 5.91 NRG1 4.65
NQO1 22.08 PDGFA 9.22 MTDH 5.86 SFN 4.62
IGFBP3 20.73 FGD6 9.20 MLLT3 5.86 DDX10 4.62
EGF 19.61 NF1 9.11 NPM1 5.82 FGR 4.61
ANPEP 19.04 CDKN2B 9.05 HMGN2 5.81 SKI 4.49
SOCS1 19.01 SPINT2 8.98 SFPQ 5.80 PRKCA 4.46
PLK2 16.06 ODZ1 8.49 ABCC4 5.79 TFDP1 4.40
TNFRSF1B 15.22 CLTC 8.46 MDM2 5.68 CEBPG 4.39
MYRIP 15.15 STK32B 8.20 FGFR1 5.64 BRAF 4.38
MYD88 15.15 NDC80 7.90 HMGB1 5.59 GSPT1 4.37
GSTM3 15.06 RB1 7.77 MMP14 5.54 EGR1 4.35
LEP 15.01 DEPDC1 7.73 ARID4A 5.50 KIF21A 4.27
SKIL 14.88 ABCG2 7.72 RAP1A 5.50 E2F3 4.26
CCL2 14.46 DHRS2 7.59 ARHGAP5 5.49 PKMYT1 4.24
AXL 14.40 SEPP1 7.56 CDKL1 5.48 HSPH1 4.19
RET 13.89 TGFA 7.36 PECAM1 5.32 PRKCE 4.18
RAB27B 13.85 TP53BP2 7.30 PRKCB1 5.31 CENPC1 4.17
TIE1 13.52 TGFB3 7.29 TJP1 5.30 KITLG 4.12
CSF3 13.09 FES 7.27 XRCC4 5.27 TAF1 4.12
THBS1 12.34 ASPM 7.19 MYBL1 5.20 CANX 4.07
WNT2B 12.12 CDK2 7.06 KRT18 5.18 NOTCH4 4.07
TNK1 11.09 PFDN4 7.05 USP7 5.13 CDC42BPA 4.01
 
Table 6.19: Differentially expressed genes for Zta and acZta 
132 genes are expressed at greater than 4 fold difference between Zta and acZta.  Higher 
expression in Zta cells is highlighted yellow and higher for acZta is in blue. 
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NOTCH2
SOCS1
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PSMD2: FD=149.94
SOCS1: FD=73.33
NOTCH2: FD=55.76
SERPINE1: FD=15.64 
ZtaAAA / acZta
SERPINE2
 
 
Figure 6.20: Scattergraph of average ΔCT for ZtaAAA and acZta 
QPCR was performed using the Biotrove Cancer OpenArray. Scattergraphs showing a 
comparison of gene expression levels, using ΔCT, are shown for ZtaAAA and acyclovir 
treated Zta (acZta).  Some outlying results are highlighted and the Fold Difference (FD) 
in expression for these genes is shown to the right of the graphs.  
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Gene FD Gene FD Gene FD Gene FD
PSMD2 149.94 MYLK 8.11 HMGB3 5.78 EGLN1 4.80
SOCS1 73.33 MYB 7.97 NFKB2 5.75 TFRC 4.80
NOTCH2 55.76 LEP 7.97 SNRPB2 5.74 MKI67 4.78
ITGB3 29.58 TP53BP2 7.92 COX6C 5.73 PRKCA 4.76
ETV1 23.91 MRPL13 7.72 NPM1 5.69 SYNCRIP 4.68
NQO1 18.48 TGFB2 7.55 MYRIP 5.69 FES 4.66
MYD88 18.42 ASPM 7.44 CDKL1 5.68 AXL 4.66
NMBR 18.02 BTK 7.43 AP2M1 5.64 SMAD1 4.65
MTDH 17.79 DEPDC1 7.37 RB1 5.63 REL 4.65
IGFBP3 17.14 ERBB4 7.31 THBS1 5.62 TMEFF1 4.61
TIE1 15.98 TGFBI 7.21 RAB27B 5.60 MSH6 4.57
CD34 15.71 PLK2 7.09 RALBP1 5.57 MMP9 4.56
SERPINE1 15.64 GPR126 7.06 FAS 5.53 PIK3CA 4.51
AKR1C2 15.31 TNK1 6.93 TGFBR2 5.36 HSPH1 4.46
SKIL 14.16 SKI 6.91 USP7 5.28 CENPC1 4.40
TNFRSF1B 13.09 ITGA3 6.86 GTF2I 5.23 MUC1 4.33
TPT1 12.36 ERBB3 6.85 RAD50 5.22 CLTC 4.33
CCL2 11.90 NF1 6.82 MAPK13 5.22 DDX10 4.28
RAP1A 11.56 MLLT3 6.74 KRAS 5.16 CCNB1 4.27
CDK2 10.57 PRKCB1 6.68 TIMP3 5.14 PCTK2 4.26
PDGFA 10.54 EGF 6.53 EGR1 5.13 PRKAR1A 4.22
ANPEP 10.25 WNT2 6.47 CSF3 5.13 PDGFB 4.22
GSTM3 9.94 UCHL5 6.44 KIF21A 5.11 SEPP1 4.22
RET 9.52 KIF14 6.43 SEMA3C 5.09 MELK 4.21
ARHGAP5 9.45 CHPT1 6.19 TNF 5.07 DHRS2 4.20
NDC80 9.26 HMGN2 6.14 CEBPG 5.06 CDC42BPA 4.18
PFDN4 8.92 TGFA 6.10 MLF1IP 5.05 CCT5 4.13
IGFBP4 8.88 STK3 6.03 GSPT1 5.03 ABCB1 4.12
CRHR1 8.76 HMGB1 6.02 MDM2 5.03 SOCS3 4.10
PDGFRA 8.75 SFPQ 6.01 SPINT2 5.00 FBN2 4.07
ABCC4 8.72 YES1 5.90 CDKN2A 4.98 SRPX 4.07
FGD6 8.45 HSPA4 5.90 E2F3 4.94 E2F5 4.06
BAG3 8.35 BRCA2 5.89 RAI2 4.91 MAPRE1 4.06
CDKN2B 8.14 XRCC4 5.82 ODZ1 4.90 EVL 4.03
 
Table 6.21: Differentially expressed genes for ZtaAAA and acZta 
QPCR analysis was performed on RNA from cells transfected ZtaAAA or with Zta then 
treated with acyclovir (acZta).  136 genes had a greater than 4 fold difference (FD) in 
expression for ZtaAAA and acZta.  Genes highlighted in yellow had higher expression 
in ZtaAAA cells and blue genes had higher expression in acZta cells.    
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Prediction of ZREs in differentially expressed genes 
In order to develop a concept of a mechanism that could be responsible for Zta affecting 
expression of these cellular genes, the presence of ZREs in the promoter regions of 
differentially expressed genes was examined.  
There are 17 genes with a difference in expression greater than 8 fold between Zta and 
pBabe, ZtaAAA and pBabe or both.  These are detailed in Table 6.22.  A Biomart 
(http://www.biomart.org/) query was designed to extract the 1000bp 5’ to the coding 
region for each gene from Ensembl (www.ensembl.org).  Each sequence was searched 
using a MS Word macro (modified from a macro created by James Heather) to identify 
any potential ZREs located in the DNA sequence.  The macro involved matching to 7 
bp core ZRE sequences that Zta has been experimentally verified as being able to bind 
to.  Identified sites were classified as ZRE class I, II or III (Karlsson et al., 2008b).  
Only two genes, Notch2 (FD = 14.74) and TPT1 (FD = 12.16), contained no potential 
sites.  The other 15 genes contained between 1 and 7 ZRE sites. 
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Table 6.22: Table of number of ZREs in promoter region of genes with differential 
expression between cells transfected with Zta or ZtaAAA 
Genes with a difference in expression between Zta and pBabe, ZtaAAA and pBabe or 
both of greater than 8-fold were selected.  The 1000bp 5’ to the coding region of each 
gene was obtained from Ensembl (www.ensembl.org) using BioMart. Each sequence 
was searched using a MS Word macro for ZREs that Zta is known to be able to bind to.  
The number of type I, II and III ZREs is shown for each gene.   
Gene Pair FD Type I Type II Type III Total
PSMD2 p/Zta,  p/AAA 147.74 1 2 3
SOCS1 AAA/p, Zta/p 41.64 1 3 4
NOTCH2 AAA/p, Zta/p 39.98 0
CD70 Zta/p, Zta/AAA 26.86 1 3 4
PFDN4 AAA/p, Zta/p 15.17 2 2
CP Zta/p, AAA/p 13.43 4 4
TPT1 AAA/p 12.16 0
SKIL AAA/p, Zta/p 12.12 1 6 7
WNT2 Zta/p 12.05 1 2 3
CDK2 AAA/p 10.51 2 2
LCK Zta/p 9.71 1 1
MATN3 Zta/p 9.49 1 1
PDGFA AAA/p 9.41 3 3
FOS Zta/p, AAA/p 9.41 2 1 3
MTDH AAA/p 8.84 1 3 4
ID1 AAA/Zta 8.25 1 1
NDC80 AAA/p 8.22 2 1 3
ZREs in 1000bp 5' of gene
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41 genes showed a difference in expression between Zta and acZta of 10 fold or more 
(Figure 6.23).   These 41 genes were analysed for ZREs in the same way described 
above.  Only NOTCH2 (FD = 27.40) and TPT1 (FD = 10.45) contained no ZREs. 
A genome wide search for ZREs by Kirsty Flower et al (Flower et al., 2011) found that 
97.3% of human genes contained at least one potential ZRE in the 1000bp upstream of 
the gene start.  The sites are not thought to be retained in the genome for Zta binding but 
rather as a result of similarity to other binding sites (AP1) or by chance. However the 
presence of a ZRE means the site is available for Zta binding to potentially affect gene 
expression.  At least 6 human host genes are known to be directly regulated by Zta 
through ZREs in the promoters.  They are DHRS9 (Jones et al., 2007), EGR1 (Chang et 
al., 2006), CIITA (Li et al., 2009), IL-8 (Hsu et al., 2008), IL-10 (Mahot et al., 2003) 
and IL-13 (Tsai et al., 2009).  The other genes were not part of the array but EGR1 
showed a FD of 5.13 ZtaAAA/acZta, 4.35 for Zta/acZta and 3.93 for AAA/pBabe.  
Other potential mechanisms for Zta affecting cellular gene expression are as a 
downstream effect from Zta-regulated activation of a pathway e.g. MAPK pathway 
(Chang et al., 2006) or activation or repression via a binding partner.  One example of 
this is Zta interacts directly with C/EBPα and C/EBPβ in vivo, and is thus able to inhibit 
activation of TNFR1 by C/EBPα and C/EBPβ (Bristol et al., 2010).  
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Figure 6.23: Table of number of ZREs in promoter region of genes with differential 
expression in cells transfected with Zta and treated with acyclovir 
Genes with a difference in expression between Zta and acZta, acZta and pBabe or both 
of greater than 10-fold were selected and analysed for ZREs in the 1000bp 5’ to the 
gene start as in Figure 6.22.  
Gene Pair FD Type I Type II Type III Total
PSMD2 ac/Zta 156.39 1 2 3
CD34 Zta/ac 45.92 2 2
AKR1C2 Zta/ac 45.44 3 3
ETV1 Zta/ac 36.81 1 1
ITGB3 Zta/ac 34.13 2 1 3
TGFBI Zta/ac 30.23 2 2
NOTCH2 Zta/ac 27.40 0
NMBR Zta/ac 26.47 1 1 2
WNT2 Zta/ac 26.34 1 2 3
TGFB2 Zta/ac 26.12 5 5
BTK Zta/ac 25.56 2 2
GPR126 Zta/ac 25.26 1 1 2
NQO1 Zta/ac 22.08 4 4
IGFBP3 Zta/ac 20.73 1 1
EGF Zta/ac 19.61 2 2
ANPEP Zta/ac 19.04 1 1 2
SOCS1 Zta/ac 19.01 1 3 4
PLK2 Zta/ac 16.06 3 3 6
TNFRSF1B Zta/ac 15.22 1 1 2
MYRIP Zta/ac 15.15 2 2 4
MYD88 Zta/ac 15.15 1 1
GSTM3 Zta/ac 15.06 3 3
LEP Zta/ac 15.01 2 2
SKIL Zta/ac 14.88 1 6 7
CCL2 Zta/ac 14.46 6 6
AXL Zta/ac 14.40 5 1 6
RET Zta/ac 13.89 1 1 2
RAB27B Zta/ac 13.85 3 3
TIE1 Zta/ac 13.52 1 1 2
CSF3 Zta/ac 13.09 3 1 4
THBS1 Zta/ac 12.34 1 1 3 5
WNT2B Zta/ac 12.12 2 2
TNK1 Zta/ac 11.09 1 1
MRPL13 Zta/ac 10.99 1 1
CRHR1 Zta/ac 10.87 1 2 3
PDGFRA Zta/ac 10.71 1 1
UCHL5 Zta/ac 10.69 2 1 3
ERBB3 Zta/ac 10.57 2 2
RAI2 Zta/ac 10.52 1 3 4
TPT1 Zta/ac 10.45 0
SOCS3 Zta/ac 10.27 1 1 1 3
ZREs in 1000bp 5' of gene
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6.2.2.4 Pathway Interaction Database 
An analysis of the data with Pathway Interaction Database (PID) 
(http://pid.nci.nih.gov/) was performed in order to get an impression of how some of the 
differentially expressed genes may relate to one another in the cell.  The PID is a fully 
curated database of known biomolecular interactions and signalling pathways of key 
cellular processes.  It can be searched with a group of, for example, experimentally 
identified genes in order to elucidate potential connections between them.   The 44 
genes which showed a fold difference in expression greater than 5 between Zta/ 
ZtaAAA and/or pBabe were entered into the database and pathways containing a 
significant number of these genes were identified (Table 6.24).  The associated p-value 
was calculated by PID.  As the pool of genes on the Biotrove Cancer Array was selected 
for their relationship to this disease, it was to be expected that many would be involved 
in the same pathways.  However this still provides an interesting starting point for 
clarifying what possible influence Zta may have in host cells.  Interestingly one of the 
hits was the Transcriptional Targets of AP1 (Fra).  As an AP-1 transcription factor, Fra 
and Zta can recognise and bind the same motifs e.g. tgagtca (Welter et al., 1995).  This 
provides a mechanism for Zta to affect transcription of the same cellular target genes as 
Fra and other Ap1 transcription factors. 
Another interesting match from the PID was the p73 transcription factor network.  EBV 
associated gastric carcinoma shows a loss of p73 expression.  In addition specific dense 
methylation of the 5’ UTR and exon 1 is near universal in EBV positive gastric 
carcinoma samples and absent in almost all EBV negative samples (Ushiku et al., 
2007).  There is also specific increased methylation of other promoters in EBV positive 
samples including 10 that were included in the QPCR array (Kang et al., 2002; Kang et 
al., 2008; Ryan et al., 2010).  Six of these genes had results from the array with a 
greater than 3 fold difference.  These are shown in Table 6.25, along with the numbers 
of ZREs found 5’ to the gene.  All six contained ZREs in this promoter region.  All 
genes except APC contained at least one type 3 methylation dependent ZRE. 
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These results give an impression of the potentially wide reaching impact Zta may have 
both directly and indirectly on host cell gene expression. 
 
Pathway Genes P-value
Regulation of nuclear SMAD2/3 signaling CDK2, CDKN2B, FOS, SERPINE1, SKIL 0.00010
IL2-mediated signaling events CDK2, FOS, LCK, SOCS1 0.00028
HIF-1-alpha transcription factor network CA9, CP, FOS, SERPINE1 0.00059
uPA and uPAR-mediated signaling ITGA3, ITGB3, SERPINE1 0.00184
FOXM1 transcription factor network BRCA2, CDK2, FOS 0.00184
Ceramide signaling pathway IGF1, PDGFA, TNF 0.00284
IL12-mediated signaling events FOS, LCK, SOCS1 0.00669
E2F transcription factor network CDK2, E2F3, SERPINE1 0.00934
Integrin family cell surface interactions ITGA3, ITGB3 0.00999
p73 transcription factor network BRCA2, CDK2, SERPINE1 0.01030
Ephrin B reverse signaling ITGB3, LCK 0.01310
BARD1 signaling events CDK2, RAD50 0.01310
Osteopontin-mediated events FOS, ITGB3 0.01390
IL23-mediated signaling events ITGA3, TNF 0.01920
Transcriptional targets of AP1 (Fra1 and Fra2) ATF4, DCN 0.01920
ATR signaling pathway BRCA2, CDK2 0.02210
amb2 Integrin signaling LCK, TNF 0.02310
PLK1 signaling events NDC80, TPT1 0.02840
Regulation of RhoA activity ARHGAP5, ARHGEF5 0.02840
Transcriptional targets of deltaNp63 isoforms BRCA2, ITGA3 0.03060
Fanconi anemia pathway BRCA2, RAD50 0.03170
Downstream signaling in naïve CD8+ T cells FOS, TNF 0.03170
Signaling events mediated by PTP1B ITGB3, LCK 0.03510
PDGF receptor signaling network PDGFA 0.03520
PDGFR-beta signaling pathway FOS, ITGB3, LCK 0.03520
SHP2 signaling IGF1, LCK 0.04360
IL4-mediated signaling events ITGB3, SOCS1 0.05120
Regulation of retinoblastoma protein CDK2, E2F3 0.05380
 
 
Table 6.24: Pathway Interaction Database 
Pathways identified using Pathway Interaction Database (http://pid.nci.nih.gov) from 
genes with > 5 Fold Expression difference in cells transfected with either Zta or 
ZtaAAA. 
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Table 6.25: Genes from QPCR array that show increased methylation in EBV positive carcinoma 
10 genes that are specifically highly methylated in EBV positive gastric carcinoma were part of the QPCR cancer array (references in right 
column).  Results from the array greater than 3 fold are shown.  The ZREs found in 1000 bp 5’ to the coding region are shown for these genes.    
 Fold Difference (p-value) ZREs in 1000bp 5’  
Gene Zta/pBabe ZtaAAA/pBabe Zta/ZtaAAA Zta/acZta Type 1 Type 2 Type 3 Reference 
APC       9.24 2 - - (Kang et al., 2002) 
BRCA2 3.86 6.01   5.05 2 1 3 (Ryan et al., 2010) 
CCND1                (Ryan et al., 2010) 
CDKN2A 0.20 (4.89)     0.15 (6.76) 1 2 3 (Ryan et al., 2010) 
ICAM1            (Ryan et al., 2010) 
ID2            (Ryan et al., 2010) 
IGF2            (Kang et al., 2008) 
IGFBP3   3.04    20.73 - - 1 (Ryan et al., 2010) 
PTEN       3.00 - - 2 (Kang et al., 2002) 
THBS1       12.34 1 1 3 (Kang et al., 2002) 
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6.3 Discussion 
Attempts to assess the interactions between CT mutants and known Zta interacting 
proteins using pulldown experiments were unsuccessful.  However co-expression of Zta 
and two other proteins, p53 and C/EBPα, revealed some interesting observations.  
 
Co-expression of p53 and Zta resulted in a rapid degradation of both proteins.  In a 
cycloheximide time course experiment, Zta expression was abolished after 2 hours.  p53 
expression was almost completely reduced by the same time point. Zta-dependent 
degradation of p53 has been reported in p53-null human osteosarcoma SaOS-2 and 
2KO (mouse embryonic p53-/mdm2- fibroblast) cells (Sato et al., 2009).  This 
ubiquitin-mediated proteasomal degradation of p53 by BZLF1 occurs independently of 
the key p53 regulator, MDM2.  Co-expression of p53 and Zta in IMR-90, HeLa and 
D98/HE-R1cells by Zhang and colleagues resulted in inhibition of the transactivating 
function of Zta (Zhang et al., 1994).  However the levels of Zta protein expressed 
remained stable when expressed with p53. 
 
When co-expressed with p53, The CT mutant ZtaAAA was expressed at higher levels 
than Zta.  However this was still considerably decreased from Zta / PCDNA3 
expression levels (Figure 6.8).  This suggests there is some effect on this interaction 
either directly from the extreme CT of BZLF1 or as a result of a loss of function due to 
altered interaction with the extreme CT elsewhere in Zta.  This agrees with Zhang and 
colleagues who found the zipper region of Zta essential for p53 interaction (Zhang et 
al., 1994).   
 
The coordinated degradation of Zta with p53 observed may be influenced by the cell 
type and also by the high levels of p53 expression.  As p53 regulates the expression of 
genes involved in apoptosis, it is possible that a downstream target of p53 may 
influence the levels of Zta.    
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Co-expression of Zta and C/EBPα led to the expression of both Zta and a smaller 
amount of a larger species of Zta.  This was stable in a cycloheximide time course 
experiment for 24 hours.  Co-expression of the mutant ZtaAAA and C/EBPα did not 
reveal the same larger form of Zta.   
Post-translational modification of Zta may play a pivotal role in both the regulation of 
gene expression in the lytic cycle and DNA replication (Wang et al., 2005).    
Modification of Zta with the ubiquitin-related protein SUMO-1 can occur at lysine 12 
(Adamson and Kenney, 2001).  Sumoylation of Zta leads to higher levels of BMRF1 
following lytic cycle induction, suggesting it may have an important role in EBV lytic 
replication (Adamson, 2005).  Mutation of lysine 12 to alanine, disrupting the 
sumoylation site, results in a defect in EBV lytic cycle DNA replication (Deng et al., 
2001).   
Further work on this would establish the type of modification present on Zta, possibly 
through antibodies directed against different modifications.  Analysis with mutants 
could show which regions of Zta are important for this and confirm the importance of 
the extreme CT as demonstrated by the single band seen with ZtaAAA co-expression. 
 
It would be interesting to complete both in vitro and in vivo experiments with the 
expression vectors for p53, BGLF4, BMRF1, C/EBPα, NFκB p65 and RaRα to 
establish if any of the mutants of Zta have a disrupted association with these proteins. In 
addition further work needs to be completed to establish if the double band seen in co-
expression with C/EBPα is due to modification of Zta.  The band is approximately 12 
kDa larger then Zta 
 
The QPCR array provided some evidence that this strategy could be useful in 
identifying cellular genes influenced by Zta.  Two examples are given below. 
Expression of the gene EGR-1 was found to be 3.93 fold higher in ZtaAAA cells than 
pBabe cells.  Chang and colleagues have previously shown Zta activation of the cellular 
transcription factor EGR-1 (Chang et al., 2006).  Their promoter assay analysis revealed 
2 regions responsive to activation by Zta.  They identified two adjacent sequences 
similar to ZREs in the first site. Analysis of this region with our ZRE macro revealed 
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one type III ZRE (GGAGCGA).  The second region identified as responsive to 
activation by Zta contains no known ZREs.  As an additional mechanism for activating 
EGR-1, Zta activates the ERK signalling pathway, resulting in binding of the Elk-1 
transcription complex to the SRE-Ets site in the EGR-1 promoter (Chang et al., 2006). 
The gene TGFβ1 showed a 30 fold difference in expression between Zta and acZta.  
Cayrol and colleagues have previously shown an increased expression of TGFβ1 in 
response to Zta (Cayrol and Flemington, 1995) and expression of TGFβ1 can lead to the 
upregulation of p27, a cyclin dependent kinase inhibitor, causing cell cycle arrest 
(Toyoshima and Hunter, 1994).  In addition, upregulation of TGFβ1 and other 
immunosuppressive cytokines may function to suppress the immune response of host 
cells (Israel and Kenney, 2005). 
Further investigation into other high scoring genes could potentially clarify the role of 
Zta in influencing cellular genes.   
Some more information is given below on some of the most differentially expressed 
genes that could be worthy of further experimental investigation: 
PSMD2 
pBabe / ZtaAAA; FD=106.27  
acZta / ZtaAAA; FD=149.94  
PSMD2 is a subunit of the 19S proteosome regulator.  It also interacts with TNF 1 
receptor (Boldin et al., 1995) so may feature in TNF signalling pathway. 
 
CD34 
Zta/acZta; FD= 45.92  
CD34 is a cell surface glycoprotein and a cell-cell adhesion factor.  It is selectively 
expressed on hematopoietic progenitor cells.   
 
AKR1C2 
Zta/acZta; FD= 45.44  
AKR1C2 is an aldo/keto reductase with a high affinity for bile acid. 
 
ETV1 
Zta/acZta; FD= 36.81  
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ETV1 is a transcription factor.  Altered expression of ETV1 was observed in Primary 
Effusion Lymphoma which is associated with KSHV and mostly co-infected with EBV 
(Roy et al., 2011)  
It would be useful to elucidate the molecular mechanisms of cellular protein regulation 
by Zta to increase understanding of the interactions between EBV and host cells and 
also facilitate the development of anti-viral therapy strategies. 
Analysis was limited to duplicate data sets due to cost restraints.  Ideally more replcates 
would be performed to enable a measurement of significance to be applied to the 
results.  However this analysis can be viewed as an initial attempt to identify 
differentially regulated host genes in response to a replication competent versus a 
replication incompetent mutant of Zta. 
Ideally the array would have been flexible to allow inclusion of other genes of interest 
as well as EBV genes to provide to more complete context for the results.  Further 
analysis would ideally utilise different cell types to elucidate cell specific or global 
effects.  Results could be verified using additional Q-PCR or TaqMan experiments. 
Further information about the mechanisms of the influence of Zta on specific host genes 
could be gained through the use of promoter assays to confirm Zta activity as a 
transcription factor. Analysis of protein levels could also provide functional 
confirmation.   
 
For a wider investigation, mass spectrometry following a pulldown of interacting 
proteins could be utilised.  Any proteomic differences identified between cells 
transfected with Zta, mutant or empty vector could be investigated further.   
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Chapter 7      Discussion 
The importance of methylation dependent recognition by Zta as a critical factor in the 
EBV infective cycle is becoming increasingly apparent (Bergbauer et al., 2010; Kalla et 
al., 2010; Flower et al., 2011).   
I demonstrated that ZRE3 when methylated at both CpG motifs, was a stronger binding 
site for Zta than the half methylated site studied by Bhende et al (Bhende et al., 2005).  
This showed that methylation at sites 1’ and 0 also contribute to methylation dependent 
site recognition by Zta (Figure 3.2).  Individual analysis revealed a contribution from 
each of the methylated cytosines although this was unequal.  The strongest individual 
site was meC1’, followed by meC-2, with an approximately equal contribution from 
meC0 and meC-1’.   This in vitro evidence was supported by the structural modelling of 
Zta bound to methylated ZRE3 performed by Petosa and colleagues (Karlsson et al., 
2008a) which showed that all four methylated cytosines make contact with Zta.     
 
Zta was the first transcription factor identified to demonstrate enhanced binding to 
normally repressive methylated DNA in a sequence dependent manner.  Precise 
elucidation of the DNA:protein interaction that makes this recognition possible through 
the determination of the contribution of individual methylated cytosines and modelling 
may help identify other proteins that utilise a similar mechanism.   
 
Zta helps enable EBV to achieve a balance between establishing latency in newly 
infected cells and the lytic replicative cycle (Kalla et al., 2010). Methylation and the 
methylation dependent functionality of Zta play a key role in this process.  The viral 
DNA in a newly infected cell is not yet methylated.  Zta is unable to activate the lytic 
cycle, as ZREs in the promoters of key lytic cycle genes, including BMRF1, 
BSLF2/BMLF1, BSRF1 and BBLF4, are unmethylated so unavailable for activation by 
Zta (Kalla et al., 2010).  This allows establishment of latency and long term persistence 
of the virus.  Methylation of the viral genome occurs progressively after infection, 
resulting in a heavily methylated genome by 4 weeks post infection, allowing Zta to 
activate the lytic cycle when conditions permit (Kalla et al., 2010). Bergbauer and 
colleagues have identified over 20 EBV promoters that are potentially recognised by Zta 
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in a methylation dependent manner, including BALF2, BMRF1, BBLF4, BALF5 and 
BSLF2/BMLF1 (Bergbauer et al., 2010).   
 
Zta C189 has been shown to be critical for methylation detection and this residue was 
conserved in over half of 50 aligned human BZIP proteins (Petosa et al., 2006).  It is 
therefore possible that more cellular BZip proteins possessing a cysteine at this position 
may demonstrate enhanced binding to methylated DNA recognition sequences.  The 
human transcription factor C/EBPα has recently been shown to possess methylation 
dependent binding ability (Rishi et al., 2010). 
 
KSHV is closely related to EBV and demonstrates a similar biphasic genome 
methylation, however it does not possess a Zta homologue.  Methylation dependent 
activation by a cellular transcription factor could provide a potential mechanism for 
overcoming inhibition by methylation in the reactivation of  KSHV and other related 
viruses lacking a Zta homologue (Flower et al., 2011).   
 
DNA binding experiments revealed that the rhesus LCV homologue ZtaRh acts in a 
very similar methylation dependent manner to Zta.  Thus EBV is probably not unique 
amongst lymphocryptoviruses to utilise this novel method of overcoming transcriptional 
repression of methylated DNA.  It would be interesting to examine binding by Zta 
homologues in other LCVs to establish the evolution of this mechanism and if it is 
conserved across the genus.  
 
ZtaRh can be seen as a natural mutant of Zta in that it utilises the same molecular 
strategy to perform equivalent biologic tasks (Wang, 2005).  Although I demonstrated 
that the binding recognition of ZREs was similar, there are notable genomic differences 
in ZREs between EBV and RhLCV.  In particular there is no Rp ZRE3 equivalent site 
in RhLCV.  Luciferase reporter assays showed that methylation is still critical for RhRp 
activation but the addition of a ZRE3 site did not increase RhRp promoter strength.  As 
there are no additional known ZREs in RhRp there may be a more important role in 
RhLCV for Rp ZRE2.  It would be interesting to learn if this is due to physical 
differences in the proteins or differences in the viral or cellular environment.  
Development of a suitable Rhesus cell line would be required to fully understand how 
ZtaRh functions as a transcription factor in the natural host cell. 
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There is an identical repertoire of both latent and lytic genes between EBV and RhLCV 
(Rivailler et al., 2002).  This close genetic relationship between the two viruses shows 
RhLCV may be a valuable model for studying how different viral genes contribute to 
infection and pathogenesis of EBV.  Rivailler and colleagues have been successful in 
producing an LCV positive lymphoma in immunosuppressed rhesus macaques infected 
with RhLCV (Rivailler et al., 2004).  Discovery of differences and similarities between 
the two viruses such as a variation in viral ZREs and recognition of these sites could be 
informative in interpreting how the two viruses could prove useful in the development 
of new treatments or vaccines against EBV. 
 
As ZtaRh is not defective in DNA binding, the inability to cause cell cycle arrest and 
lytic reactivation must occur via an independent mechanism.  Cell cycle analysis using 
domain swap mutants revealed that differences in the transactivation domain could 
account for ZtaRh being unable to cause cell cycle arrest.  As experiments were not 
performed in the host cell for ZtaRh, it is not surprising that control over a complex 
mechanism such as the cell cycle was not maintained.  However the loss of lytic 
reactivation function could be mapped to the three extreme CT amino acids and the 
mutant ZtaAAA is entirely defective in lytic reactivation.  An almost complete loss of 
expression of selected early and late genes was observed in cells transfected with ZtaRh, 
with Rta expression at approximately 50% of that in cells transfected with Zta.  Cells 
transfected with ZtaAAA did not have reduced expression of Rta or BBLF2/3, although 
expression of other early and late genes was compromised.  The mutant Rh_LNF 
restored Rta expression but not BBLF2/3 or later genes showing an independent 
mechanism.  This shows that an extreme CT comprised of either AAA or LNF can 
express Rta but the ZtaRh sequence of I-- was defective. 
 
The nine extreme CT amino acids have not been crystallised and are not part of any 
modelling.  The preceding amino acids fold back and make contacts with the zipper 
domain that are stabilising for dimerisation (Petosa et al., 2006).  Cross-linking has 
suggested this contact continues to the extreme CT of Zta (Schelcher et al., 2007) and 
the loss of this could be causative for the observed functional defects in extreme CT 
mutants.  Alternatively this may be a result of alterations in interactions with host or 
viral proteins.   
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Co-expression of Zta and known binding partners in HEK293 cells revealed two 
interesting observations; Zta and p53 demonstrated instability and a larger additional 
Zta protein was observed when co-expressed with C/EBPα (Figure 6.7).  Both of these 
effects were abrogated when p53 or C/EBPα were co-expressed with ZtaAAA instead, 
suggesting these extreme CT residues may be important in interacting with other 
proteins. Completion of the pulldown experiments could clarify the role of this region in 
Zta’s interaction with key partner proteins.   
 
Further experiments to support the current evidence indicating contact between the 
extreme CT of Zta and the zipper domain would clarify the remaining unsolved 
structure of Zta.  To validate the structure of this region protein NMR spectroscopy or 
further crystallisation and modelling of Zta would reveal more clearly the formation the 
CT of Zta.  This would allow the actual effect of mutants in this region on the structure 
to be revealed.   
 
Results obtained using the QPCR Cancer array suggest this could be a plausible strategy 
to learn more about the cellular impact of the expression of Zta and Zta mutants.  For 
example ZtaAAA showed a 3.93 fold increase in EGR-1 expression (p=0.05).  
Upregulation of EGR-1 by Zta has been shown by Chang and colleagues to be essential 
for reactivation of EBV from latency through binding to the EGR-1 promoter (Chang et 
al., 2006).  Activation by Zta is thought to occur through a Serum Response Element 
and two ZREs (Heather et al., 2009).   One of the ZREs contains a CpG site and EGR-1 
is methylated in B-cells (Heather et al., 2009).  Heather and colleagues demonstrated 
with EMSA that binding to the methylated ZRE was enhanced 10 fold over the same 
unmethylated ZRE.  Zta C189A was greatly compromised in interaction with the 
methylated site.  Methylation of an EGR-1 promoter construct resulted in 4 fold 
increase in activation in HeLa cells, although another epithelial cell line showed no 
increase (Heather et al., 2009).   
 
ZtaAAA is not defective for DNA binding, so increased EGR-1 expression would be 
expected despite the inability of ZtaAAA to reactivate EBV.  Zta also showed increased 
EGR-1 expression (FD=2.5) although this was not significant.  The use of more 
replicates to increase significance and a tailored selection of genes, including viral 
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genes, could be very informative about the effects of Zta.  It would be interesting to 
analyse C189S using this system as this could be revealing on the effects of methylation 
sensitive binding by Zta.  ChIP-Sequencing (chromatin immunoprecipitation 
sequencing) could be a useful tool to reveal the role of Zta as a transcription factor, both 
in the viral and human genome.  This could be linked to methylation status to find the 
impact of methylation sensitive DNA binding by Zta in vivo. 
 
In summary, methylation dependent recognition of ZREs in viral and host genes is 
increasingly being recognised as an important factor in both the infection and activation 
of EBV.  This appears to be a feature shared with RhLCV.  The structure of the extreme 
CT of Zta is not yet clear but these residues are to be important for some functions of 
Zta, either operating as a stabilising influence in the zipper region or affecting protein 
interactions.  Zta appears to have a wide range of effects on host cell gene expression, 
probably through actions both as a transcription factor and direct and indirect 
interactions with host cell proteins. 
 
 - 204 - 
 
Chapter 8      References 
 
 
Adamson, A.L. (2005). Effects of SUMO-1 upon Epstein-Barr virus BZLF1 function 
and BMRF1 expression. Biochem Biophys Res Commun 336, 22-28. 
Adamson, A.L., Darr, D., Holley-Guthrie, E., Johnson, R.A., Mauser, A., Swenson, J., 
and Kenney, S. (2000). Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 
activate the ATF2 transcription factor by increasing the levels of phosphorylated p38 
and c-Jun N-terminal kinases. J Virol 74, 1224-1233. 
Adamson, A.L., and Kenney, S. (1999). The Epstein-Barr virus BZLF1 protein interacts 
physically and functionally with the histone acetylase CREB-binding protein. J Virol 
73, 6551-6558. 
Adamson, A.L., and Kenney, S. (2001). Epstein-barr virus immediate-early protein 
BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies. J Virol 75, 
2388-2399. 
Adamson, A.L., and Kenney, S.C. (1998). Rescue of the Epstein-Barr virus BZLF1 
mutant, Z(S186A), early gene activation defect by the BRLF1 gene product. Virology 
251, 187-197. 
Alfieri, C., Birkenbach, M., and Kieff, E. (1991). Early events in Epstein-Barr virus 
infection of human B lymphocytes. Virology 181, 595-608. 
Amon, W., and Farrell, P.J. (2005). Reactivation of Epstein-Barr virus from latency. 
Rev Med Virol 15, 149-156. 
Anagnostopoulos, I., Herbst, H., Niedobitek, G., and Stein, H. (1989). Demonstration of 
monoclonal EBV genomes in Hodgkin's disease and Ki-1-positive anaplastic large cell 
lymphoma by combined Southern blot and in situ hybridization. Blood 74, 810-816. 
Asai, R., Kato, A., Kato, K., Kanamori-Koyama, M., Sugimoto, K., Sairenji, T., 
Nishiyama, Y., and Kawaguchi, Y. (2006). Epstein-Barr virus protein kinase BGLF4 is 
a virion tegument protein that dissociates from virions in a phosphorylation-dependent 
process and phosphorylates the viral immediate-early protein BZLF1. J Virol 80, 5125-
5134. 
Asai, R., Kato, A., and Kawaguchi, Y. (2009). Epstein-Barr Virus Protein Kinase 
BGLF4 Interacts with Viral Transactivator BZLF1 and Regulates Its Transactivation 
Activity. J Gen Virol. 
Bailey, S.G., Verrall, E., Schelcher, C., Rhie, A., Doherty, A.J., and Sinclair, A.J. 
(2009). Functional interaction between Epstein-Barr virus replication protein Zta and 
host DNA damage response protein 53BP1. J Virol 83, 11116-11122. 
Bartel, D.P. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 
116, 281-297. 
 - 205 - 
 
Baumann, M., Feederle, R., Kremmer, E., and Hammerschmidt, W. (1999). Cellular 
transcription factors recruit viral replication proteins to activate the Epstein-Barr virus 
origin of lytic DNA replication, oriLyt. Embo J 18, 6095-6105. 
Bergbauer, M., Kalla, M., Schmeinck, A., Gobel, C., Rothbauer, U., Eck, S., Benet-
Pages, A., Strom, T.M., and Hammerschmidt, W. (2010). CpG-methylation regulates a 
class of Epstein-Barr virus promoters. PLoS Pathog 6. 
Bernardi, R., and Pandolfi, P.P. (2003). Role of PML and the PML-nuclear body in the 
control of programmed cell death. Oncogene 22, 9048-9057. 
Bhende, P.M., Seaman, W.T., Delecluse, H.J., and Kenney, S.C. (2004). The EBV lytic 
switch protein, Z, preferentially binds to and activates the methylated viral genome. Nat 
Genet 36, 1099-1104. 
Bhende, P.M., Seaman, W.T., Delecluse, H.J., and Kenney, S.C. (2005). BZLF1 
activation of the methylated form of the BRLF1 immediate-early promoter is regulated 
by BZLF1 residue 186. J Virol 79, 7338-7348. 
Binne, U.K., Amon, W., and Farrell, P.J. (2002). Promoter sequences required for 
reactivation of Epstein-Barr virus from latency. J Virol 76, 10282-10289. 
Boldin, M.P., Mett, I.L., and Wallach, D. (1995). A protein related to a proteasomal 
subunit binds to the intracellular domain of the p55 TNF receptor upstream to its 'death 
domain'. FEBS Lett 367, 39-44. 
Borza, C.M., and Hutt-Fletcher, L.M. (2002). Alternate replication in B cells and 
epithelial cells switches tropism of Epstein-Barr virus. Nat Med 8, 594-599. 
Bristol, J.A., Robinson, A.R., Barlow, E.A., and Kenney, S.C. (2010). The Epstein-Barr 
virus BZLF1 protein inhibits tumor necrosis factor receptor 1 expression through effects 
on cellular C/EBP proteins. J Virol 84, 12362-12374. 
Burkitt, D. (1958). A sarcoma involving the jaws in African children. Br J Surg 46, 218-
223. 
Carey, M., Kolman, J., Katz, D.A., Gradoville, L., Barberis, L., and Miller, G. (1992). 
Transcriptional synergy by the Epstein-Barr virus transactivator ZEBRA. J Virol 66, 
4803-4813. 
Cayrol, C., and Flemington, E. (1996a). G0/G1 growth arrest mediated by a region 
encompassing the basic leucine zipper (bZIP) domain of the Epstein-Barr virus 
transactivator Zta. J Biol Chem 271, 31799-31802. 
Cayrol, C., and Flemington, E.K. (1995). Identification of cellular target genes of the 
Epstein-Barr virus transactivator Zta: activation of transforming growth factor beta igh3 
(TGF-beta igh3) and TGF-beta 1. J Virol 69, 4206-4212. 
Cayrol, C., and Flemington, E.K. (1996b). The Epstein-Barr virus bZIP transcription 
factor Zta causes G0/G1 cell cycle arrest through induction of cyclin-dependent kinase 
inhibitors. Embo J 15, 2748-2759. 
 - 206 - 
 
Chan, C.K., Mueller, N., Evans, A., Harris, N.L., Comstock, G.W., Jellum, E., Magnus, 
K., Orentreich, N., Polk, B.F., and Vogelman, J. (1991). Epstein-Barr virus antibody 
patterns preceding the diagnosis of nasopharyngeal carcinoma. Cancer Causes Control 
2, 125-131. 
Chang, E.T., and Adami, H.O. (2006). The enigmatic epidemiology of nasopharyngeal 
carcinoma. Cancer Epidemiol Biomarkers Prev 15, 1765-1777. 
Chang, Y., Chang, S.S., Lee, H.H., Doong, S.L., Takada, K., and Tsai, C.H. (2004). 
Inhibition of the Epstein-Barr virus lytic cycle by Zta-targeted RNA interference. J Gen 
Virol 85, 1371-1379. 
Chang, Y., Lee, H.H., Chen, Y.T., Lu, J., Wu, S.Y., Chen, C.W., Takada, K., and Tsai, 
C.H. (2006). Induction of the early growth response 1 gene by Epstein-Barr virus lytic 
transactivator Zta. J Virol 80, 7748-7755. 
Chee, A.V., Lopez, P., Pandolfi, P.P., and Roizman, B. (2003). Promyelocytic leukemia 
protein mediates interferon-based anti-herpes simplex virus 1 effects. J Virol 77, 7101-
7105. 
Cho, M.S., and Tran, V.M. (1993). A concatenated form of Epstein-Barr viral DNA in 
lymphoblastoid cell lines induced by transfection with BZLF1. Virology 194, 838-842. 
Cho, Y., Ramer, J., Rivailler, P., Quink, C., Garber, R.L., Beier, D.R., and Wang, F. 
(2001). An Epstein-Barr-related herpesvirus from marmoset lymphomas. Proc Natl 
Acad Sci U S A 98, 1224-1229. 
Clarke, P.A., Sharp, N.A., and Clemens, M.J. (1990). Translational control by the 
Epstein-Barr virus small RNA EBER-1. Reversal of the double-stranded RNA-induced 
inhibition of protein synthesis in reticulocyte lysates. Eur J Biochem 193, 635-641. 
Crawford, D.H. (2001). Biology and disease associations of Epstein-Barr virus. Philos 
Trans R Soc Lond B Biol Sci 356, 461-473. 
Daibata, M., Humphreys, R.E., Takada, K., and Sairenji, T. (1990). Activation of latent 
EBV via anti-IgG-triggered, second messenger pathways in the Burkitt's lymphoma cell 
line Akata. J Immunol 144, 4788-4793. 
Daibata, M., Speck, S.H., Mulder, C., and Sairenji, T. (1994). Regulation of the BZLF1 
promoter of Epstein-Barr virus by second messengers in anti-immunoglobulin-treated B 
cells. Virology 198, 446-454. 
Davison, A.J. (2002). Evolution of the herpesviruses. Vet Microbiol 86, 69-88. 
Deaton, A.M., and Bird, A. (2011). CpG islands and the regulation of transcription. 
Genes Dev 25, 1010-1022. 
Deng, Z., Chen, C.J., Zerby, D., Delecluse, H.J., and Lieberman, P.M. (2001). 
Identification of acidic and aromatic residues in the Zta activation domain essential for 
Epstein-Barr virus reactivation. J Virol 75, 10334-10347. 
 - 207 - 
 
Dreyfus, D. H., Nagasawa, M., Kelleher, C. A., Gelfand, E. W. (2001). Stable 
expression of Epstein-Barr virus BZLF-1-encoded ZEBRA protein activates p53-
dependent transcription in human Jurkat T-lymphoblastoid cells. Blood 96, 625-34. 
 
Ehlers, B., Ochs, A., Leendertz, F., Goltz, M., Boesch, C., and Matz-Rensing, K. 
(2003). Novel simian homologues of Epstein-Barr virus. J Virol 77, 10695-10699. 
Ehlers, B., Spiess, K., Leendertz, F., Peeters, M., Boesch, C., Gatherer, D., and 
McGeoch, D.J. (2010). Lymphocryptovirus phylogeny and the origins of Epstein-Barr 
virus. J Gen Virol 91, 630-642. 
Ehlers, B., Ulrich, S., and Goltz, M. (1999). Detection of two novel porcine 
herpesviruses with high similarity to gammaherpesviruses. J Gen Virol 80 ( Pt 4), 971-
978. 
Epstein, M.A., Henle, G., Achong, B.G., and Barr, Y.M. (1965). Morphological and 
Biological Studies on a Virus in Cultured Lymphoblasts from Burkitt's Lymphoma. J 
Exp Med 121, 761-770. 
Faller, D.V., Mentzer, S.J., and Perrine, S.P. (2001). Induction of the Epstein-Barr virus 
thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy 
for Epstein-Barr virus-associated malignancies. Curr Opin Oncol 13, 360-367. 
Farrell, P.J., Rowe, D.T., Rooney, C.M., and Kouzarides, T. (1989). Epstein-Barr virus 
BZLF1 trans-activator specifically binds to a consensus AP-1 site and is related to c-fos. 
Embo J 8, 127-132. 
Faulkner, G.C., Burrows, S.R., Khanna, R., Moss, D.J., Bird, A.G., and Crawford, D.H. 
(1999). X-Linked agammaglobulinemia patients are not infected with Epstein-Barr 
virus: implications for the biology of the virus. J Virol 73, 1555-1564. 
Feederle, R., Kost, M., Baumann, M., Janz, A., Drouet, E., Hammerschmidt, W., and 
Delecluse, H.J. (2000). The Epstein-Barr virus lytic program is controlled by the co-
operative functions of two transactivators. Embo J 19, 3080-3089. 
Feng, W.H., Westphal, E., Mauser, A., Raab-Traub, N., Gulley, M.L., Busson, P., and 
Kenney, S.C. (2002). Use of adenovirus vectors expressing Epstein-Barr virus (EBV) 
immediate-early protein BZLF1 or BRLF1 to treat EBV-positive tumors. J Virol 76, 
10951-10959. 
Fickenscher, H., and Fleckenstein, B. (2001). Herpesvirus saimiri. Philos Trans R Soc 
Lond B Biol Sci 356, 545-567. 
Fixman, E.D., Hayward, G.S., and Hayward, S.D. (1992). trans-acting requirements for 
replication of Epstein-Barr virus ori-Lyt. J Virol 66, 5030-5039. 
Flemington, E., and Speck, S.H. (1990a). Autoregulation of Epstein-Barr virus putative 
lytic switch gene BZLF1. J Virol 64, 1227-1232. 
Flemington, E., and Speck, S.H. (1990b). Epstein-Barr virus BZLF1 trans activator 
induces the promoter of a cellular cognate gene, c-fos. J Virol 64, 4549-4552. 
 - 208 - 
 
Flemington, E., and Speck, S.H. (1990c). Identification of phorbol ester response 
elements in the promoter of Epstein-Barr virus putative lytic switch gene BZLF1. J 
Virol 64, 1217-1226. 
Flemington, E.K. (2001). Herpesvirus lytic replication and the cell cycle: arresting new 
developments. J Virol 75, 4475-4481. 
Flower, K., Thomas, D., Heather, J., Ramasubramanyan, S., Jones, S., and Sinclair, A.J. 
(2011). Epigenetic Control of Viral Life-Cycle by a DNA-Methylation Dependent 
Transcription Factor. PLoS One 6, e25922. 
Foss, H.D., Herbst, H., Hummel, M., Araujo, I., Latza, U., Rancso, C., Dallenbach, F., 
and Stein, H. (1994). Patterns of cytokine gene expression in infectious mononucleosis. 
Blood 83, 707-712. 
Francis, A.L., Gradoville, L., and Miller, G. (1997). Alteration of a single serine in the 
basic domain of the Epstein-Barr virus ZEBRA protein separates its functions of 
transcriptional activation and disruption of latency. J Virol 71, 3054-3061. 
Fruehling, S., and Longnecker, R. (1997). The immunoreceptor tyrosine-based 
activation motif of Epstein-Barr virus LMP2A is essential for blocking BCR-mediated 
signal transduction. Virology 235, 241-251. 
Gallagher, A., Armstrong, A.A., MacKenzie, J., Shield, L., Khan, G., Lake, A., Proctor, 
S., Taylor, P., Clements, G.B., and Jarrett, R.F. (1999). Detection of Epstein-Barr virus 
(EBV) genomes in the serum of patients with EBV-associated Hodgkin's disease. Int J 
Cancer 84, 442-448. 
Gao, Z., Krithivas, A., Finan, J.E., Semmes, O.J., Zhou, S., Wang, Y., and Hayward, 
S.D. (1998). The Epstein-Barr virus lytic transactivator Zta interacts with the helicase-
primase replication proteins. J Virol 72, 8559-8567. 
Garcia, V.E., Quiroga, M.F., Ochoa, M.T., Ochoa, L., Pasquinelli, V., Fainboim, L., 
Olivares, L.M., Valdez, R., Sordelli, D.O., Aversa, G., Modlin, R.L., and Sieling, P.A. 
(2001). Signaling lymphocytic activation molecule expression and regulation in human 
intracellular infection correlate with Th1 cytokine patterns. J Immunol 167, 5719-5724. 
Gibbs, R.A., Rogers, J., Katze, M.G., Bumgarner, R., Weinstock, G.M., Mardis, E.R., 
Remington, K.A., Strausberg, R.L., Venter, J.C., Wilson, R.K., and Consortium, 
R.M.G.S.a.A. (2007). Evolutionary and biomedical insights from the rhesus macaque 
genome. Science 316, 222-234. 
Gires, O., Kohlhuber, F., Kilger, E., Baumann, M., Kieser, A., Kaiser, C., Zeidler, R., 
Scheffer, B., Ueffing, M., and Hammerschmidt, W. (1999). Latent membrane protein 1 
of Epstein-Barr virus interacts with JAK3 and activates STAT proteins. Embo J 18, 
3064-3073. 
Gires, O., Zimber-Strobl, U., Gonnella, R., Ueffing, M., Marschall, G., Zeidler, R., 
Pich, D., and Hammerschmidt, W. (1997). Latent membrane protein 1 of Epstein-Barr 
virus mimics a constitutively active receptor molecule. Embo J 16, 6131-6140. 
 - 209 - 
 
Glover, J.N., and Harrison, S.C. (1995). Crystal structure of the heterodimeric bZIP 
transcription factor c-Fos-c-Jun bound to DNA. Nature 373, 257-261. 
Greenspan, J.S., Greenspan, D., Lennette, E.T., Abrams, D.I., Conant, M.A., Petersen, 
V., and Freese, U.K. (1985). Replication of Epstein-Barr virus within the epithelial cells 
of oral "hairy" leukoplakia, an AIDS-associated lesion. N Engl J Med 313, 1564-1571. 
Gruffat, H., Manet, E., and Sergeant, A. (2002). MEF2-mediated recruitment of class II 
HDAC at the EBV immediate early gene BZLF1 links latency and chromatin 
remodeling. EMBO Rep 3, 141-146. 
Grunewald, V., Bonnet, M., Boutin, S., Yip, T., Louzir, H., Levrero, M., Seigneurin, 
J.M., Raphael, M., Touitou, R., Martel-Renoir, D., Cochet, C., Durandy, A., Andre, P., 
Lau, W., Zeng, Y., and Joab, I. (1998). Amino-acid change in the Epstein-Barr-virus 
ZEBRA protein in undifferentiated nasopharyngeal carcinomas from Europe and North 
Africa. Int J Cancer 75, 497-503. 
Gutensohn, N., and Cole, P. (1980). Epidemiology of Hodgkin's disease. Semin Oncol 
7, 92-102. 
Gutsch, D.E., Holley-Guthrie, E.A., Zhang, Q., Stein, B., Blanar, M.A., Baldwin, A.S., 
and Kenney, S.C. (1994). The bZIP transactivator of Epstein-Barr virus, BZLF1, 
functionally and physically interacts with the p65 subunit of NF-kappa B. Mol Cell Biol 
14, 1939-1948. 
Halder, S., Murakami, M., Verma, S.C., Kumar, P., Yi, F., and Robertson, E.S. (2009). 
Early events associated with infection of Epstein-Barr virus infection of primary B-
cells. PLoS One 4, e7214. 
Hammerschmidt, W., and Sugden, B. (1988). Identification and characterization of 
oriLyt, a lytic origin of DNA replication of Epstein-Barr virus. Cell 55, 427-433. 
Heather, J., Flower, K., Isaac, S., and Sinclair, A.J. (2009). The Epstein-Barr Virus 
Lytic Cycle Activator Zta Interacts With Methylated ZRE In Promoter Of Host Target 
Gene Egr1. J Gen Virol. 
Henle, G., Henle, W., and Diehl, V. (1968). Relation of Burkitt's tumor-associated 
herpes-ytpe virus to infectious mononucleosis. Proc Natl Acad Sci U S A 59, 94-101. 
Herrmann, K., Frangou, P., Middeldorp, J., and Niedobitek, G. (2002). Epstein-Barr 
virus replication in tongue epithelial cells. J Gen Virol 83, 2995-2998. 
Hicks, M.R., Al-Mehairi, S.S., and Sinclair, A.J. (2003). The zipper region of Epstein-
Barr virus bZIP transcription factor Zta is necessary but not sufficient to direct DNA 
binding. J Virol 77, 8173-8177. 
Hicks, M.R., Balesaria, S., Medina-Palazon, C., Pandya, M.J., Woolfson, D.N., and 
Sinclair, A.J. (2001). Biophysical analysis of natural variants of the multimerization 
region of Epstein-Barr virus lytic-switch protein BZLF1. J Virol 75, 5381-5384. 
Ho, M., Miller, G., Atchison, R.W., Breinig, M.K., Dummer, J.S., Andiman, W., Starzl, 
T.E., Eastman, R., Griffith, B.P., Hardesty, R.L., and et al. (1985). Epstein-Barr virus 
 - 210 - 
 
infections and DNA hybridization studies in posttransplantation lymphoma and 
lymphoproliferative lesions: the role of primary infection. J Infect Dis 152, 876-886. 
Hochberg, D., Souza, T., Catalina, M., Sullivan, J.L., Luzuriaga, K., and Thorley-
Lawson, D.A. (2004). Acute infection with Epstein-Barr virus targets and overwhelms 
the peripheral memory B-cell compartment with resting, latently infected cells. J Virol 
78, 5194-5204. 
Hong, Y., Holley-Guthrie, E., and Kenney, S. (1997). The bZip dimerization domain of 
the Epstein-Barr virus BZLF1 (Z) protein mediates lymphoid-specific negative 
regulation. Virology 229, 36-48. 
Hsu, M., Wu, S.Y., Chang, S.S., Su, I.J., Tsai, C.H., Lai, S.J., Shiau, A.L., Takada, K., 
and Chang, Y. (2008). Epstein-Barr virus lytic transactivator Zta enhances chemotactic 
activity through induction of interleukin-8 in nasopharyngeal carcinoma cells. J Virol 
82, 3679-3688. 
Huen, D.S., Henderson, S.A., Croom-Carter, D., and Rowe, M. (1995). The Epstein-
Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa B and 
cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic 
domain. Oncogene 10, 549-560. 
Israel, B.F., and Kenney, S. (2005). EBV Lytic Infection. In: Epstein-Barr Virus, ed. E. 
Robertson: Caister Academic Press, 571-611. 
Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., and Forman, D. (2011). Global 
cancer statistics. CA Cancer J Clin 61, 69-90. 
Jones, H.W., Jr., McKusick, V.A., Harper, P.S., and Wuu, K.D. (1971). George Otto 
Gey. (1899-1970). The HeLa cell and a reappraisal of its origin. Obstet Gynecol 38, 
945-949. 
Jones, R.J., Dickerson, S., Bhende, P.M., Delecluse, H.J., and Kenney, S.C. (2007). 
Epstein-Barr virus lytic infection induces retinoic acid-responsive genes through 
induction of a retinol-metabolizing enzyme, DHRS9. J Biol Chem 282, 8317-8324. 
Kalla, M., Schmeinck, A., Bergbauer, M., Pich, D., and Hammerschmidt, W. (2010). 
AP-1 homolog BZLF1 of Epstein-Barr virus has two essential functions dependent on 
the epigenetic state of the viral genome. Proc Natl Acad Sci U S A 107, 850-855. 
Kang, G.H., Lee, S., Cho, N.Y., Gandamihardja, T., Long, T.I., Weisenberger, D.J., 
Campan, M., and Laird, P.W. (2008). DNA methylation profiles of gastric carcinoma 
characterized by quantitative DNA methylation analysis. Lab Invest 88, 161-170. 
Kang, G.H., Lee, S., Kim, W.H., Lee, H.W., Kim, J.C., Rhyu, M.G., and Ro, J.Y. 
(2002). Epstein-barr virus-positive gastric carcinoma demonstrates frequent aberrant 
methylation of multiple genes and constitutes CpG island methylator phenotype-
positive gastric carcinoma. Am J Pathol 160, 787-794. 
Karlsson, Q.H., Schelcher, C., Verrall, E., Petosa, C., and Sinclair, A.J. (2008a). 
Methylated DNA recognition during the reversal of epigenetic silencing is regulated by 
 - 211 - 
 
cysteine and serine residues in the Epstein-Barr virus lytic switch protein. PLoS Pathog 
4, e1000005. 
Karlsson, Q.H., Schelcher, C., Verrall, E., Petosa, C., and Sinclair, A.J. (2008b). The 
reversal of epigenetic silencing of the EBV genome is regulated by viral bZIP protein. 
Biochem Soc Trans 36, 637-639. 
Keating, S., Prince, S., Jones, M., and Rowe, M. (2002). The lytic cycle of Epstein-Barr 
virus is associated with decreased expression of cell surface major histocompatibility 
complex class I and class II molecules. J Virol 76, 8179-8188. 
Kenney, S., Kamine, J., Holley-Guthrie, E., Lin, J.C., Mar, E.C., and Pagano, J. (1989). 
The Epstein-Barr virus (EBV) BZLF1 immediate-early gene product differentially 
affects latent versus productive EBV promoters. J Virol 63, 1729-1736. 
Kieff, E., and Rickinson, A.B. (2007). Epstein-Barr virus and its replication. In: Fields 
Virology, vol. 2: Lippincott Williams & Wilkins, 2603-2654. 
Kilger, E., Kieser, A., Baumann, M., and Hammerschmidt, W. (1998). Epstein-Barr 
virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which 
simulates an activated CD40 receptor. Embo J 17, 1700-1709. 
Klose, R.J., and Bird, A.P. (2006). Genomic DNA methylation: the mark and its 
mediators. Trends Biochem Sci 31, 89-97. 
Kolman, J.L., Taylor, N., Gradoville, L., Countryman, J., and Miller, G. (1996). 
Comparing transcriptional activation and autostimulation by ZEBRA and ZEBRA/c-Fos 
chimeras. J Virol 70, 1493-1504. 
Komano, J., Maruo, S., Kurozumi, K., Oda, T., and Takada, K. (1999). Oncogenic role 
of Epstein-Barr virus-encoded RNAs in Burkitt's lymphoma cell line Akata. J Virol 73, 
9827-9831. 
Kouzarides, T., Packham, G., Cook, A., and Farrell, P.J. (1991). The BZLF1 protein of 
EBV has a coiled coil dimerisation domain without a heptad leucine repeat but with 
homology to the C/EBP leucine zipper. Oncogene 6, 195-204. 
Krappmann, D., Patke, A., Heissmeyer, V., and Scheidereit, C. (2001). B-cell receptor- 
and phorbol ester-induced NF-kappaB and c-Jun N-terminal kinase activation in B cells 
requires novel protein kinase C's. Mol Cell Biol 21, 6640-6650. 
Kudoh, A., Daikoku, T., Sugaya, Y., Isomura, H., Fujita, M., Kiyono, T., Nishiyama, 
Y., and Tsurumi, T. (2004). Inhibition of S-phase cyclin-dependent kinase activity 
blocks expression of Epstein-Barr virus immediate-early and early genes, preventing 
viral lytic replication. J Virol 78, 104-115. 
Kudoh, A., Fujita, M., Kiyono, T., Kuzushima, K., Sugaya, Y., Izuta, S., Nishiyama, Y., 
and Tsurumi, T. (2003). Reactivation of lytic replication from B cells latently infected 
with Epstein-Barr virus occurs with high S-phase cyclin-dependent kinase activity while 
inhibiting cellular DNA replication. J Virol 77, 851-861. 
 - 212 - 
 
Landschulz, W.H., Johnson, P.F., and McKnight, S.L. (1988). The leucine zipper: a 
hypothetical structure common to a new class of DNA binding proteins. Science 240, 
1759-1764. 
Lee, M.A., Diamond, M.E., and Yates, J.L. (1999). Genetic evidence that EBNA-1 is 
needed for efficient, stable latent infection by Epstein-Barr virus. J Virol 73, 2974-2982. 
Lerner, M.R., Andrews, N.C., Miller, G., and Steitz, J.A. (1981). Two small RNAs 
encoded by Epstein-Barr virus and complexed with protein are precipitated by 
antibodies from patients with systemic lupus erythematosus. Proc Natl Acad Sci U S A 
78, 805-809. 
Levitskaya, J., Sharipo, A., Leonchiks, A., Ciechanover, A., and Masucci, M.G. (1997). 
Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat 
domain of the Epstein-Barr virus nuclear antigen 1. Proc Natl Acad Sci U S A 94, 
12616-12621. 
Li, D., Qian, L., Chen, C., Shi, M., Yu, M., Hu, M., Song, L., Shen, B., and Guo, N. 
(2009). Down-regulation of MHC class II expression through inhibition of CIITA 
transcription by lytic transactivator Zta during Epstein-Barr virus reactivation. J 
Immunol 182, 1799-1809. 
Li, H.P., Leu, Y.W., and Chang, Y.S. (2005). Epigenetic changes in virus-associated 
human cancers. Cell Res 15, 262-271. 
Lieberman, P.M., Hardwick, J.M., Sample, J., Hayward, G.S., and Hayward, S.D. 
(1990). The zta transactivator involved in induction of lytic cycle gene expression in 
Epstein-Barr virus-infected lymphocytes binds to both AP-1 and ZRE sites in target 
promoter and enhancer regions. J Virol 64, 1143-1155. 
Lin, J.C., Smith, M.C., and Pagano, J.S. (1984). Prolonged inhibitory effect of 9-(1,3-
dihydroxy-2-propoxymethyl)guanine against replication of Epstein-Barr virus. J Virol 
50, 50-55. 
Liu, S., Borras, A.M., Liu, P., Suske, G., and Speck, S.H. (1997a). Binding of the 
ubiquitous cellular transcription factors Sp1 and Sp3 to the ZI domains in the Epstein-
Barr virus lytic switch BZLF1 gene promoter. Virology 228, 11-18. 
Liu, S., Liu, P., Borras, A., Chatila, T., and Speck, S.H. (1997b). Cyclosporin A-
sensitive induction of the Epstein-Barr virus lytic switch is mediated via a novel 
pathway involving a MEF2 family member. Embo J 16, 143-153. 
Lo, K.W., and Huang, D.P. (2002). Genetic and epigenetic changes in nasopharyngeal 
carcinoma. Semin Cancer Biol 12, 451-462. 
Lu, J., Chen, S.Y., Chua, H.H., Liu, Y.S., Huang, Y.T., Chang, Y., Chen, J.Y., Sheen, 
T.S., and Tsai, C.H. (2000). Upregulation of tyrosine kinase TKT by the Epstein-Barr 
virus transactivator Zta. J Virol 74, 7391-7399. 
Lu, J., Chua, H.H., Chen, S.Y., Chen, J.Y., and Tsai, C.H. (2003). Regulation of matrix 
metalloproteinase-1 by Epstein-Barr virus proteins. Cancer Res 63, 256-262. 
 - 213 - 
 
Macsween, K.F., and Crawford, D.H. (2003). Epstein-Barr virus-recent advances. 
Lancet Infect Dis 3, 131-140. 
Mahot, S., Sergeant, A., Drouet, E., and Gruffat, H. (2003). A novel function for the 
Epstein-Barr virus transcription factor EB1/Zta: induction of transcription of the hIL-10 
gene. J Gen Virol 84, 965-974. 
Manet, E., Gruffat, H., Trescol-Biemont, M.C., Moreno, N., Chambard, P., Giot, J.F., 
and Sergeant, A. (1989). Epstein-Barr virus bicistronic mRNAs generated by facultative 
splicing code for two transcriptional trans-activators. Embo J 8, 1819-1826. 
Marafioti, T., Hummel, M., Foss, H.D., Laumen, H., Korbjuhn, P., Anagnostopoulos, I., 
Lammert, H., Demel, G., Theil, J., Wirth, T., and Stein, H. (2000). Hodgkin and reed-
sternberg cells represent an expansion of a single clone originating from a germinal 
center B-cell with functional immunoglobulin gene rearrangements but defective 
immunoglobulin transcription. Blood 95, 1443-1450. 
Mauser, A., Holley-Guthrie, E., Zanation, A., Yarborough, W., Kaufmann, W., 
Klingelhutz, A., Seaman, W.T., and Kenney, S. (2002a). The Epstein-Barr virus 
immediate-early protein BZLF1 induces expression of E2F-1 and other proteins 
involved in cell cycle progression in primary keratinocytes and gastric carcinoma cells. 
J Virol 76, 12543-12552. 
Mauser, A., Saito, S., Appella, E., Anderson, C.W., Seaman, W.T., and Kenney, S. 
(2002b). The Epstein-Barr virus immediate-early protein BZLF1 regulates p53 function 
through multiple mechanisms. J Virol 76, 12503-12512. 
Maxwell, A., McCudden, C., Wians, F., and Willis, M. (2009). Recent Advances in the 
Detection of Prostate Cancer Using Epigenetic Markers in Commonly Collected 
Laboratory Samples. Lab Medicine 40, 171-178. 
McDonald, C.M., Petosa, C., and Farrell, P.J. (2009). Interaction of Epstein-Barr virus 
BZLF1 C-terminal tail structure and core zipper is required for DNA replication but not 
for promoter transactivation. J Virol 83, 3397-3401. 
Mentzer, S.J., Perrine, S.P., and Faller, D.V. (2001). Epstein--Barr virus post-transplant 
lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of 
viral target genes with arginine butyrate. Transpl Infect Dis 3, 177-185. 
Middleton, T., and Sugden, B. (1994). Retention of plasmid DNA in mammalian cells is 
enhanced by binding of the Epstein-Barr virus replication protein EBNA1. J Virol 68, 
4067-4071. 
Moghaddam, A., Koch, J., Annis, B., and Wang, F. (1998). Infection of human B 
lymphocytes with lymphocryptoviruses related to Epstein-Barr virus. J Virol 72, 3205-
3212. 
Moghaddam, A., Rosenzweig, M., Lee-Parritz, D., Annis, B., Johnson, R.P., and Wang, 
F. (1997). An animal model for acute and persistent Epstein-Barr virus infection. 
Science 276, 2030-2033. 
 - 214 - 
 
Molesworth, S.J., Lake, C.M., Borza, C.M., Turk, S.M., and Hutt-Fletcher, L.M. (2000). 
Epstein-Barr virus gH is essential for penetration of B cells but also plays a role in 
attachment of virus to epithelial cells. J Virol 74, 6324-6332. 
Moore, P.S., and Chang, Y. (1995). Detection of herpesvirus-like DNA sequences in 
Kaposi's sarcoma in patients with and without HIV infection. N Engl J Med 332, 1181-
1185. 
Moore, S.M., Cannon, J.S., Tanhehco, Y.C., Hamzeh, F.M., and Ambinder, R.F. (2001). 
Induction of Epstein-Barr virus kinases to sensitize tumor cells to nucleoside analogues. 
Antimicrob Agents Chemother 45, 2082-2091. 
Morgenstern, J.P., and Land, H. (1990). Advanced mammalian gene transfer: high titre 
retroviral vectors with multiple drug selection markers and a complementary helper-free 
packaging cell line. Nucleic Acids Res 18, 3587-3596. 
Morrison, T.E., and Kenney, S.C. (2004). BZLF1, an Epstein-Barr virus immediate-
early protein, induces p65 nuclear translocation while inhibiting p65 transcriptional 
function. Virology 328, 219-232. 
Morrison, T.E., Mauser, A., Wong, A., Ting, J.P., and Kenney, S.C. (2001). Inhibition 
of IFN-gamma signaling by an Epstein-Barr virus immediate-early protein. Immunity 
15, 787-799. 
Mueller, N., Evans, A., Harris, N.L., Comstock, G.W., Jellum, E., Magnus, K., 
Orentreich, N., Polk, B.F., and Vogelman, J. (1989). Hodgkin's disease and Epstein-
Barr virus. Altered antibody pattern before diagnosis. N Engl J Med 320, 689-695. 
Murray, P.G., and Young, L.S. (2001). Epstein-Barr virus infection: basis of 
malignancy and potential for therapy. Expert Rev Mol Med 2001, 1-20. 
Nemerow, G.R., Mold, C., Schwend, V.K., Tollefson, V., and Cooper, N.R. (1987). 
Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr 
virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 
complement fragment C3d. J Virol 61, 1416-1420. 
Nemerow, G.R., Wolfert, R., McNaughton, M.E., and Cooper, N.R. (1985). 
Identification and characterization of the Epstein-Barr virus receptor on human B 
lymphocytes and its relationship to the C3d complement receptor (CR2). J Virol 55, 
347-351. 
Niederman, J.C., Miller, G., Pearson, H.A., Pagano, J.S., and Dowaliby, J.M. (1976). 
Infectious mononucleosis. Epstein-Barr-virus shedding in saliva and the oropharynx. N 
Engl J Med 294, 1355-1359. 
Niedobitek, G., Agathanggelou, A., Rowe, M., Jones, E.L., Jones, D.B., Turyaguma, P., 
Oryema, J., Wright, D.H., and Young, L.S. (1995). Heterogeneous expression of 
Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma. Blood 86, 659-665. 
O'Shea, E.K., Rutkowski, R., and Kim, P.S. (1989). Evidence that the leucine zipper is a 
coiled coil. Science 243, 538-542. 
 - 215 - 
 
Packham, G., Economou, A., Rooney, C.M., Rowe, D.T., and Farrell, P.J. (1990). 
Structure and function of the Epstein-Barr virus BZLF1 protein. J Virol 64, 2110-2116. 
Petosa, C., Morand, P., Baudin, F., Moulin, M., Artero, J.B., and Muller, C.W. (2006). 
Structural basis of lytic cycle activation by the Epstein-Barr virus ZEBRA protein. Mol 
Cell 21, 565-572. 
Pfitzner, E., Becker, P., Rolke, A., and Schule, R. (1995). Functional antagonism 
between the retinoic acid receptor and the viral transactivator BZLF1 is mediated by 
protein-protein interactions. Proc Natl Acad Sci U S A 92, 12265-12269. 
Pfuller, R., and Hammerschmidt, W. (1996). Plasmid-like replicative intermediates of 
the Epstein-Barr virus lytic origin of DNA replication. J Virol 70, 3423-3431. 
Prokhortchouk, A., Hendrich, B., Jorgensen, H., Ruzov, A., Wilm, M., Georgiev, G., 
Bird, A., and Prokhortchouk, E. (2001). The p120 catenin partner Kaiso is a DNA 
methylation-dependent transcriptional repressor. Genes Dev 15, 1613-1618. 
Radkov, S.A., Touitou, R., Brehm, A., Rowe, M., West, M., Kouzarides, T., and Allday, 
M.J. (1999). Epstein-Barr virus nuclear antigen 3C interacts with histone deacetylase to 
repress transcription. J Virol 73, 5688-5697. 
Ragoczy, T., and Miller, G. (2001). Autostimulation of the Epstein-Barr virus BRLF1 
promoter is mediated through consensus Sp1 and Sp3 binding sites. J Virol 75, 5240-
5251. 
Reimann, K.A., Li, J.T., Veazey, R., Halloran, M., Park, I.W., Karlsson, G.B., Sodroski, 
J., and Letvin, N.L. (1996). A chimeric simian/human immunodeficiency virus 
expressing a primary patient human immunodeficiency virus type 1 isolate env causes 
an AIDS-like disease after in vivo passage in rhesus monkeys. J Virol 70, 6922-6928. 
Rishi, V., Bhattacharya, P., Chatterjee, R., Rozenberg, J., Zhao, J., Glass, K., Fitzgerald, 
P., and Vinson, C. (2010). CpG methylation of half-CRE sequences creates C/EBPalpha 
binding sites that activate some tissue-specific genes. Proc Natl Acad Sci U S A 107, 
20311-20316. 
Rivailler, P., Carville, A., Kaur, A., Rao, P., Quink, C., Kutok, J.L., Westmoreland, S., 
Klumpp, S., Simon, M., Aster, J.C., and Wang, F. (2004). Experimental rhesus 
lymphocryptovirus infection in immunosuppressed macaques: an animal model for 
Epstein-Barr virus pathogenesis in the immunosuppressed host. Blood 104, 1482-1489. 
Rivailler, P., Jiang, H., Cho, Y.G., Quink, C., and Wang, F. (2002). Complete 
nucleotide sequence of the rhesus lymphocryptovirus: genetic validation for an Epstein-
Barr virus animal model. J Virol 76, 421-426. 
Robertson, K.D., and Ambinder, R.F. (1997). Methylation of the Epstein-Barr virus 
genome in normal lymphocytes. Blood 90, 4480-4484. 
Rochford, R., Miller, C.L., Cannon, M.J., Izumi, K.M., Kieff, E., and Longnecker, R. 
(1997). In vivo growth of Epstein-Barr virus transformed B cells with mutations in 
latent membrane protein 2 (LMP2). Arch Virol 142, 707-720. 
 - 216 - 
 
Rodriguez, A., Armstrong, M., Dwyer, D., and Flemington, E. (1999). Genetic 
dissection of cell growth arrest functions mediated by the Epstein-Barr virus lytic gene 
product, Zta. J Virol 73, 9029-9038. 
Roizman, B., and Baines, J. (1991). The diversity and unity of Herpesviridae. Comp 
Immunol Microbiol Infect Dis 14, 63-79. 
Rooney, C.M., Rowe, D.T., Ragot, T., and Farrell, P.J. (1989). The spliced BZLF1 gene 
of Epstein-Barr virus (EBV) transactivates an early EBV promoter and induces the virus 
productive cycle. J Virol 63, 3109-3116. 
Rowe, D.T. (1999). Epstein-Barr virus immortalization and latency. Front Biosci 4, 
D346-371. 
Rowe, M., Peng-Pilon, M., Huen, D.S., Hardy, R., Croom-Carter, D., Lundgren, E., and 
Rickinson, A.B. (1994). Upregulation of bcl-2 by the Epstein-Barr virus latent 
membrane protein LMP1: a B-cell-specific response that is delayed relative to NF-
kappa B activation and to induction of cell surface markers. J Virol 68, 5602-5612. 
Roy, D., Sin, S.H., Damania, B., and Dittmer, D.P. (2011). Tumor suppressor genes 
FHIT and WWOX are deleted in primary effusion lymphoma (PEL) cell lines. Blood. 
Ryan, J.L., Jones, R.J., Kenney, S.C., Rivenbark, A.G., Tang, W., Knight, E.R., 
Coleman, W.B., and Gulley, M.L. (2010). Epstein-Barr virus-specific methylation of 
human genes in gastric cancer cells. Infect Agent Cancer 5, 27. 
Sample, J., Henson, E.B., and Sample, C. (1992). The Epstein-Barr virus nuclear 
protein 1 promoter active in type I latency is autoregulated. J Virol 66, 4654-4661. 
Sample, J., Young, L., Martin, B., Chatman, T., Kieff, E., and Rickinson, A. (1990). 
Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C 
genes. J Virol 64, 4084-4092. 
Sato, Y., Shirata, N., Kudoh, A., Iwahori, S., Nakayama, S., Murata, T., Isomura, H., 
Nishiyama, Y., and Tsurumi, T. (2009). Expression of Epstein-Barr virus BZLF1 
immediate-early protein induces p53 degradation independent of MDM2, leading to 
repression of p53-mediated transcription. Virology 388, 204-211. 
Sato, Y., Shirata, N., Murata, T., Nakasu, S., Kudoh, A., Iwahori, S., Nakayama, S., 
Chiba, S., Isomura, H., Kanda, T., Tsurumi, T. (2010). Transient increases in p53-
responsible gene expression at early stages of Epstein-Barr virus productive replication. 
Cell Cycle 9, 807-14.  
 
Sayos, J., Wu, C., Morra, M., Wang, N., Zhang, X., Allen, D., van Schaik, S., 
Notarangelo, L., Geha, R., Roncarolo, M.G., Oettgen, H., De Vries, J.E., Aversa, G., 
and Terhorst, C. (1998). The X-linked lymphoproliferative-disease gene product SAP 
regulates signals induced through the co-receptor SLAM. Nature 395, 462-469. 
Scharenberg, A.M., Humphries, L.A., and Rawlings, D.J. (2007). Calcium signalling 
and cell-fate choice in B cells. Nat Rev Immunol 7, 778-789. 
 - 217 - 
 
Schelcher, C., Al Mehairi, S., Verrall, E., Hope, Q., Flower, K., Bromley, B., Woolfson, 
D.N., West, M.J., and Sinclair, A.J. (2007). Atypical bZIP Domain of Viral 
Transcription Factor Contributes to Stability of Dimer Formation and Transcriptional 
Function. J Virol 81, 7149-7155. 
Schelcher, C., Valencia, S., Delecluse, H.J., Hicks, M., and Sinclair, A.J. (2005). 
Mutation of a single amino acid residue in the basic region of the Epstein-Barr virus 
(EBV) lytic cycle switch protein Zta (BZLF1) prevents reactivation of EBV from 
latency. J Virol 79, 13822-13828. 
Schepers, A., Pich, D., and Hammerschmidt, W. (1996). Activation of oriLyt, the lytic 
origin of DNA replication of Epstein-Barr virus, by BZLF1. Virology 220, 367-376. 
Shannon-Lowe, C., and Rowe, M. (2011). Epstein-Barr virus infection of polarized 
epithelial cells via the basolateral surface by memory B cell-mediated transfer infection. 
PLoS Pathog 7, e1001338. 
Shannon-Lowe, C.D., Neuhierl, B., Baldwin, G., Rickinson, A.B., and Delecluse, H.J. 
(2006). Resting B cells as a transfer vehicle for Epstein-Barr virus infection of epithelial 
cells. Proc Natl Acad Sci U S A 103, 7065-7070. 
Shimizu, N., Tanabe-Tochikura, A., Kuroiwa, Y., and Takada, K. (1994). Isolation of 
Epstein-Barr virus (EBV)-negative cell clones from the EBV-positive Burkitt's 
lymphoma (BL) line Akata: malignant phenotypes of BL cells are dependent on EBV. J 
Virol 68, 6069-6073. 
Sinclair, A.J. (2003). bZIP proteins of human gammaherpesviruses. J Gen Virol 84, 
1941-1949. 
Sinclair, A.J. (2006). Unexpected structure of Epstein-Barr virus lytic cycle activator 
Zta. Trends Microbiol 14, 289-291. 
Sinclair, A.J., Brimmell, M., Shanahan, F., and Farrell, P.J. (1991). Pathways of 
activation of the Epstein-Barr virus productive cycle. J Virol 65, 2237-2244. 
Sinclair, A.J., Palmero, I., Peters, G., and Farrell, P.J. (1994). EBNA-2 and EBNA-LP 
cooperate to cause G0 to G1 transition during immortalization of resting human B 
lymphocytes by Epstein-Barr virus. Embo J 13, 3321-3328. 
Sista, N.D., Barry, C., Sampson, K., and Pagano, J. (1995). Physical and functional 
interaction of the Epstein-Barr virus BZLF1 transactivator with the retinoic acid 
receptors RAR alpha and RXR alpha. Nucleic Acids Res 23, 1729-1736. 
Sista, N.D., Pagano, J.S., Liao, W., and Kenney, S. (1993). Retinoic acid is a negative 
regulator of the Epstein-Barr virus protein (BZLF1) that mediates disruption of latent 
infection. Proc Natl Acad Sci U S A 90, 3894-3898. 
Smith, P.R., de Jesus, O., Turner, D., Hollyoake, M., Karstegl, C.E., Griffin, B.E., 
Karran, L., Wang, Y., Hayward, S.D., and Farrell, P.J. (2000). Structure and coding 
content of CST (BART) family RNAs of Epstein-Barr virus. J Virol 74, 3082-3092. 
 - 218 - 
 
Smith, R.F., and Smith, T.F. (1989). Identification of new protein kinase-related genes 
in three herpesviruses, herpes simplex virus, varicella-zoster virus, and Epstein-Barr 
virus. J Virol 63, 450-455. 
Spear, P.G., and Longnecker, R. (2003). Herpesvirus entry: an update. J Virol 77, 
10179-10185. 
Speck, S.H., Chatila, T., and Flemington, E. (1997). Reactivation of Epstein-Barr virus: 
regulation and function of the BZLF1 gene. Trends Microbiol 5, 399-405. 
Swaminathan, S. (2008). Noncoding RNAs produced by oncogenic human 
herpesviruses. J Cell Physiol 216, 321-326. 
Swenson, J.J., Mauser, A.E., Kaufmann, W.K., and Kenney, S.C. (1999). The Epstein-
Barr virus protein BRLF1 activates S phase entry through E2F1 induction. J Virol 73, 
6540-6550. 
Szekely, L., Selivanova, G., Magnusson, K.P., Klein, G., and Wiman, K.G. (1993). 
EBNA-5, an Epstein-Barr virus-encoded nuclear antigen, binds to the retinoblastoma 
and p53 proteins. Proc Natl Acad Sci U S A 90, 5455-5459. 
Takada, K., and Ono, Y. (1989). Synchronous and sequential activation of latently 
infected Epstein-Barr virus genomes. J Virol 63, 445-449. 
Takase, K., Kelleher, C.A., Terada, N., Jones, J.F., Lucas, J.J., and Gelfand, E.W. 
(1996). Dissociation of EBV genome replication and host cell proliferation in anti-IgG-
stimulated Akata cells. Clin Immunol Immunopathol 81, 168-174. 
Tao, Q., and Robertson, K.D. (2003). Stealth technology: how Epstein-Barr virus 
utilizes DNA methylation to cloak itself from immune detection. Clin Immunol 109, 53-
63. 
Tarakanova, V.L., Leung-Pineda, V., Hwang, S., Yang, C.W., Matatall, K., Basson, M., 
Sun, R., Piwnica-Worms, H., Sleckman, B.P., and Virgin, H.W.t. (2007). Gamma-
herpesvirus kinase actively initiates a DNA damage response by inducing 
phosphorylation of H2AX to foster viral replication. Cell Host Microbe 1, 275-286. 
Taylor, N., Flemington, E., Kolman, J.L., Baumann, R.P., Speck, S.H., and Miller, G. 
(1991). ZEBRA and a Fos-GCN4 chimeric protein differ in their DNA-binding 
specificities for sites in the Epstein-Barr virus BZLF1 promoter. J Virol 65, 4033-4041. 
Thompson, M.P., Aggarwal, B.B., Shishodia, S., Estrov, Z., and Kurzrock, R. (2003). 
Autocrine lymphotoxin production in Epstein-Barr virus-immortalized B cells: 
induction via NF-kappaB activation mediated by EBV-derived latent membrane protein 
1. Leukemia 17, 2196-2201. 
Thompson, M.P., and Kurzrock, R. (2004). Epstein-Barr virus and cancer. Clin Cancer 
Res 10, 803-821. 
Thorley-Lawson, D.A., and Gross, A. (2004). Persistence of the Epstein-Barr virus and 
the origins of associated lymphomas. N Engl J Med 350, 1328-1337. 
 - 219 - 
 
Tierney, R.J., Kirby, H.E., Nagra, J.K., Desmond, J., Bell, A.I., and Rickinson, A.B. 
(2000). Methylation of transcription factor binding sites in the Epstein-Barr virus latent 
cycle promoter Wp coincides with promoter down-regulation during virus-induced B-
cell transformation. J Virol 74, 10468-10479. 
Tomkinson, B., Robertson, E., and Kieff, E. (1993). Epstein-Barr virus nuclear proteins 
EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation. J 
Virol 67, 2014-2025. 
Toyoshima, H., and Hunter, T. (1994). p27, a novel inhibitor of G1 cyclin-Cdk protein 
kinase activity, is related to p21. Cell 78, 67-74. 
Tsai, S.C., Lin, S.J., Chen, P.W., Luo, W.Y., Yeh, T.H., Wang, H.W., Chen, C.J., and 
Tsai, C.H. (2009). EBV Zta protein induces the expression of interleukin-13, promoting 
the proliferation of EBV-infected B cells and lymphoblastoid cell lines. Blood 114, 109-
118. 
Tsurumi, T., Fujita, M., and Kudoh, A. (2005). Latent and lytic Epstein-Barr virus 
replication strategies. Rev Med Virol 15, 3-15. 
Tugizov, S.M., Berline, J.W., and Palefsky, J.M. (2003). Epstein-Barr virus infection of 
polarized tongue and nasopharyngeal epithelial cells. Nat Med 9, 307-314. 
Urier, G., Buisson, M., Chambard, P., and Sergeant, A. (1989). The Epstein-Barr virus 
early protein EB1 activates transcription from different responsive elements including 
AP-1 binding sites. Embo J 8, 1447-1453. 
Ushiku, T., Chong, J.M., Uozaki, H., Hino, R., Chang, M.S., Sudo, M., Rani, B.R., 
Sakuma, K., Nagai, H., and Fukayama, M. (2007). p73 gene promoter methylation in 
Epstein-Barr virus-associated gastric carcinoma. Int J Cancer 120, 60-66. 
Verma, R.P., and Hansch, C. (2006). Chemical Toxicity on HeLa Cells. Curr Med 
Chem 13, 423-448. 
Vermeulen, K., Van Bockstaele, D.R., and Berneman, Z.N. (2003). The cell cycle: a 
review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 36, 131-
149. 
Vetsika, E.K., and Callan, M. (2004). Infectious mononucleosis and Epstein-Barr virus. 
Expert Rev Mol Med 6, 1-16. 
Wagner, H.J., Bein, G., Bitsch, A., and Kirchner, H. (1992). Detection and 
quantification of latently infected B lymphocytes in Epstein-Barr virus-seropositive, 
healthy individuals by polymerase chain reaction. J Clin Microbiol 30, 2826-2829. 
Waltzer, L., Bourillot, P.Y., Sergeant, A., and Manet, E. (1995). RBP-J kappa 
repression activity is mediated by a co-repressor and antagonized by the Epstein-Barr 
virus transcription factor EBNA2. Nucleic Acids Res 23, 4939-4945. 
Waltzer, L., Logeat, F., Brou, C., Israel, A., Sergeant, A., and Manet, E. (1994). The 
human J kappa recombination signal sequence binding protein (RBP-J kappa) targets 
 - 220 - 
 
the Epstein-Barr virus EBNA2 protein to its DNA responsive elements. Embo J 13, 
5633-5638. 
Waltzer, L., Perricaudet, M., Sergeant, A., and Manet, E. (1996). Epstein-Barr virus 
EBNA3A and EBNA3C proteins both repress RBP-J kappa-EBNA2-activated 
transcription by inhibiting the binding of RBP-J kappa to DNA. J Virol 70, 5909-5915. 
Wang, F. (2005). Epstein-Barr Virus related Lymphocryptoviruses of Old and New 
World nonhuman primates. In: Epstein-Barr Virus, ed. E. Robertson: Caister Academic 
Press, 691-709. 
Wang, F., Rivailler, P., Rao, P., and Cho, Y. (2001). Simian homologues of Epstein-
Barr virus. Philos Trans R Soc Lond B Biol Sci 356, 489-497. 
Wang, P., Day, L., Dheekollu, J., and Lieberman, P.M. (2005). A redox-sensitive 
cysteine in Zta is required for Epstein-Barr virus lytic cycle DNA replication. J Virol 
79, 13298-13309. 
Wang, Y.C., Huang, J.M., and Montalvo, E.A. (1997). Characterization of proteins 
binding to the ZII element in the Epstein-Barr virus BZLF1 promoter: transactivation by 
ATF1. Virology 227, 323-330. 
Watt, F., and Molloy, P.L. (1988). Cytosine methylation prevents binding to DNA of a 
HeLa cell transcription factor required for optimal expression of the adenovirus major 
late promoter. Genes Dev 2, 1136-1143. 
Welter, J.F., Crish, J.F., Agarwal, C., and Eckert, R.L. (1995). Fos-related antigen (Fra-
1), junB, and junD activate human involucrin promoter transcription by binding to 
proximal and distal AP1 sites to mediate phorbol ester effects on promoter activity. J 
Biol Chem 270, 12614-12622. 
Westphal, E.M., Mauser, A., Swenson, J., Davis, M.G., Talarico, C.L., and Kenney, 
S.C. (1999). Induction of lytic Epstein-Barr virus (EBV) infection in EBV-associated 
malignancies using adenovirus vectors in vitro and in vivo. Cancer Res 59, 1485-1491. 
Williams, H., and Crawford, D.H. (2006). Epstein-Barr virus: the impact of scientific 
advances on clinical practice. Blood 107, 862-869. 
Williams, H., Macsween, K., McAulay, K., Higgins, C., Harrison, N., Swerdlow, A., 
Britton, K., and Crawford, D. (2004). Analysis of immune activation and clinical events 
in acute infectious mononucleosis. J Infect Dis 190, 63-71. 
Wilson, J.B., Bell, J.L., and Levine, A.J. (1996). Expression of Epstein-Barr virus 
nuclear antigen-1 induces B cell neoplasia in transgenic mice. Embo J 15, 3117-3126. 
Wu, F.Y., Chen, H., Wang, S.E., ApRhys, C.M., Liao, G., Fujimuro, M., Farrell, C.J., 
Huang, J., Hayward, S.D., and Hayward, G.S. (2003). CCAAT/enhancer binding 
protein alpha interacts with ZTA and mediates ZTA-induced p21(CIP-1) accumulation 
and G(1) cell cycle arrest during the Epstein-Barr virus lytic cycle. J Virol 77, 1481-
1500. 
 - 221 - 
 
Wu, F.Y., Wang, S.E., Chen, H., Wang, L., Hayward, S.D., and Hayward, G.S. (2004). 
CCAAT/enhancer binding protein alpha binds to the Epstein-Barr virus (EBV) ZTA 
protein through oligomeric interactions and contributes to cooperative transcriptional 
activation of the ZTA promoter through direct binding to the ZII and ZIIIB motifs 
during induction of the EBV lytic cycle. J Virol 78, 4847-4865. 
Wysokenski, D.A., and Yates, J.L. (1989). Multiple EBNA1-binding sites are required 
to form an EBNA1-dependent enhancer and to activate a minimal replicative origin 
within oriP of Epstein-Barr virus. J Virol 63, 2657-2666. 
Xia, T., O'Hara, A., Araujo, I., Barreto, J., Carvalho, E., Sapucaia, J.B., Ramos, J.C., 
Luz, E., Pedroso, C., Manrique, M., Toomey, N.L., Brites, C., Dittmer, D.P., and 
Harrington, W.J., Jr. (2008). EBV microRNAs in primary lymphomas and targeting of 
CXCL-11 by ebv-mir-BHRF1-3. Cancer Res 68, 1436-1442. 
Yates, J., Warren, N., Reisman, D., and Sugden, B. (1984). A cis-acting element from 
the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in 
latently infected cells. Proc Natl Acad Sci U S A 81, 3806-3810. 
Yoshizaki, T., Sato, H., Murono, S., Pagano, J.S., and Furukawa, M. (1999). Matrix 
metalloproteinase 9 is induced by the Epstein-Barr virus BZLF1 transactivator. Clin 
Exp Metastasis 17, 431-436. 
Young, L.S., and Rickinson, A.B. (2004). Epstein-Barr virus: 40 years on. Nat Rev 
Cancer 4, 757-768. 
Young, L.S., Yao, Q.Y., Rooney, C.M., Sculley, T.B., Moss, D.J., Rupani, H., Laux, G., 
Bornkamm, G.W., and Rickinson, A.B. (1987). New type B isolates of Epstein-Barr 
virus from Burkitt's lymphoma and from normal individuals in endemic areas. J Gen 
Virol 68 ( Pt 11), 2853-2862. 
Zalani, S., Coppage, A., Holley-Guthrie, E., and Kenney, S. (1997). The cellular YY1 
transcription factor binds a cis-acting, negatively regulating element in the Epstein-Barr 
virus BRLF1 promoter. J Virol 71, 3268-3274. 
Zalani, S., Holley-Guthrie, E., and Kenney, S. (1995). The Zif268 cellular transcription 
factor activates expression of the Epstein-Barr virus immediate-early BRLF1 promoter. 
J Virol 69, 3816-3823. 
Zalani, S., Holley-Guthrie, E.A., Gutsch, D.E., and Kenney, S.C. (1992). The Epstein-
Barr virus immediate-early promoter BRLF1 can be activated by the cellular Sp1 
transcription factor. J Virol 66, 7282-7292. 
Zerby, D., Chen, C.J., Poon, E., Lee, D., Shiekhattar, R., and Lieberman, P.M. (1999). 
The amino-terminal C/H1 domain of CREB binding protein mediates zta transcriptional 
activation of latent Epstein-Barr virus. Mol Cell Biol 19, 1617-1626. 
Zhang, J., Chen, H., Weinmaster, G., and Hayward, S.D. (2001). Epstein-Barr virus 
BamHi-a rightward transcript-encoded RPMS protein interacts with the CBF1-
associated corepressor CIR to negatively regulate the activity of EBNA2 and NotchIC. J 
Virol 75, 2946-2956. 
 - 222 - 
 
Zhang, Q., Gutsch, D., and Kenney, S. (1994). Functional and physical interaction 
between p53 and BZLF1: implications for Epstein-Barr virus latency. Mol Cell Biol 14, 
1929-1938. 
Zhang, Q., Hong, Y., Dorsky, D., Holley-Guthrie, E., Zalani, S., Elshiekh, N.A., Kiehl, 
A., Le, T., and Kenney, S. (1996). Functional and physical interactions between the 
Epstein-Barr virus (EBV) proteins BZLF1 and BMRF1: Effects on EBV transcription 
and lytic replication. J Virol 70, 5131-5142. 
Zhou, S., Fujimuro, M., Hsieh, J.J., Chen, L., and Hayward, S.D. (2000). A role for 
SKIP in EBNA2 activation of CBF1-repressed promoters. J Virol 74, 1939-1947. 
Zou, W., Wang, J., and Zhang, D.E. (2007). Negative regulation of ISG15 E3 ligase 
EFP through its autoISGylation. Biochem Biophys Res Commun 354, 321-327. 
 
 
